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Abstract of Dissertation
Vena cava filters (VCFs) are mechanical devices implanted in the inferior vena cava
to trap thrombi from travelling to the pulmonary circulation, resulting in pulmonary
embolism. VCFs are available as permanent or non-permanent, retrievable devices
and are generally indicated for use in patients unable to receive systemic
anticoagulation or at exceedingly high risk for pulmonary embolism (PE).
Retrievable devices allow for removal of the VCF once the contraindication to
anticoagulation or high risk of PE has abated. Since the introduction of retrievable
VCFs in the early 2000’s, use of VCFs has increased three-fold, with >85% of all VCFs
placed being retrievable. Complications due to indwelling VCFs are time-dependent
and the FDA-recommended time periods for retrieval fall within 50-70 days postimplantation. However, retrieval rates are low. Generally around 30% of all VCFs
are retrieved in eligible patients, with the remainder becoming permanent despite
no indication for the VCF to remain in place. These studies sought to quantify the
epidemiology of VCF use, and retrieval in Kentucky and nationally, and to inform
future clinical interventions to increase retrieval rates. The following objectives
were achieved: 1) describe treatment patterns for patients hospitalized with PE or
other venous thromboembolism including VCF utilization and anticoagulation, 2)
characterize patients who do and do not receive VCFs, 3) evaluate retrieval rates
among subgroups of patients and identify factors associated with retrieval, and 4)
evaluate a minimal intervention performed in the University of Kentucky hospital
aimed at increasing VCF retrieval rates. Finally, a review of the literature was
conducted to identify interventions that have increased retrieval rates at individual
hospitals. All these data will be useful in developing a future institutional-level
intervention to increase retrieval rates to better improve the quality of patient care.
Key words: vena cava filters, venous thromboembolism, pulmonary embolism,
retrieval, quality of care
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CHAPTER 1: INTRODUCTION TO VENA CAVA FILTERS
Venous thromboembolism epidemiology and treatment
Venous thromboembolism (VTE) includes both deep vein thrombosis (DVT) of the
legs or pelvis and pulmonary embolism (PE). VTE incidence is estimated to be about
124 to 138 events per 100,000 person-years – equally divided between DVT alone
and PE with or without DVT, with recurrence in approximately 30% of patients
within 10 years. 1,2 VTE carries a high risk of mortality, with 30-day case-fatality
rates of nearly 17% for PE and nearly 7% for DVT, a risk which increases with age. 2
The majority (~60%) of VTE is secondary to known major risk factors such as
hospitalization, trauma, surgery, and cancer while also influenced by myriad of
other clinical factors, treatment regimens, and acquired or inherited thrombophilia.
3

Treatment of VTE is addressed by the American College of Chest Physicians (ACCP
or CHEST) guidelines. 4 Updated as recently as 2016, the ACCP guidelines generally
recommend systemic anticoagulation in the form of oral anticoagulants (OAC,
warfarin, rivaroxaban, dabigatran, apixaban, edoxaban) or low-molecular weigh
heparin (LMWH, tinzaparin, dalteparin, enoxaparin) for at least 3 months after VTE.
Vena cava filters (VCFs) are devices usually implanted in the inferior vena cava to
mechanically prevent thrombi migrating from the lower extremities to the
pulmonary circulation (Figure 1.1). Designs of these device differ by manufacturer
and model, but generally include an umbrella-like design to catch thrombi, barbed

1

arms that embed into the endothelium of the vena cava, and snare hooks to facilitate
retrieval (Figure 1.2). ACCP recommendations are limited for VCFs in saying that
they are considered only a last resort in patients with severe risk of PE and should
never be used in patients that can use anticoagulants. As an introduction to VCFs,
the utilization of and evidence supporting their use will be reviewed.

Vena cava filter utilization
Despite strong, Grade 1B (“high evidence”) recommendations by the ACCP guideline
panel to not utilize VCFs but in the most severe cases, VCFs are still used in
approximately 10% of all VTE cases and nearly 20% of all PE cases.

5,6

Overall

utilization has steadily increased, especially with the introduction of retrievable, or
optional, VCFs in 2003. 5,7,8 Use of VCFs is associated with patients deemed at high
risk of recurrent VTE and/or high bleed risk including those with active cancer,
advanced age, prior bleeding, trauma, surgery, and unstable patients. 5,7 Estimates of
VCF placements in the U.S. have increased from ~3,000 devices per year during
1979 through 1984, up to 92,000 devices placed in 2006. 5 Utilization of VCFs may
be excessive in the U.S., with utilization outpacing European nations by 25 to 40fold.

Evidence for vena cava filters
Prior to 2015, only one randomized controlled trial had evaluated the efficacy of
VCFs for prevention of pulmonary embolism. The Prévention du Risque d’Embolie

2

Pulmonaire par Interruption Cave (PREPIC) study randomized patients with
proximal DVT with or without PE to receive standard anticoagulant treatment with
or without a VCF. 9 At this time, only permanent VCFs were available on the market.
After eight years of follow-up, there was a significant protective effect of VCFs on
pulmonary embolism (6.2% vs. 15.1%, P=0.008), a significant increase in DVTs
associated with VCFs (35.7% vs. 27.5%, P=0.042), and no difference in mortality. In
2015, PREPIC2 data were released which updated the evidence for retrievable VCFs.
10

With a similar design applied to 399 patients, results at six months of follow-up

showed a non-significant reduction in PE and other outcomes including DVT, major
bleeding, and death. Overall, the PREPIC and PREPIC2 studies did not supply clear
evidence for the use of VCFs, mainly due to the fact that the population studied is
not considered the population in whom VCFs are usually indicated, i.e. those who
have absolute or relative contraindications to anticoagulation. However, given that
it would likely be difficult and unethical to conduct such a study, observational
studies must fill in the evidence gap.

Observational studies have shown mixed results both in favor and against the
utilization of VCFs in multiple patients groups. Stein et al showed an overall
protective effect of VCFs for in-hospital mortality in stable, unstable, and elderly
patients.

11,12

These studies are potentially biased given that the authors used

National Inpatient Sample discharge data, which include no basis to establish
temporality. Similarly, Isogai and colleagues associated VCFs with an overall
protective effect for in-hospital mortality in a Japanese study of patients with

3

pulmonary embolism using propensity score techniques to reduce sample bias. 13 A
pooled analysis of eight controlled studies evaluating prophylactic use of VCF filters
(i.e. no VTE present) found a consistent protective benefit for PE and fatal PE with
inconsistent findings for subsequent risk of DVT associated reduction in with VCF
use. 14 This study found the number needed to treat to prevent one PE event ranged
from 109 up to 962 patients in this setting.

A number of studies have also refuted the effectiveness claims of VCFs. Using data
from California, VCFs were found to be used in patients with greater comorbidity,
PE, bleeding, cancer, and prior stroke. 15 In adjusted analyses, VCF placement was
not associated with a significant reduction in recurrent PE but was associated with
higher risk of DVT – consistent with the findings of the PREPIC trial. Another study
conducted in patients with cancer-associated VTE found that those patients with a
VCF had higher mortality and recurrent VTE events compared to those treated with
anticoagulation in propensity score weighted analyses. 16 Muriel et al evaluated
survival effects of VCFs in patients with VTE and high bleeding risk. 17 Using a
propensity-score matched sample, they found a non-significant reduction in allcause death with VCF use (6.6% vs. 10.2%, P=0.12), a significant reduction in PErelated mortality (1.7% vs. 4.9%, P=0.03), and much higher risk for recurrent VTE
with VCF placement (6.1% vs. 0.6%, P<0.001). Hemmila and colleagues investigated
the survival benefit for prophylactic use of VCFs found that patients with a VCF in
place had no impact on mortality and increased the risk of DVT. 18 The most recent
study by White et al also used propensity score matched samples and found that

4

VCFs had a protective effect in for 30- and 90-day risk of death only in patients with
active bleeding with no effect observed in patients with no contraindication to
anticoagulation. 19

Although there is a general lack of consensus in the evidence, 20 VCFs are widely
accepted and utilized – again in roughly 10% of all VTE cases and to an equal degree
for prophylactic indications. 5 Some physicians have even called for alarm given that
VCFs have generally been approved by the U.S. Food and Drug Administration (FDA)
using the 510(k) process, which has been condemned by the Institute on Medicine.
20

This process relies on existing information for a predicate device and allows for

marketing of a new device with minimal data submission to the FDA, with few
exceptions for prospective safety data collection or small trials to determine safety.
21

In this article subtitled, “How Could a Medical Device Be So Well Accepted

Without Any Evidence of Efficacy?” the authors conclude that while RCTs will
continue to lag behind in the information needed to guide clinical practice around
VCFs, informed consent must be offered to patients so that the lack of evidence and
growing evidence of harm can be considered by patients at the point of care. 20

Complication rates of vena cava filters
In addition to the lack of evidence for efficacy, there are also complications related
to VCF use that must be considered. Major complications can include the
aforementioned increased risk of DVT, thrombosis in the inferior vena cava, device
fracture and migration, and device perforation of the inferior vena cava and internal
5

organs. Complication rates appear to be on a device-by-device basis. 22 A study by
Peterson and colleagues showed that roughly 1-in-5 patients with a VCF had a
complication including: VCF thrombi (9.5%), DVT (4.7%), VCF penetration of the
blood vessel (2.9%), and device migration (0.4%). 23 In the FDA’s own Manufacturer
and User Facility Device Experience (MAUDE) database between 2009-2012, 1,606
adverse events associated with VCFs were reported including 350 device fractures,
215 whole device migrations, 154 partial device embolizations, 197 VCF tilts, and
228 vena cava penetrations. 24 This, again, varied considerably across six individual
types of filters included in the study and was mostly reported for retrievable VCFs. 24
Although PE may be prevented, the observed increased risk of DVT is not benign
with up to 30% of patients developing post-thrombotic syndrome, which can have
long-term effects on quality of life. 25-27

Complications reported with VCFs are generally outside of 30 days postimplantation, i.e. they are associated with longer indwell times of retrievable VCFs.
28,29

In response to this concern, the FDA released an initial Safety Communication

regarding retrieval of VCFs in 2010. 30 Citing a study which modeled the inflection
point of the net clinical benefit of VCFs, the FDA formally recommended that VCFs
be removed within 29 to 54 days after implantation or when clinically indicated,
which can be interpreted as when the patient can be anticoagulated or is no longer
at a substantial risk for PE.

31

The communication also detailed ongoing data

collection through post-market surveillance and ongoing clinical study. 30

6

Guidelines impacting use of vena cava filters
Despite a lack of evidence and concern about complications, VCF utilization has
been shown to continue to increase over the last several decades. 5 As mentioned,
the ACCP guidelines, which are widely used for educating clinicians on treatment for
VTE, are conservative in regards to VCF use and consider the device a “last resort.”
However, these guidelines are not the sole influence on medical practice
surrounding VCF. Two specialties that interact with decision-making for VCFs
include (vascular) interventional radiology and trauma who have created
independent guidelines.

The American College of Radiology and Society of Interventional Radiology (SIR)
guidelines cover the practice of interventional radiologists who are most often
placing VCFs after patients are referred to their service from other specialties. The
most recent 2011 guidelines are considered more liberal in VCF use compared to
the ACCP guidelines, allowing and recommending VCF use for patients with VTE
who are contraindicated to anticoagulation, prophylactically in those with trauma,
bariatric surgery, or spinal cord injury and no VTE, as well as in patients with VTE
treated with anticoagulation if there is recurrence or progression of the VTE,
massive PE or massive clot burden, free-floating DVT, or in severe cardiopulmonary
disease (Table 1.1). 32 To compare, ACCP guidelines recommend VCFs only when a
contraindication to anticoagulation exists, specifically recommending against the
other points made by the SIR guidelines and no recommendation for patients with
recurrent VTE. It is logical to assume that those placing the devices will follow the

7

guidelines of their parent society. As a result, concordance with the ACCP guidelines
is generally dismal with one study showing 41.3% of VCF placements following
recommendations from ACCP. 33 This is contrasted with up to 95.7% concordance
with SIR guidelines.

Trauma surgeons may also place VCFs in the acute care setting, relying on guidance
from the Eastern Association for the Surgery of Trauma (EAST) guidelines.

34

Dealing with a special patient population that may include multiple bone fractures,
severe blunt or penetrating trauma, as well as the need for multiple surgeries, the
inherent risk of VTE is high. These patients make up the vast majority of
prophylactic use of VCFs, which is approximately 50% of the VCF utilization. 28 The
EAST guidelines make “Level III” recommendations meaning there is only
retrospective, opinion, or case study data to support the claim. Nevertheless, they
call for prophylactic use only in “very-high risk” trauma patients who have high
bleeding risk, noting particularly older age along with hemorrhagic injuries or risk
factors.

34

EAST guidelines also acknowledge prophylactic use as controversial,

owning to the lack of evidence but also the lack of approved indication according to
the product labeling. They further suggest that identification of the proper trauma
patient group, via risk factor assessment, is needed so VCFs are allocated efficiently.
These guidelines have not been updated since 2002.

The EAST and SIR guidelines have impacted the overall utilization of VCFs in the U.S.
In a trend analysis, introduction of the EAST guidelines were associated with an

8

increase in VCF utilization of 138% while the SIR guidelines in 2006 were associated
with an additional 122% increase. 35 The ACCP guidelines in 2008 and 2012 as well
as decreased reimbursement from Medicare were also associated with a leveling off
in utilization in that period.35 Further, there was an increase in legal suits against
some manufacturers throughout this period that may have added to the cooling off
of the VCF market.

Comparisons of these guidelines vary given the different patient groups studied.
However, one study conducted a cost effectiveness analysis in trauma patients,
applying the guidelines as prophylactic (EAST, SIR) or non-prophylactic (ACCP) use
of VCFs.

36

The authors found that for the overall trauma patient population, VCFs

are more costly than no treatment and also result in in fewer quality-adjusted lifeyears. However, to the point of better identifying more appropriate subgroups for
prophylactic treatment made earlier in the EAST guidelines, the authors found that
VCFs were cost-effective if the risk of VTE was around 10% or greater (i.e. greater
than double the risk than the general trauma population). Prophylactic VCF
utilization was cost-effective only if the likelihood of complications associated with
anticoagulation was at least 10-times the risk in the general trauma population.
During the initial hospitalization, VCFs were cost-effective at an incremental costeffectiveness ratio of nearly $400,000 per quality-adjusted life year, which would
fail to reach the acceptable threshold by any normal cost-effectiveness
considerations. 36

9

Variation in the utilization and retrieval of vena cava filters
Multiple guidelines and limited evidence appears to have made a practice
environment that varies from institution-to-institution and across state and
geographical areas. White et al conducted a study of hospitals in California. Of the
263 hospitals included, variation in use of VCFs for active VTE ranged from 0% to
nearly 40% with an overall mean use of 15% of all VTE cases. Of this variation,
18.5% was attributable to between hospital differences, with the rest attributed to
patient factors or unmeasured characteristics. 37

Using a trauma-specific database, Dossett et al observed what they referred to as
“unwarranted national variation” in the use of prophylactic VCFs. 38 They observed
variation in use of 0 to 13 prophylactic VCFs per 100 trauma patients. They also
included a metric for “high-risk patients” in line with who would be considered high
risk of VTE according to the EAST guidelines, with the goal of only utilizing VCFs in
those patients at high risk. They found that median use was centralized around the
EAST recommendations at 1.1 VCFs used per high-risk patient (i.e. patients who
were not “high risk” received a VCF despite lack of need, indicating potential
overuse by 50% of all trauma centers) but this ranged up to 206 VCFs used per highrisk patient in the most extreme case. Each study contributed some of the
unobserved factors potentially contributing to this variation as “regional culture,”
hospital culture, and engrained physician practices. The Dossett study also notes
that if high utilization of VCFs was clearly associated with improved outcomes, the
push would be to increase utilization in centers found to be under-utilizing VCFs in
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their study. 38 However, prophylactic VCF use remains controversial, off-label, and
lacks clinical trial evidence to support this use.

Appropriateness of the use of VCFs is a moot point once placement has occurred.
The shift in focus becomes the retrieval of the device once the indication for
placement has abated, i.e. the patient is no longer at high risk for PE and/or the
patient can initiate anticoagulation. Clinical studies like PREPIC2, even in a
controlled environment with dedicated follow-up periods, retrieved roughly 80% of
all VCFs placed after 3 months. In real-world clinical practice, however, this rate is
closer to an estimated mean of 30%,
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with some institutions reporting VCF

retrieval as low as 8%. 39 Retrieval is pivotal to the safety of these devices, again
because complication rates are correlated with longer indwell times.
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Dismal

retrieval rates are associated with poor patient follow-up and fractionated care
given that the physicians placing the filters, mainly interventional radiologists, are
not generally part of the follow-up plan. 40-42 Thus, the majority of patients are likely
discharged without any plans for follow-up for VCF retrieval, making the device de
facto permanent in these people. The previously mentioned FDA safety
communication relays only that retrieval is a goal, not necessarily specifying the
correct patient population or indications for which VCFs should be used. 30 Thus,
VCFs are a medical device likely being overused given the paucity of data and one
that is not consistently retrieved in a timely fashion, which is likely due to a lack of
planning in post hoc patient care.
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Figure 1.1: Diagram of vena cava filter placement in the inferior vena cava to
prevent clot movement from lower extremities.
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Figure 1.2: Examples of four vena cava filter models showing filter sections,
barbs, and retrieval hooks
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Table 1.1: Comparison of guidelines impacting utilization of vena cava filters
Scenario for VCF
ACCP Guidelines
SIR Guidelines
placement
VTE with anticoagulation

Recommends

Recommends with

against VCFs

progression, large clot
burden, free-floating thrombi,
or severe cardiopulmonary
disease.

VTE with contraindication

Recommends VCF

Recommends VCF

No specific

Recommends VCF

to anticoagulation
Recurrent VTE

recommendation
Trauma (prophylaxis)

Recommends

Recommends consideration of

against VCF

VCF

Bariatric surgery

Recommends

No specific recommendation

(prophylaxis)

against VCF

Spinal cord injury

Recommends

(prophylaxis)

against VCF
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Recommends VCF

HYPOTHESIS AND AIMS OF THIS DISSERTATION

I believe that the use of VCFs is highly variable and the outcomes poorly described.
Understanding the epidemiology of VCF utilization can inform interventions to
improve the quality of care for patients with VTE, ensuring that the correct patients
receive VCFs and that post-implantation care is provided. The goal of this
dissertation work is to describe and model the use and retrieval of VCFs. I will also
be evaluate to efficacy and toxicity outcomes and provide some pilot work to
address low retrieval rates as outlined in the Aims below.
Specific Aims
Thus, I present these specific aims for this dissertation and address them in the next
five chapters.
1)

Assess utilization and variation in utilization of VCFs in acute care hospitals
in Kentucky

2) Evaluate retrieval rates and factors associated with retrieval in a national
cohort
3) Compare outcomes between patients treated with VCFs with and without
anticoagulation, versus anticoagulation alone in a cancer patient subgroup at
high risk of recurrent events
4) Evaluate an intervention to increase retrieval rates in the Interventional
Radiology clinic at the University of Kentucky hospital
5) Perform a literature review of interventions to increase retrieval rates at
other institutions to inform future efforts

15

CHAPTER 2: HOSPITAL VARIATION AND PATIENT CHARACTERISTICS
ASSOCIATED WITH VENA CAVA FILTER UTILIZATION IN ACUTE CARE
HOSPITALS IN KENTUCKY

Study 2.1: Addresses VCF utilization in Kentucky hospitals by evaluating patient and
hospital factors associated with use. This study has been published in the journal
Medical Care.

Citation: Brown, Joshua D., and Jeffery C. Talbert. "Hospital Variation and Patient
Characteristics Associated With Vena Cava Filter Utilization." Medical Care (2016).
Ahead of print.

Study 2.2: Evaluates hospital-level variation in VCF utilization to observe whether it
is explained by patient and hospital-level factors and to observe outliers along this
continuum. This study has been published in the journal JAMA Surgery as a research
letter and is formatted accordingly.

Citation: Brown, Joshua D., and Jeffery C. Talbert. “Variation in the Use of Vena Cava
Filters for Venous Thromboembolism in Hospitals in Kentucky.” JAMA Surgery
(2016). doi:10.1001/jamasurg.2016.1004
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Study 2.1: Hospital Variation and Patient Characteristics Associated With Vena
Cava Filter Utilization

Abstract

Introduction: There is wide variation in the use of vena cava filter (VCFs).
Objectives: This study assessed the hospital and patient characteristics associated
with VCF use in deep vein thrombosis (DVT) and pulmonary embolism (PE).
Methods: Inpatient discharge data from all acute care hospitals with DVT/PE in
Kentucky were used. Hierarchical logistic regression models were used to evaluate
the relationships of study variables with VCF use.
Results: During the study period, 81,922 discharges for DVT/PE were observed and
10.5% of these received a VCF. This included 12,083 cases of PE+DVT, 18,571 cases
of PE only, and 51,268 cases of DVT only. VCF use among these groups was 22.7%,
6.0%, and 7.8%, respectively. In adjusted analyses, VCF use was associated with
increasing age, indicating that those over age 65 were twice as likely to receive a
filter compared to the reference (21-25 year-old) group. Significant comorbidities
associated with VCF use included cancer, liver disease, cerebrovascular disease,
atrial fibrillation, anemia, and concurrent bleeding. Lower extremity, proximal
DVTs, and patients receiving thrombolytic therapy or embolectomy, those having
surgery, and those who were unstable or had trauma, were also more likely to
receive a filter. Among cancer types, brain and metastatic tumors were significantly
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associated with VCF use. Between-hospital variation after controlling for all
covariates was 7.1%.
Conclusion: There was high variation in use of VCFs. Several high-risk subgroups
were more likely to use VCFs including older adults and those with cancer and
concurrent bleeding.
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Introduction

Increased utilization of vena cava filters (VCFs) for venous thromboembolism (VTE)
has correlated with technical improvements in placement of VCFs as well as
development of retrievable devices. 5 By 2006, roughly 9% of cases of deep vein
thrombosis (DVT) and 12% of pulmonary embolism (PE) received a VCF and has
continued to increase into 2012 with an estimated 259,000 VCFs placed in patients
in the United States. 43,44

This increase persists despite mixed recommendations and an overall lack of
evidence for the use of VCFs. 20 American College of Chest Physicians guidelines
recommend VCF use only if the patient has a contraindication to systemic
anticoagulation as a last resort. 45 Conversely, The American College of Radiology
and Society of Interventional Radiology guidelines support prophylactic VCF use for
patients determined to be at high risk of developing DVT or PE.

46,47

These

contrasting recommendations are important considering that in a study conducted
at one academic medical center, nearly one-half of all VCFs placed were for
prophylactic purposes and only a third of uses are associated with clear bleedrelated contraindications to anticoagulation. 44 Another study corroborated these
findings showing that up to 50% of VCFs used in trauma patients are
“unwarranted.” 48
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Given the potential for suboptimal use of VCFs and the wide variation in use
between hospitals, 37 it is important to understand the hospital- and patient-level
factors associated with utilization. Identifying these factors will assist in assessing
the quality of care for patients presenting with DVT/PE and can also indicate
subpopulations that may be of interest for future research. Thus, this study sought
to characterize patients with VTE who received VCFs and to observe the amount of
variation between hospitals. A cancer subgroup will also be analyzed with the same
methodology due the high rates of VTE and potential of high bleeding risk in that
population.

Methods

Data source
State Inpatient Database (SID) data from Kentucky (years 2008-2014) were used.
SID data are analogous to National Inpatient Sample (NIS) data but are state-specific
and include all discharges instead of a probabilistic sample. 49 Data include patient
demographic variables (age, gender, race, insurance, ZIP codes) and diagnosis and
procedure fields. Data are de-identified and do not include unique patient
identifiers, so no longitudinal tracking is possible. Thus, data represent discharges
and may contain multiple records for the same person representing unique
hospitalizations for that person. We use the terminology “patients” to distinguish
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each unique hospitalization/discharge. The University of Kentucky Institutional
Review Board approved of this study.

Study variables
The coding algorithms used are presented in the Appendix and are based on
previously published coding algorithms. 15,37,50-52 All diagnoses for DVT PE were
identified for those 21 and older from acute care hospitals. VCF use was identified
by ICD-9-CM procedure code 38.7. Discharges from hospitals where no VCFs were
placed over the entire 7-year period were excluded to avoid bias due to hospitals
lacking the ability to perform the procedure. Variation in VCF use was described by
the mean, median, interquartile range (IQR), and coefficient of variation.

Patients were classified as having DVT only, PE only, or having PE+DVT.
Comorbidities identified included cancer, chronic obstructive pulmonary disease,
cerebrovascular disease (CVD), atrial fibrillation (AFib), liver disease, hypertension,
heart failure, hyperlipidemia, myocardial infarction, cellulitis, trauma, diabetes,
infection, pneumonia, renal disease, bleeding, anemia, and sepsis/septic shock. 53 In
addition, thrombolytic therapy and embolectomy/thrombectomy procedures were
identified. Unstable patients were identified as those with shock or by use of a
ventilator. Invasive surgical procedures were identified using a validated algorithm.
54

Discharge statuses of “deceased” or “transferred” were also recorded. Age was

categorized by 5-year intervals. Race was categorized white, black, or other and
insurance was classified as commercial, Medicaid, Medicare, or other/self-pay.
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Individual hospitals were classified as being urban or rural, teaching or nonteaching, and categorized into quartiles by hospital bed size.

Statistical analysis
Comparisons were conducted between demographic and clinical characteristics
using t-tests and chi-squared tests where appropriate using an a priori, two-sided
significance level of 0.05. P-values are reported for comparisons between VCF users
and non-users.

Based on previous studies the likelihood of receiving a VCF has a moderate
association with the hospital where treatment occurs. 37 This is likely influenced at
the institutional level by physician preferences and hospital policies and practices.
To account for this natural clustering effect and its impact on treatment, hierarchical
generalized linear modeling was used (henceforth: hierarchical logistic models) for
the binary outcome of VCF use. 55 These models included random effects for each
hospital and fixed effects for other covariates. 55,56 The first model included hospital
random effects only. The second model included level-1 fixed effects, which are
patient demographic and clinical characteristics. Level-2 effects, i.e., hospital
characteristics, were included in a separate model alone and in the final full model,
which included all random and level-1 and level-2 fixed effects. A cancer-only model
was also estimated in the cancer subgroup with additional variables for cancer site
(Table 2.4).
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Odds ratios (ORs) and their 95% confidence intervals are presented for each
variable from the final, full model. The intraclass correlation coefficient (ICC) was
calculated for each model, which measures the variation explained by the hospital
random effects. The p-value associated with the ICC corresponds to the comparison
of between-hospital variance with p<0.05 showing significant differences. In
addition, c-statistics were calculated as a measure of model discriminatory power
between VCF users and non-users. Akaike (AIC) and Bayesian (BIC) information
criterion were included to compare across models, which measure the fit of the
models while penalizing for added parameters. All analyses were conducted using
SAS version 9.4 (SAS Institute, Cary, NC).
Results
A total of 70 acute care hospitals were included in the state. Of these, 11 hospitals
placed no VCFs and were excluded (N=2,435 patients, 2.9% of total discharges).
Among the remaining institutions (N=59), VCF use ranged from 0.4% to 15.2%,
mean 7.2%, median 7.2%, IQR 4.1% to 10.1%, and coefficient of variation of 0.54.

During the period 2008 to 2014, there were 81,922 VTE-related hospital discharges
and 10.5% of patients (N=7,786) received a VCF. The VCF group tended to have an
older age distribution, and have more PE+DVT, cancer, cerebrovascular disease,
atrial fibrillation, anemia, and trauma compared to those without VCFs (Table 2.1).
The VCF group was also likely to be unstable, have proximal and lower DVTs, have
bleeding, and receive thrombolysis.

23

The random effects only model resulted in an ICC of 12.0% (p<0.001) and c-statistic
0.62, showing that there was a significant difference between hospitals, which
explained 12% of the overall variance in use (Table 2.2). Adding level-1 patient-level
covariates, the ICC was 12.7% (p<0.001) and the c-statistic was 0.81 showing no
change in the explained variance for the random effects parameter and an overall
strong discriminatory ability for the model. The full model included random effects
with both level-1 and level-2 fixed effects. This model had an ICC of 7.1% (p<0.001)
and c-statistic of 0.81. The cancer only model had an ICC of 3.5% (p<0.001) and cstatistic of 0.81.

The results of the full model (Table 2.3) showed that beginning at 46-50 years of
age, the odds of receiving a VCF increased compared to the reference group (21-25
years-old). This trend continued with those over the age of 65 being roughly twice
as likely to receive a VCF. VCFs were also associated with the commercial insurance
category being more likely than those in the other/self-pay insurance category.
Black race was also associated with lower odds of receiving VCFs compared to white
race (OR=0.83 [0.75-0.92]).

Clinical characteristics were highly associated with VCF use. Compared to patients
with DVT only, those with PE only (OR=3.84 [3.46-4.25]) and PE+DVT (OR=2.73
[2.57-2.90]) were much more likely to receive VCFs. Among DVTs, those with lower
DVTs were more than six-fold more likely to receive a VCF compared to upper
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extremity DVTs. Those with bleeding, cancer, liver disease, anemia, and atrial
fibrillation were also more likely to receive VCFs.

Among those with cancer (N=13,104), 1,613 (12.3%) used VCFs. In the cancer-only
model, estimates for demographic and clinical characteristics were similar to the
primary model and are not shown. The most common cancers were lung (N=3,931,
30.0% of all cancers) and colorectal cancer (N=1,392, 10.6%). Of the twenty-two
cancer sites identified, all but five had higher utilization of VCFs than in the average
cohort (Table 2.4). The highest VCF use was associated with brain tumors (24.4%),
cervical (17.0%), stomach and small intestine (16.3%), colorectal (16.2%), and
bladder (15.6%). After controlling for all other variables, brain tumors (OR=2.31
[1.65-3.23]) remained the only significantly associated tumor site with VCF use
while leukemia and breast cancers were negatively associated with use.

Discussion
The primary findings suggest that while there is a wide variation in VCF utilization
between institutions, most of that variation is controlled for by patient and hospital
characteristics. In the final model, very little variation (~7%) in VCF use was
attributed to differences between hospitals. This differs from an analogous study by
White et al. using California SID data. Their results showed more variation (IQR
6.23%-18.14%) in VCF use and more variation (>12%) attributed to between
hospital comparisons. This indicates that VCF utilization between hospitals varies
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widely not only within a state, but also between states, as our coefficient of variation
was smaller (0.54 vs. 0.65).

Among comorbid conditions considered, our results show strong associations with
VCF use and cancer, cerebrovascular, atrial fibrillation, anemia, and concurrent
bleeding. This suggests that consideration of baseline risk of thromboembolic and
bleeding events is considered at the point of care. However, competing guideline
statements make it difficult to assess the appropriateness of VCF use in subgroups at
a high-risk of VTE, but not necessarily contraindicated to anticoagulation. The
clearest indication for VCF use may be in those with concurrent bleeding in addition
to the VTE already present. In this study, over 20% of patients with bleeding
received a VCF and were 2.7 times more likely to receive a filter in adjusted
analyses. VCF use was also associated with characteristics that potentially indicate
severity including unstable patients, surgery, receipt of thrombolysis or
embolectomy procedures, and trauma.

The association between cancer, VTE, and presence of multiple risk factors for
bleeding prompted a more detailed look into individual cancers. Patients with
cancer are at an exceedingly high risk of VTE compared to the general population. 57
Further, given the complexity of regimens, multiple drug-drug, and drug-disease
interactions, and side effects of cancer treatments as well as many surgical
procedures, it is possible that systemic anticoagulation is considered infeasible or is
contraindicated for many cancer patients. 58 However, prior studies have shown that
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anticoagulants are often used in addition to VCFs. 16,44 In this study, VCF use was
highest for brain cancers, due to the high risk of intracranial bleeding, and with
metastatic cancers. Surprisingly, lung cancers, which are often considered as a very
high-risk group for cancer-associated VTE and highly prevalent in Kentucky, 59 were
not associated with increased use.

The evidence for VCFs for PE/DVT is mixed, making conclusive arguments for its use
difficult. In the PREPIC 9 and PREPIC2 10 randomized trials, no significant benefits
were observed with VCFs with anticoagulation versus anticoagulation alone during
short- and long-term follow-up. Observational studies show that VCFs are
associated with improvements in short-term outcomes such as in-hospital mortality,
30-day mortality, and a reduction in subsequent PE events among all VTE patients
and certain subgroups (trauma, unstable, and elderly). 11,13,14,60 Other studies have
shown little or no benefit with VCFs, especially with longer follow-up. 15-18

Retrievable filters have become widely used in the last decade. Sarosiek et al.
evaluated the use of retrievable filters and subsequent complications at a single
academic center. 44 Their main findings showed there was attempted retrieval in
only 10% of VCFs. Of those retrieved, one-quarter were removed during the index
hospitalization and the median time-to-retrieval was observed to be 122 days after
placement. Their study further emphasized the lack of follow-up for patients
receiving a VCF and a number of serious complications including filter fracture and
migration. The authors emphasized the need for follow-up and proper retrieval of
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devices to avoid complications associated with VCFs. This has been observed in
other studies, as well, showing that utilization and retrieval rates as potential
quality of care issues and deserve dedicated interventions to ensure quality
outcomes for patients. 61-63

It has also been suggested that use of VCFs, as well as their retrieval, is influenced by
reimbursement rates.

44

Our findings seem to refute this strong assumption

regarding use of VCFs, at least in a case-by-case (i.e. hospital) basis. Using the ICC to
measure the impact of hospitals in the current study, the full model showed that
only 7.1% of the variance in the model was explained by the discharge hospital. Our
results suggest that there is not major variance between hospitals after controlling
for patient and hospital characteristics and does not support the notion of pervasive
overuse of VCFs in order to increase reimbursement.

Although our results suggest no institutional deviance in VCF use, there may still
exist a general overuse of these devices, which is not definitively supported by
current evidence and is further confounded given the lack of consensus in treatment
guidelines. There is a great need for additional research in the effectiveness of VCFs
in real-world practice, especially for subgroups at highest risk of complications (e.g.
cancer and high bleeding risk). While randomized studies are not likely to be
conducted to fill these knowledge gaps, well-conducted effectiveness studies using
observational data should be used.
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Limitations
Due to the nature of the data, detailed information on medication utilization is not
possible with discharge data. This is important to distinguish those who would and
would not use anticoagulants in place of, or concurrently with, VCFs as these groups
may differ in clinical presentation and treatment course. Previous studies have
shown that anticoagulants are often used with VCFs, likely proving that use persists
without clear contraindications to anticoagulation therapy. 44 Further, as the data
includes no unique patient-identifying variable, it is possible that multiple records
for the same individual are included in the analyses. This would be due to multiple
hospitalizations over the time period, including patients who transfer from one
facility to another. To investigate the impact of transfers, we included an indicator
for whether a patient transferred or not, as this may also indicate severity and
influence whether a patient receives a VCF from that institution. At both a patientlevel and institutional-level, transfer status and transfer rate were not significantly
associated with VCF utilization. Finally, the data represent the patient population
and medical practice within Kentucky and may have limited generalizability to other
areas due to differences in comorbid conditions and practices between regions.
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Conclusion
In this study of VCF use in Kentucky, we found that much of the between hospital
variation is explained by observed hospital and patient characteristics and little
variation existed between hospitals after controlling for these factors. More
research is needed to assess the effectiveness of VCFs, especially in high-risk
subgroups such as cancer, elderly, high bleed risk, and trauma patients.
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Table 2.1: Comparison of patient characteristics between vena cava filter
users and non-users
%
No VCF
VCF
Receiving
N=74,136
N=7,786
Characteristic
VCF
N
%
N
%
Age group
21-25
1,309
1.8%
64
0.8%
4.7%
26-30
1,958
2.6%
109
1.4%
5.3%
31-35
2,416
3.3%
140
1.8%
5.5%
36-40
3,092
4.2%
205
2.6%
6.2%
41-45
4,021
5.4%
292
3.8%
6.8%
46-50
5,225
7.1%
416
5.3%
7.4%
51-55
6,565
8.9%
605
7.8%
8.4%
56-60
7,148
9.6%
716
9.2%
9.1%
61-65
7,801
10.5%
875
11.2%
10.1%
66-70
7,780
10.5%
963
12.4%
11.0%
71-75
7,572
10.2%
950
12.2%
11.1%
76-80
7,188
9.7%
941
12.1%
11.6%
81+
12,061 16.3% 1,510
19.4%
11.1%
Gender
Female
39,048 52.7% 3,982
51.1%
9.3%
Male
35,088 47.3% 3,804
48.9%
9.8%
Race
White
65,860 88.8% 7,068
90.8%
9.7%
Black
6,746
9.1%
540
6.9%
7.4%
Other
1,530
2.1%
178
2.3%
10.4%
Other/SelfInsurance
10,187 13.7%
949
12.2%
pay
8.5%
Medicaid
2,930
4.0%
210
2.7%
6.7%
Medicare
24,275 32.7% 2,603
33.4%
9.7%
Commercial
36,744 49.6% 4,024
51.7%
9.9%
Clot type
DVT only
47,274 63.8% 3,994
51.3%
7.8%
PE only
17,466 23.6% 1,105
14.2%
6.0%
PE with DVT
9,396
12.7% 2,687
34.5%
22.2%
Comorbidity
Cancer
11,491 15.5% 1,613
20.7%
12.3%
Metastatic
6,087
8.2%
959
12.3%
cancer
13.6%
Heart failure
14,069 19.0% 1,470
18.9%
9.5%
Liver disease
3,224
4.3%
420
5.4%
11.5%
Renal disease 20,516 27.7% 2,233
28.7%
9.8%
Diabetes
20,656 27.9% 2,111
27.1%
9.3%
Stroke
4,893
6.6%
798
10.2%
14.0%
Hypertension 45,317 61.1% 4,954
63.6%
9.9%
Hyperlipidemi 23,826 32.1% 2,603
33.4%
9.8%
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Table 2.1: Comparison of patient characteristics between vena cava filter
users and non-users
a
Atrial
10,868 14.7% 1,424
18.3%
Fibrillation
11.6%
Cellulitis
6,284
8.5%
398
5.1%
6.0%
COPD
23,630 31.9% 2,528
32.5%
9.7%
Sepsis/Septic
7,821
10.5%
908
11.7%
shock
10.4%
Infection/
25,051 33.8% 2,712
34.8%
Pneumonia
9.8%
Anemia
24,874 33.6% 3,538
45.4%
12.5%
Myocardial
6,700
9.0%
793
10.2%
infarction
10.6%
Trauma
3,143
4.2%
558
7.2%
15.1%
Thrombolytic
1,571
2.1%
546
7.0%
therapy
25.8%
Embolectomy
249
0.3%
68
0.9%
21.5%
Unstable/
3,455
4.7%
567
7.3%
ventilator
14.1%
Proximal DVT 12,651 17.1% 2,966
38.1%
19.0%
Lower DVT
31,538 42.5% 5,997
77.0%
16.0%
Bleeding
4,612
6.2%
1,173
15.1%
20.3%
Surgery
14,340 19.3% 2,177
28.0%
13.2%
Deceased
4,200
5.7%
436
5.6%
9.4%
Transfer
1,907
2.6%
155
2.0%
7.5%
Urban/rural
Rural
19,096 25.8% 1,692
21.7%
8.1%
status
Urban
55,040 74.2% 6,094
78.3%
10.0%
Teaching
Non-teaching 36,792 49.6% 3,210
41.2%
status
8.0%
Teaching
37,344 50.4% 4,576
58.8%
10.9%
Bed size
≤75 beds
2,500
3.4%
99
1.3%
3.8%
76-135 beds
6,216
8.4%
331
4.3%
5.1%
136-275 beds 18,761 25.3% 1,718
22.1%
8.4%
≥276 beds
46,659 62.9% 5,638
72.4%
10.8%
Abbreviations: aOR=adjusted odds ratio; CI=confidence interval; VCF=vena cava
filter; DVT=deep vein thrombosis; PE=pulmonary embolism; COPD=chronic
obstructive pulmonary disease
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Table 2.2: Fit statistics of hierarchical logistic models predicting vena cava filter use
Model 1:
Model 1
Model 1
Full model: Cancer
Random
+ level 1
+ level-2
Model 1 +
model b
effects only fixed
fixed
level 1 and
effects
effects
level-2
fixed
effects a
Intercept (SE)
-2.70 (0.09) -5.76 (0.18) -3.38 (0.20) -6.50 (0.26) -7.10 (0.86)
Hospital
0.45 (0.10)
0.48 (0.11)
0.22 (0.05)
0.25 (0.06)
0.12 (0.04)
random
effects, 𝜏 (SE)
ICCc
12.0%
12.7%
6.4%
7.1%
3.5%
C-statistic
0.62
0.81
0.62
0.81
0.81
d
AIC
50326.46
42570.91
50301.07
42548.15
-d
BIC
50330.61
42670.58
50315.61
42658.19
-a Level 1 fixed effects are patient level fixed effects including all demographic and clinical
characteristics. Level-2 fixed effects are hospital characteristics .
b Cancer only model included only individuals with cancer and the individual sites of cancer
(Table 4). Fit statistics are not included since it was not compared to other models.
c Intraclass correlation coefficient: The proportion of the model variance explained by the
“hospital” parameter; e.g. 12.0% of the Model 1 variance is explained by the hospital where
a person is discharged. Calculated by 𝜏/ 𝜏+3.29 for a binary logit model. All ICC values
between hospitals were significant at p<0.001.
d Akaike information criterion and Bayesian information criterion fit statistics for
comparison between models. Each measures the model fit but penalizes for additional
parameters added to each model. Smaller values are preferred; thus, the full model is
preferred over Model 1.
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Table 2.3: Hierarchical logistic regression results of patient characteristics
associated with use of vena cava filters
Variable
aOR
95% CI
Age
21-25
Ref.
Ref.
Ref.
26-30
1.12
0.80
1.56
31-35
1.14
0.82
1.57
36-40
1.25
0.92
1.70
41-45
1.25
0.93
1.69
46-50
1.38
1.04
1.84
51-55
1.55
1.17
2.06
56-60
1.57
1.19
2.08
61-65
1.74
1.32
2.30
66-70
2.00
1.51
2.65
71-75
1.99
1.50
2.64
76-80
2.11
1.59
2.79
81+
2.18
1.65
2.88
Gender
Female
Ref.
Ref.
Ref.
Male
1.05
1.00
1.10
Race
White
Ref.
Ref.
Ref.
Black
0.83
0.75
0.92
Other
1.13
0.95
1.35
Insurance
Other/self-pay
Ref.
Ref.
Ref.
Medicaid
1.01
0.85
1.19
Medicare
1.05
0.96
1.15
Commercial
1.25
1.15
1.36
Clot type
DVT only
Ref.
Ref.
Ref.
PE only
3.84
3.46
4.25
PE with DVT
2.73
2.57
2.90
Comorbidities
Cancer
1.27
1.18
1.38
Metastatic cancer
1.28
1.16
1.41
Heart failure
1.01
0.94
1.08
Liver disease
1.23
1.09
1.38
Renal disease
0.94
0.88
1.00
Diabetes
1.03
0.97
1.09
Stroke
1.53
1.40
1.67
Hypertension
1.02
0.96
1.08
Hyperlipidemia
0.95
0.90
1.00
Atrial Fibrillation
1.24
1.15
1.33
Cellulitis
0.78
0.70
0.87
COPD
1.03
0.98
1.09
Sepsis/Septic shock
1.00
0.90
1.10
Infection/Pneumonia
1.03
0.97
1.10
34

Table 2.3: Hierarchical logistic regression results of patient characteristics
associated with use of vena cava filters
Anemia
1.58
1.50
1.67
Myocardial infarction
0.99
0.91
1.08
Trauma
1.62
1.46
1.81
Thrombolytic therapy
2.32
2.06
2.61
Embolectomy
1.51
1.11
2.05
Unstable/ventilator
1.37
1.21
1.55
Proximal DVT
1.54
1.45
1.63
Lower DVT
6.49
5.92
7.11
Bleeding
2.72
2.51
2.94
Surgery
1.84
1.72
1.96
Discharged
Deceased
0.63
0.56
0.70
Transfer
0.89
0.74
1.06
Metropolitan status Rural
Ref.
Ref.
Ref.
Urban
0.87
0.62
1.23
Teaching status
Non-teaching
Ref.
Ref.
Ref.
Teaching
1.46
1.04
2.06
Bed size
≤75 beds
Ref.
Ref.
Ref.
76-135 beds
1.41
0.85
2.32
136-275 beds
2.41
1.48
3.91
≥276 beds
3.06
1.77
5.29
Abbreviations: aOR=adjusted odds ratio; CI=confidence interval; VCF=vena cava
filter; DVT=deep vein thrombosis; PE=pulmonary embolism; COPD=chronic
obstructive pulmonary disease
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Table 2.4: Association between vena cava filter use and cancer site (N=13,104)
Cancer site
Total N
% Using
aORa
95% CI
VCF
Oral
146
8.2%
0.67
0.35
1.30
Skin
180
13.9%
1.06
0.66
1.73
Bone/soft tissue
167
11.4%
0.90
0.52
1.56
Stomach/small intestine
313
16.3%
1.17
0.80
1.70
Colorectal
1,392
16.2%
1.25
0.99
1.57
Liver
217
9.2%
0.85
0.50
1.45
Pancreas
796
11.2%
0.76
0.57
1.03
Lung/larynx/pleura
3,931
11.4%
1.02
0.83
1.25
Breast
776
7.6%
0.65
0.47
0.91
Uterus
312
15.1%
1.02
0.69
1.49
Cervix
165
17.0%
1.37
0.84
2.22
Ovarian
468
14.7%
1.13
0.81
1.58
Prostate
613
14.2%
0.98
0.72
1.32
Testicular
61
13.1%
1.62
0.66
3.95
Bladder
360
15.6%
1.12
0.79
1.58
Kidney
476
11.3%
1.09
0.76
1.55
Brain
308
24.4%
2.31
1.65
3.23
Thyroid
44
18.2%
1.22
0.46
3.24
Myeloma
378
12.2%
0.96
0.66
1.39
Leukemia
766
7.0%
0.64
0.46
0.90
Lymphoma
293
7.2%
0.76
0.46
1.26
Endocrine
121
14.0%
0.92
0.31
2.75
Metastatic
7,046
13.6%
1.13
1.00
1.29
aCancer-specific regression model included all covariates from the primary model.
Results for those variables were not meaningfully different and are excluded here
for brevity.
Abbreviations: aOR=adjusted odds ratio; CI=confidence interval; VCF=vena cava
filter
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Appendix Table 2.1: Coding algorithm for conditions and procedures
Disease/procedures
Code type
Codes
Inferior vena cava filter
ICD-9-CM Procedure
38.7
Pulmonary embolism
ICD-9-CM Diagnosis
415.1x
Deep vein thrombosis
ICD-9-CM Diagnosis
451.xx, 453.xx
Unstable
ICD-9-CM Diagnosis
785.5, V46.1
Cancer
ICD-9-CM Diagnosis
140.xx-195.xx, 200.xx208.xx
Metastatic cancer
ICD-9-CM Diagnosis
196.xx-199.xx, 209.71,
209.74, 511.81, 789.51
Heart failure
ICD-9-CM Diagnosis
398.91, 402.01, 402.11,
402.91, 404.01, 404.03,
404.11, 404.13, 404.91,
404.93
Liver disease
ICD-9-CM Diagnosis
570.xx-573.xx
Diabetes
ICD-9-CM Diagnosis
250.xx
Renal disease
ICD-9-CM Diagnosis
403.01, 403.11, 403.91,
404.02, 404.03, 404.12,
404.13, 404.92, 404.93,
580.xx-588.xx, V42.0,
V45.1, V56.x
Cerebrovascular disease
ICD-9-CM Diagnosis
362.34, 430.xx-438.xx
Hypertension
ICD-9-CM Diagnosis
401.xx-405.xx
Hyperlipidemia
ICD-9-CM Diagnosis
272.xx
Atrial fibrillation
ICD-9-CM Diagnosis
427.31
Cellulitis
ICD-9-CM Diagnosis
626.xx
Chronic obstructive
ICD-9-CM Diagnosis
416.8, 416.9, 490.xxpulmonary disease
505.xx, 506.4, 508.1,
508.8
Sepsis/septic shock
ICD-9-CM Diagnosis
038.x, 995.91, 785.52
Infection/pneumonia
ICD-9-CM Diagnosis
001.x-139.x, 480.xx488.xx
Anemia
ICD-9-CM Diagnosis
280.xx-285.xx
Myocardial infarction
ICD-9-CM Diagnosis
410.xx, 412.xx
Trauma
ICD-9-CM Diagnosis
800.xx-829.xx, 850.xx854.xx, 860.xx-897.xx,
925.xx-929.xx, 940.xx957.xx
Bleeding
ICD-9-CM Diagnosis
430.xx, 431.xx, 456.0,
456.20, 530.82, 531.xx534.xx, 578.1, 530.7,
569.3, 578.0, 578.9,
V12.71
Thrombolysis
ICD-9-CM Procedure
99.10
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Appendix Table 2.1: Coding algorithm for conditions and procedures
Embolectomy
ICD-9-CM Procedure
38.00, 38.05, 38.07, 38.09,
38.08
Surgery
ICD-9-CM Procedure
Surgery Flag definition
for invasive surgeries16
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Study 2.2: Variation in the Use of Vena Cava Filters for Venous
Thromboembolism in Hospitals in Kentucky

Introduction

Use of vena cava filters (VCFs) has increased over the last decade without clear
indication in many patients. 64,65 This increase in use has been suggested to be
partially motivated by upcoding for increased reimbursement, given that placement
of a VCF increases the reimbursement rate for venous thromboembolism by 250%.
65

Wide variation in VCF utilization between institutions has been observed. 37 This
variation may be influenced by many factors including the case-mix of patients, as
well as institutional-level factors and physician preferences. 37 We analyzed the
relationship of VCF use for venous thromboembolism (VTE) with institutional-level
factors and patient variables to determine whether differences can be explained by
observable factors rather than potential reimbursement upcoding.
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Methods

We used Kentucky inpatient discharge data from all acute care hospitals during
2008-2014. These data represent all discharges in the state and include up to
twenty-five diagnosis and procedure fields as well as hospital variables.

Diagnoses for deep vein thrombosis (DVT) or pulmonary embolism (PE) were
identified. 50 VCF use was identified by ICD-9-CM procedure code 38.7. Prophylactic
VCF use without DVT or PE was excluded. Institution-level factors included bed size,
teaching/non-teaching status, and urban status. Case-mix comorbidities included
cancer, chronic obstructive pulmonary disease (COPD), cerebrovascular disease,
atrial fibrillation, liver disease, hypertension, heart failure, hyperlipidemia,
myocardial infarction, cellulitis, trauma, diabetes, infection, renal disease, bleeding,
anemia, and sepsis/septic shock based on previously published coding algorithms.
37,52,64

Case-mix variables were entered into the model as the proportion of patients

with each condition at each hospital. The ratio of VTE events attributable to PEs
versus DVTS at each hospital was included given that VCF use is more commonly
used with PE. The proportion of patients dying or transferring and the percent
receiving surgery, thrombolysis, or embolectomy was also included. 53

A final linear model included the percent VCF utilization as the dependent variable
and controlled for all covariates. Model assumptions were inspected including plots
of the predicted values and the fitted model residuals. VCF use was plotted by year
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and the overall trend from 2008 to 2014 was evaluated. All analyses were
conducted using JMP Pro 12 (SAS Institute, Cary, NC). The University of Kentucky
Institutional Review Board approved of this study.

Results

Seventy hospitals were included in the analysis including 84,357 VTE-related
discharges with 7,337 (8.7%) receiving VCFs. Overall use was 10% in 2008 and
decreased to 7.5% by 2014 (p<0.001 for all trends; Figure 2.1). Hospital use ranged
from 0% up to 15.2% with mean utilization of 6.1% (standard deviation 4.4%,
median 6.7%, coefficient of variation 0.73). The variation between institutions was
consistent throughout the time period. In adjusted analysis, VCF use was most
strongly associated with case-mix, mainly the PE-to-DVT ratio. Other case-mix
variables associated with increased VCF use were atrial fibrillation and cancer
(Table 2.5). The model fit the data well, with R2=0.97 and normally distributed
residuals (Figure 2.2). Restricting the sample to hospitals with at least 50 PE/DVT
discharges, similar results were observed with R 2=0.99. Table 2.6 compares patients
at the University of Kentucky hospital, which had the highest overall utilization of
VCFs at 15.2%. Overall, patients at the University of Kentucky hospital are worse off
based on the comorbidities measured, which makes the utilization lay on the curve
of the expected utilization produced by the model.
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Discussion

These results showed a wide distribution in the utilization of VCF for VTE in
Kentucky that is explained almost completely by patient case-mix and institutional
characteristics. Lack of residual variation between institutions after controlling for
these variables suggests that there may not be substantive overuse of VCFs to
increase reimbursement. However, there may still be a systematic overuse of VCFs
given conflicting guidelines and lack of apparent indications for many patients in a
prior study. 64 Additional work is needed to determine whether the rate of VCF use
is appropriate.

Acknowledgements
Data were collected by the Kentucky Cabinet for Health and Family Services (KHA
HCUP), Office of Health Policy and provided by the University of Kentucky Center for
Clinical and Translational Science Enterprise Data Trust. The project described was
supported by the National Center for Advancing Translational Sciences, National
Institutes of Health, through grant number UL1TR000117. The content is solely the
responsibility of the authors and does not necessarily represent the official views of
the NIH.

42

Figure 2.1: Trend in vena cava filter (VCF) use during 2008-2014. Tests for
trend showed a 25% decrease in overall use (p<0.001), 33% decrease (p<0.001) for
pulmonary embolism (PE) alone and with deep vein thrombosis (DVT), and a 19%
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(p<0.001) decrease for DVT alone.

Figure 2.2: Actual versus predicted VCF utilization of the full model. The
goodness of fit for the model produced R2=0.97, showing a very strong fit to the
data. Full model included all case-mix variables to control for differences in patient
population between institutions. Red lines are the best-fit regression line and the
95% significance limits of the fitted model. Blue horizontal line represents the
predicted mean from the model.
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Table 2.5: Scaled regression estimates of covariates predicting percent of
PE/DVT patients receiving inferior vena cava filter
Regression Term

Scaled

p-value

Estimatea

Lower

Upper

95%

95%

Intercept

6.29

<. 0001

5.87

6.71

PE-to-DVT ratio

7.96

<. 0001

6.61

9.30

Embolectomy

2.80

0.001

1.22

4.37

Cancer

3.83

0.003

1.36

6.31

Thrombolysis

-2.17

0.007

-3.70

-0.64

Trauma

-2.00

0.032

-3.82

-0.18

COPD

-1.75

0.043

-3.44

-0.06

Bed size 76-135

-0.73

0.046

-1.44

-0.01

Atrial fibrillation

1.28

0.048

0.12

2.69

Bed size ≥276

1.08

0.050

-0.07

2.24

Cerebrovascular disease

0.97

0.075

-0.10

2.05

Metropolitan area

-0.51

0.077

-1.08

0.06

Proximal DVT

-2.21

0.095

-4.83

0.41

Liver disease

-0.73

0.326

-2.21

0.75

Cellulitis

0.69

0.399

-0.94

2.31

Renal disease

0.69

0.412

-1.00

2.39

Rural area

0.34

0.415

-0.49

1.16

Diabetes

0.47

0.450

-0.78

1.72

Infection

0.56

0.479

-1.03

2.15

Surgery

-0.89

0.483

-3.43

1.65

Heart failure

0.36

0.529

-0.79

1.51

Micropolitan area

0.17

0.564

-0.44

0.79

Bed size ≤75

-0.27

0.600

-1.29

0.75

Transfer rate

0.40

0.603

-1.15

1.96

Hypertension

0.69

0.648

-2.35

3.73
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Table 2.5: Scaled regression estimates of covariates predicting percent of
PE/DVT patients receiving inferior vena cava filter
Myocardial infarction

-0.26

0.651

-1.44

0.91

Death

-0.24

0.666

-1.36

0.88

Unstable

0.35

0.759

-1.95

2.65

Bed size 136-275

-0.09

0.789

-0.75

0.58

Sepsis/septic shock

-0.24

0.794

-2.08

1.60

Concurrent bleeding

-0.12

0.827

-1.27

1.02

Non-teaching

-0.07

0.835

-0.69

0.56

Teaching

0.07

0.835

-0.56

0.69

Metastatic cancer

-0.16

0.909

-2.95

2.63

Hyperlipidemia

-0.09

0.924

-2.05

1.86

Anemia

-0.01

0.990

-1.50

1.48

aNominal

variables are expanded to each category. Continuous variables are centered on the

mean and scaled by the range/2. Estimates are ordered by significance in the model.
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Table 2.6: Comparison of University of Kentucky hospital patients with
patients in similar size hospitals by vena cava filter utilization and case-mix
comorbidities
Characteristic
UKHC
Lexington
Lexington
Louisville
Paducah
hospital

hospital

teaching

hospital

hospital
VCF utilization
Bed size

15.2%

13.0%

12.1%

7.8%

5.5%

462

344

347

285

323

Patient case-mix
Cancer

26.4%

14.4%

16.1%

13.8%

13.3%

Metastatic

13.8%

8.4%

10.9%

7.4%

5.5%

Heart failure

17.6%

17.5%

18.6%

21.4%

12.3%

Liver disease

8.9%

4.3%

4.3%

4.2%

1.3%

Renal disease

37.4%

31.3%

24.7%

29.5%

12.3%

Diabetes

24.0%

27.5%

27.6%

30.8%

20.5%

Stroke

9.7%

7.0%

8.0%

7.1%

2.7%

Hypertension

54.1%

58.9%

65.4%

66.5%

45.2%

Hyperlipidemia

22.9%

30.3%

42.9%

40.3%

12.1%

Atrial

13.1%

19.1%

18.2%

17.7%

9.3%

Cellulitis

6.9%

9.0%

7.2%

9.7%

7.8%

COPD

24.5%

28.5%

33.1%

36.4%

24.3%

Sepsis

19.0%

12.2%

7.4%

11.8%

2.3%

Infection

45.1%

34.7%

32.7%

32.8%

16.1%

Anemia

40.7%

34.6%

39.0%

35.8%

21.1%

Myocardial

13.3%

9.1%

9.9%

13.6%

2.7%

11.2%

3.0%

2.9%

3.8%

2.5%

Thrombolysis

3.7%

8.7%

4.5%

2.6%

0.4%

Embolectomy

1.3%

0.7%

0.4%

0.3%

0.2%

fibrillation

infarction
Trauma
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Table 2.6: Comparison of University of Kentucky hospital patients with
patients in similar size hospitals by vena cava filter utilization and case-mix
comorbidities
Unstable
14.4%
5.7%
5.7%
3.4%
1.1%
Bleed

10.7%

6.8%

7.8%

7.0%

5.1%

Deceased on

9.4%

6.0%

6.5%

4.9%

3.8%

discharge
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CHAPTER 3: VENA CAVA FILTER RETRIEVAL RATES AND FACTORS
ASSOCIATED WITH RETRIEVAL IN A NATIONAL COHORT

Abstract

Introduction
Retrieval of inferior vena cava filters (IVCFs) is important for the safety of these
devices as complications increase with longer dwell times. This study sought to
assess retrieval rates and patient demographic and clinical factors associated with
retrieval in a national cohort.

Methods
Patients receiving IVCFs were identified by procedural codes from the Truven
MarketScan administrative claims database. The indication for placement was
identified as pulmonary embolism (PE) with or without deep vein thrombosis
(DVT), DVT only, or prophylactic. Patient demographic and clinical characteristics
were included in proportional hazard regression models to find associations with
early (90-day) and one-year retrieval.
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Results
Of 54,766 patients receiving an IVCF, 36.9% had PE, 43.9% had DVT only, and
19.2% had no apparent VTE present. Over the one-year of follow-up, the cumulative
incidence of IVCF retrieval was 18.4%, which differed based on indication, age, and
several other key patient factors. Retrieval increased over time from a low of 14.0%
in 2010 up to approximately 24% in 2014. In adjusted time-to-event models,
increasing age, differing regions, and comorbidities associated with hyper- (e.g.
prior stroke) or hypocoagulable (e.g. prior bleeding) states were associated with
poorer retrieval. Those with and without retrieval, and those with early (≤90 day)
and late (≥120 day) retrieval, did not differ in healthcare utilization of outpatient or
inpatient visits prior to retrieval. Initiation of anticoagulation was poorly correlated
with retrieval, with anticoagulation preceding retrieval by a median of 51 days and
those without retrieval had a median of 278 days of exposure to anticoagulation.

Conclusions
IVCF retrieval has increase over time but remains suboptimal with only 1-in-5 being
retrieved within one year. Improving retrieval rates can improve patient outcomes,
prevent time-dependent complication rates, and improve clinic revenue with
patient follow-up. Retrieval should be a priority for quality improvement initiatives
at the institutional and national level.
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Introduction

Inferior vena cava filters (IVCFs) are used to mechanically prevent thrombi in the
lower extremities from migrating to the pulmonary circulation. Generally, IVCFs are
reserved for patients who have absolute or relative contraindications to systemic
anticoagulation who are at a high risk of recurrent venous thromboembolism (VTE).
45-47

With the advent of retrievable IVCFs (rIVCFs), there has been a marked

increase in overall use, especially in trauma and surgery patients. 5,6 The intuition
behind retrievable devices calls for removal once the contraindications have
subsided and patients can be initiated on anticoagulation.

In real-world settings, retrieval rates of rIVCFs are low, with reports ranging from
10-50% within individual institutions, with an estimated average near 30%. 28,66
Poor retrieval rates correspond to an increase in reported adverse events, as these
temporary devices become de facto permanent. 28 Complications associated with
VCFs include increased risk of deep vein thrombosis (DVT), inferior vena cava (IVC)
thrombosis, IVC penetration, IVCF fracture, and IVCF embolization. 28,31,67,68 Given
these trends, the U.S. Food and Drug Administration (FDA) has issued several safety
communications highlighting the need to remove IVCFs once the risk of pulmonary
embolism (PE) has subsided and anticoagulation is no longer contraindicated. 30

Little is known regarding IVCF retrieval on a national scale given most studies have
been conducted at single institutions. 31 Given the continued growth in IVCF use and
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the variation that has been observed between institutions, 37,48,69-71 assessments of
factors that drive retrieval rates on a national scale is needed to aid clinical decisionmaking. 72 This study utilized a large national database to assess IVCF retrieval and
patient factors related to retrieval as well as differences in healthcare utilization.
Further, we assessed the relationship between time to retrieval and time to
initiation of anticoagulant therapy.

Methods

Data source
This observational cohort study utilized the Truven Health Analytics MarketScan
database. The MarketScan data are administrative healthcare claims data including
medical diagnostic and procedural information and pharmacy fill records. The data
include information for roughly 40 million unique individuals per year and is
generally representative of those with commercial insurance and Medicare
supplemental coverage. The University of Kentucky Institutional Review Board
approved use of the data.

Cohort identification
All patients during the years 2010-2014 who had a IVCF placed were identified and
assigned an index based using Current Procedural Terminology (CPT: 37191, 37620,
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35940) and International Classification of Diseases, 9th revision (ICD-9: 38.7)
procedural codes. The indication for VCF was identified by ICD-9 diagnosis codes as
PE (415.1x) with or without DVT, DVT only (451.xx or 453.xx), or no apparent VTE
(prophylactic). 50 For inclusion, patients were required to be 18 years or older and
have a minimum of 6 months of pre-index time prior to IVCF placement.

Cohort characteristics
Demographic variables included age, sex, geographic region, and residence status.
Age was divided into 18-34, 35-44, 45-54, 55-64, 65-74, and 75 and older categories.
Geographic region included U.S. census regions (Northeast, North Central, South,
West, and unknown) and residence status was divided into urban or rural based on
metropolitan statistical area classifications. Patients’ insurance status was classified
as commercial or Medicare and whether or not they were enrolled in a fully or
partially capitated insurance plan and if they had a primary care provider (PCP)
assigned.

Certain concurrent conditions and procedures present during IVCF implantation
were recorded. Concurrent bleeding, unstable condition, sepsis or septic shock,
infection, anemia, trauma, and pregnancy were all recorded using ICD-9 diagnosis
codes. 15,37 Patients receiving thrombolytic therapy, embolectomy procedures, or
major surgery were identified using a combination of procedural codes. 53 Patients
who died during the hospitalization during which the IVCF was placed were also
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noted. Comorbid conditions observed in the pre-index period consisted of Charlson
comorbidities and a summed Charlson Comorbidity Index (CCI).

52,73

Outcome events
The primary outcome was IVCF retrieval identified by CPT (37193, 37203) and ICD9 (38.7) procedure codes. Given the ICD-9 procedure code for placement and
retrieval is the same, retrievals for those patients only having the ICD-9 procedure
code present had to be on separate days to record a retrieval. However, since CPT
codes and not ICD-9 codes are used for billing purposes, patients lacking the CPT
codes were the exception with >95% of all patients having CPT codes recorded.
Patients were followed forward from the index date (IVCF placement) until the IVCF
was retrieved, they died, they were lost to follow-up, or the end of the study period.
The 30, 60, 90, 180-day and one-year cumulative incidence of IVCF retrieval was
estimated using Fine and Gray’s method, accounting for death as a competing risk. 74
Time to IVCF retrieval was also reported.

Time to anticoagulation initiation
Anticoagulation initiation was assessed as the first filled prescription for an
injectable (dalteparin, enoxaparin, tinzaparin, fondaparinux) or oral (warfarin,
dabigatran, rivaroxaban, apixaban) anticoagulant. Time to anticoagulation and was
compared with the time to retrieval and described for those who did not have
retrieval during follow-up. Time for both events was calculated based on the date of
discharge from a hospitalization, if the IVCF was placed during hospitalization, or
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the day of IVCF placement if it was placed in an outpatient setting, given that
prescription medications would not be observed during a hospitalization.

Survival analysis
To identify factors associated with IVCF retrieval, we developed a Cox proportional
hazards regression model including patient demographic and clinical characteristics
typically associated with either VTE, bleed risk, or IVCF use. Additionally, measures
of comorbidity were included to scale individual’s overall health.

The

proportionality assumption for all variables was evaluated for using Schoenfeld
residuals as well as using time as an interaction term for each variable. Both
methods showed that this assumption held true. Due to collinearity with age,
insurance status of commercial or Medicare was excluded in the model. Two models
were estimated predicting 90-day and one-year retrieval. Patients who had not had
retrieval or had not died at the end of the 90-day or 365-day period were censored.
Cause-specific hazard ratios (HR) and their 95% confidence intervals (CI) were
estimated for the effect of each covariate on the retrieval rate with HR<1 indicating
lower retrieval and HR>1 indicating higher retrieval.

Case-control analysis
To understand if there are differences in recurrent events, complications, and
healthcare utilization during the post-implantation period, two post hoc nested casecontrol analyses were performed. Non-cancer patients who had a retrieval event
were matched with up to three non-cancer controls who did not have a retrieval.
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Likewise, patients who had retrieval within 90 days post-implantation (“early
retrieval”) were matched 1:1 (due to sample size) with controls who had retrieval
≥120 days post-implantation (“late retrieval”). Pairs were matched on variables
found significant in the survival analysis as well as factors related to higher
healthcare utilization including age, region, residence status, CCI score, and year of
IVCF placement. Incidence density sampling without replacement was used for
matching, allowing for controls who had at overlapping follow-up periods with
cases. Controls were given the same length of time between IVCF placement as their
respective cases to provide a consistent look-back period. Conditional logistic
regression was used to assess the association between retrieval and non-retrieval as
well as early versus late retrieval with complications (DVT, PE) and healthcare
utilization (anticoagulation use, emergency room [ER] visits, hospitalizations, and
outpatient visits) in the look-back period. VTEs coded on outpatient visits are
assumed to be for the management of the initial VTE event while hospitalizations
and emergency visits with VTEs as the primary diagnosis were assumed to be new
VTE events, thus considered to be complications. For outpatient visits, the reference
group was considered to be those who had less than the median number of visits
compared to those who had equal or more median visits. For hospitalizations and
emergency visits, those with none were used as the reference group for those with
one and those with two or more. Utilization for IVC thrombosis and IVC injury were
excluded due to low occurrence in the cohort. All analyses were conducted using
SAS Enterprise Guide version 7.1 (Cary, NC).
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Results

Patient characteristics
During 2010-2014, 54,766 patients received an IVCF and met the eligibility
requirements to be included in the study. Of these, 36.9% presented with a PE,
43.9% with DVT alone, and 19.2% had no apparent VTE present (Table 3.1). The
mean (standard deviation, SD) age of the cohort was 65 (16), 51% were female,
geographically diverse with nearly 85% residing in urban areas. Insurance details
included 13.9% of the cohort having a PCP and 8.6% having insurance with full or
partial capitated payments. A total of 1,628 (3.0%) of the cohort died during the
initial hospitalization and were not included in subsequent analyses.

Concurrent with IVCF placement, 9.1% had active bleeding, 10.5% had trauma,
1.6% were unstable, nearly 17% had active infections, and nearly 19% had anemia
(Table 3.1). Roughly one of every four patients had a major surgical procedure
performed during the same hospitalization the IVCF was placed. The most common
comorbid conditions in the cohort were hypertension (56.5%), hyperlipidemia
(33.2%), cancer (30.4%), diabetes (24.9%), and chronic obstructive pulmonary
disease (COPD, 23.6%).

Overall, 14.3% (N=7,619) of the cohort who survived the index hospitalization had
the IVCF retrieved within one-year and 8% (N=4,228) died (Table 3.2). For those
who had retrieval, the mean (SD) time-to-retrieval was 93 (78) days, with a median
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of 71 days and interquartile range (IQR) of 35-130 days. Those with PE had the
highest mean and median times-to-retrieval (101 and 81 days) compared to those
with DVT only (91 and 68 days) and compared to those with no VTE (83 and 61
days).

Figure 3.1 shows the cumulative incidence of IVCF retrieval by the index indication
and Table 3.3 shows the cumulative incidence for selected variables. At one-year,
retrieval was highest for those with no VTE on index, reaching nearly 25% (23.9%25.8%). Retrieval increased with each year of study, going from 14.0% (13.3%14.7%) in 2010 up to 38.2% (19.4%-57.0%, skewed by low follow-up time) in 2014
(P <0.001). Differences in retrieval between age groups were significant with
younger age groups having higher retrieval. For example, those aged 18-34 had oneyear retrieval of 42.8% (40.4%-45.2%) while retrieval in those 75 and older was
just 5.4% (5.0%-5.8%, P <0.001). Likewise, those without cancer had higher
retrieval compared to those with cancer (20.8% vs. 11.7%, P <0.001). Those with
commercial insurance had much higher retrieval compared to those with Medicare.
However, this effect was associated with age distribution between these two
insurance groups, i.e. 98% of the Medicare insured were ≥65 years of age.
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Factors related to retrieval
In fully adjusted analyses (Table 3.4), age remained significantly associated with
IVCF retrieval at both 90-days and 365-days of follow-up, although the association
was much stronger for the one-year model. Patients with no VTE were more likely
to have retrieval compared to those with DVT only, and there was no difference in
retrieval between those with PE compared to those with DVT. Geographic region
was also significant, with those residing in the North Central (90-days and one-year)
and West (one-year only) regions being more likely to have retrieval compared to
those in the Northeast. Likewise, urban residence was associated with slightly
higher retrieval compared to rural residence (90-days and one-year). At one-year,
capitated payment insurance types were associated with lower retrieval.

Among concurrent conditions, infection and anemia were associated with lower
retrieval at 90 days and one year while pregnancy was associated with higher
retrieval at one-year of follow-up. Other comorbid conditions associated with lower
one-year retrieval included myocardial infarction, congestive heart failure,
peripheral vascular disease, dementia, COPD, severe liver disease, paralysis, cancer,
stroke, hypertension, and coronary heart disease.

Year of filter placement was modeled both as a covariate as well as used to stratify
the analysis. In stratified analysis, no differences were observed between the
covariates and their association with IVCF retrieval compared to the base model
with year as a covariate. As a covariate, each year of IVCF placement was associated
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with increased 90-day and one-year retrieval compared to year 2010. For the final
year 2014, this corresponded to nearly a two-fold difference in retrieval rate
compared to 2010 (HR=1.90, 95% CI 1.76-2.06).

Time to anticoagulation
During follow-up, the dataset had follow-up prescription information for 37,272
persons in the cohort. Among these, 23,510 (63.1%) initiated anticoagulation with
median time to anticoagulation initiation of 17 (IQR 6-50) days. Initiation of
anticoagulation differed significantly for those who eventually had retrieval (median
11, IQR 5-31 days) and those that did not have retrieval (median 17, IQR 6-50 days,
p<0.001). Overall, time to anticoagulation and time to retrieval were poorly
correlated, with anticoagulation preceding retrieval by a median of 51 (IQR 13-110)
days. Figure 3.2 shows the correlation between the time to anticoagulation and the
time to retrieval after hospitalization. As observed, anticoagulation occurs much
earlier than retrieval (black line shows best fit of data). The red line shows the ideal
best fit line assuming that anticoagulation would be started 4 weeks prior to
retrieval so that anticoagulation can reach therapeutic levels and/or dissolution of
any clots present in the IVCF. The area between the black and red lines represents
excess exposure to IVCF indwell time beyond need, effectively exposing the
individual to complications of IVCFs for a longer period. Those who were treated
with anticoagulation had marginally longer time to retrieval than those who did not
initiate anticoagulation. For those who never had retrieval, there was a median of
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278 (IQR 98-350) days of anticoagulation treatment during the one-year follow-up
period.

Healthcare utilization
Healthcare utilization in the time period between placement and retrieval was
compared for those with retrieval versus those without and between those with an
early retrieval (≤90 days) and late retrieval (≥120 days). Total and VTE-related
outpatient visits for those with retrieval were significantly higher than those
without (Table 3.5). Meanwhile, inpatient and emergency visits were more similar
between groups. Outpatient, inpatient, and emergency visits were more similar
between early and late retrieval groups (Table 3.5). In adjusted analyses, having
more than the median number of total outpatient or VTE-related outpatient visits
was associated with over twice the odds of having a retrieval versus not (Table 3.6).
Having ≥2 hospitalizations, VTE-related and overall, was also associated with higher
odds of retrieval. For early compared to late retrieval, having ≥2 hospitalizations of
any kind was significantly associated with more early retrieval compared to late
retrieval.

Discussion

The increased utilization of IVCFs corresponded with new technology allowing for
retrieval of these devices once the indication for placement has abated. This has led
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to nearly 10% of all VTE events being treated with IVCF placement for secondary
prevention and increased IVCF utilization for prophylactic indications. Safety
studies and the one randomized trial of retrievable IVCFs have shown these devices
to be generally safe with retrieval being completed within a short period after
implantation. In PREPIC2, the only randomized trial for rIVCFs, the retrieval rate
was >90% with a dedicated 3-month follow-up visit. 10 However, in real-world
practice, estimates of the retrieval rates range much lower with an average of about
one-third of all IVCFs eventually being retrieved. 28

Eventual retrieval of IVCFs improves the safety profile of these devices as the
incidence for complications generally increases with increasing indwell times.
Patients with IVCFs are at risk for complications including IVC thrombosis, device
fracture, device migration, and DVT – risks persisting as long as the IVCF remains in
place. One study by Morales et al. evaluated the net clinical benefit of IVCFs taking
into account the known reduction in the risk of PE along with the increased
incidence of complications. This study found that there is an optimal net clinical
benefit if an IVCF is retrieved within 29-54 days after placement in prophylactic
indications. This estimate remained in favor of IVCF up to 180 days postimplantation, but data regarding complication rates beyond this time period are
scarce, and does not address the net clinical benefit in patients with active VTE. This
article was also referenced in a U.S. Food and Drug Administration (FDA) safety
communication, which responded to multiple reports of complications with IVCFs
and increasing publicity through litigation and media. The safety communication
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also detailed ongoing safety data collection through clinical studies and postmarketing surveillance.

The current analysis is consistent with other reports regarding IVCF retrieval, with
an overall retrieval of nearly 20% within 1-year. Considering that approximately
10% of all IVCFs placed are permanent devices, the effective retrieval rate was
nearer 22%. Encouragingly, the retrieval rate has increased over time, from roughly
every one out of every seven filters being retrieved in 2010 up to one out of every
four retrieved in 2014 (extrapolated due to limited follow-up in 2014). This effect is
explained by the increased attention IVCFs received over this time period including
FDA safety alerts, as well as guideline updates which called for more conservative
use of IVCFs. For those who did have their IVCF retrieved in our study, time to
retrieval was within an acceptable range with mean and median times of 93 and 71
days

post-implantation.

However,

retrieval

was

poorly

correlated

with

anticoagulation initiation – an indicator that the IVCF is no longer indicated in that
patient and should be removed as soon as possible.

Several patient-related factors were also associated with retrieval including
demographic and clinical characteristics. Most notably, increasing age of the patient
was associated with lower retrieval, likely contributed to perceived ongoing risk of
PE or a desire to not treat older individuals with anticoagulation. Region of
residence was also strongly associated with retrieval, which may indicate regional
practice differences as well as differences in patient demography. Patients living in
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an urban setting were more likely to have their filter retrieved as well, suggesting
that patients being referred to a distant medical center for IVCF placement may have
limited follow-up for retrieval. Among patient comorbidities, those considered prothrombotic (cancer, stroke, hyperlipidemia, MI) and related to bleeding (liver
disease) were associated with lower retrieval. These disease states are intuitively
associated with lower retrieval in that they reference underlying diseases which
have high clot risk or high bleed risk and are more permanent than other transient
contraindications to anticoagulation (e.g. surgery or trauma).

Other studies investigating factors associated with retrieval rates have focused on
poor patient follow-up as the primary reason IVCFs are not removed.

40,75,76

However, patient follow-up in itself can be a multi-faceted factor associated with
both institutional and patient related characteristics. To investigate this further in
our data, we matched those who had retrieval to those who did not and assessed
their healthcare utilization during follow-up, assuming that utilization of the
healthcare system is a surrogate for patient follow-up. We observed a significant,
but likely meaningless, difference in the number of outpatient visits overall and
VTE-related visits for those without retrieval. While this may indicate poorer patient
follow-up in the non-retrieval, the mean number of outpatient visits was 11.8 in the
non-retrieval group, with 75% of this group having at least 1 outpatient visit. In
comparing those with an early retrieval versus a late retrieval, we found that there
were not any differences in the number of follow-up visits between these groups.
Thus, opportunities exist to follow-up with patients regarding their IVCF, although it
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remains alarming that a quarter of patients have no follow-up recorded after
placement of an IVCF. Patient follow-up is generally left to the referring or primary
physician, with some studies showing improved retrieval if the responsibility of
follow-up is placed on the implanting physician instead. 40-42,75,76 Thus, it is likely not
a question of the amount of follow-up, but more who is following up with the
patient. This is supported further by the observation that patients who are
hospitalized with new VTE events are more likely to have retrieval, possibly due to
more specialists involved with their care (e.g. hematologists, etc.).

While there is inherent concern for patient safety associated with these low
retrieval rates, clinical practices are also financially incentivized to increase
retrieval of IVCFs. A study by d’Othée et al. showed that due to the increased cost
between retrievable and permanent devices, retrievable devices are only costeffective in interventional radiology clinics if at least 40% are eventually retrieved,
driven by separate billable procedure codes for implantation and retrieval. 77 Even
without the cost differential between permanent and retrievable devices, it is
inherent that clinic revenue will be increased with improved patient follow-up,
management, and retrieval. At least one study at a single institution evaluated the
financial feasibility of implementing a quality improvement initiative within their
clinical practice.
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They had a staggered intervention and compared baseline

retrieval rates to those achieved by issuing letters to patients and then to those
achieved with prospective follow-up of patients. Overall, their retrieval rates
increased from 8% to 40% with mailed letters and up to 52% with prospective
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follow-up. Moreover, the interventions increased the revenue to the clinic by over
$1,000 per IVCF placed via increased billing for retrieval and follow-up procedures.
Thus, although improving IVCF retrieval requires a paradigm shift in patient
management, retrieval will improve patient outcomes and provides financial
incentive to the clinic. Further, this study demonstrates that even a low cost
intervention such as mailing letters can have a large impact on retrieval rates,
potentially utilizing few resources compared to the marginal improvement
observed with more intensive follow-up.

Limitations
This study has limitations inherent to all studies utilizing administrative claims data.
79,80

Most notably, detailed clinical data are not available, including laboratory data,

tumor staging, etc. which may have impacted the study results. Further, detailed
information on the hospital or physician by whom the patient received care is not
available. Wide variation in the utilization of IVCFs has been shown in prior studies
and the general practice environment and physician practice patterns are likely to
vary. 37,70 Procedural codes were utilized to identify IVCF placement; however, these
codes are not specific to permanent or retrievable devices. As of 2006, retrievable
devices made up about 85% of the IVCF market, which likely increased to over 90%
since then. 22,25,81 Therefore, the retrieval estimates presented here are conservative.
While we only followed patient up to one-year, there was a strong plateauing of the
retrieval rate. With maximal follow-up, overall retrieval would have only reached
roughly 25% compared to the 20% observed.
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Conclusion

In this national study of IVCF retrieval, less than one out of every four filters was
retrieved within one-year. Retrieval rates differ based on patient characteristics but
increased over the study time period (2010-2014). Retrieval of IVCFs once clinically
indicated is required to optimize the net clinical benefit by removing the risk of
complications associated with these devices.
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Table 3.1: Demographic and clinical characteristics of patients receiving vena cava
filters by indication
All
Pulmonary
Deep Vein
No PE/DVT
Embolism

Thrombosis

N

%

N

%

N

%

N

%

54,766

100.0%

20,202

36.9%

24,060

43.9%

10,504

19.2%

Age Group
Mean (SD)

65 (16)

18-34

2,196

4.0%

728

3.6%

610

2.5%

858

8.2%

35-44

3,551

6.5%

1,347

6.7%

1,183

4.9%

1,021

9.7%

45-54

7,888

14.4%

3,337

16.5%

2,757

11.5%

1,794

17.1%

55-64

13,076

23.9%

5,530

27.4%

4,881

20.3%

2,665

25.4%

65-74

9,422

17.2%

3,452

17.1%

4,334

18.0%

1,636

15.6%

75 and older

17,846

32.6%

5,492

27.2%

10,038

41.7%

2,316

22.0%

64 (15)

69 (16)

60 (17)

Gender of Patient
Male

26,839

49.0%

10,217

50.6%

11,542

48.0%

5,080

48.4%

Female

27,927

51.0%

9,985

49.4%

12,518

52.0%

5,424

51.6%

Northeast

11,526

21.0%

4,154

20.6%

5,191

21.6%

2,181

20.8%

North Central

15,678

28.6%

5,752

28.5%

7,142

29.7%

2,784

26.5%

South

18,448

33.7%

6,666

33.0%

7,882

32.8%

3,900

37.1%

West

7,891

14.4%

3,158

15.6%

3,361

14.0%

1,372

13.1%

Unknown

1,223

2.2%

472

2.3%

484

2.0%

267

2.5%

Rural

8,496

15.5%

3,119

15.4%

3,381

14.1%

1,996

19.0%

Urban

46,270

84.5%

17,083

84.6%

20,679

85.9%

8,508

81.0%

Region

Residence

Concurrent conditions during hospitalization
Bleed

5,004

9.1%

1,418

7.0%

2,779

11.6%

807

7.7%

Unstable

870

1.6%

243

1.2%

464

1.9%

163

1.6%

2,351

4.3%

619

3.1%

1,360

5.7%

372

3.5%

condition
Sepsis
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Table 3.1: Demographic and clinical characteristics of patients receiving vena cava
filters by indication
All
Pulmonary
Deep Vein
No PE/DVT
Embolism

Thrombosis

N

%

N

%

N

%

N

%

Infection

9,202

16.8%

3,105

15.4%

4,680

19.5%

1,417

13.5%

Anemia

10,195

18.6%

3,193

15.8%

5,433

22.6%

1,569

14.9%

Trauma

5,777

10.5%

1,600

7.9%

3,027

12.6%

1,150

10.9%

Thrombolytic

841

1.5%

452

2.2%

316

1.3%

73

0.7%

367

0.7%

176

0.9%

149

0.6%

42

0.4%

Major surgery

13,371

24.4%

5,249

26.0%

5,836

24.3%

2,286

21.8%

Pregnant

441

0.8%

148

0.7%

221

0.9%

72

0.7%

Died during

1,628

3.0%

720

3.6%

461

1.9%

447

4.3%

therapy
Embolectomy
procedure

hospitalizatio
n
Comorbid conditions during pre-index look back
CCI score,

3.1 (3.3)

2.9 (3.3)

3.5 (3.4)

2.9 (3.3)

mean (SD)
History of

4,864

8.9%

1,522

7.5%

2,149

8.9%

1,193

11.4%

8,483

15.5%

2,587

12.8%

4,577

19.0%

1,319

12.6%

MI

3,254

5.9%

1,122

5.6%

1,623

6.7%

509

4.8%

CHF

8,464

15.5%

2,620

13.0%

4,514

18.8%

1,330

12.7%

PVD

7,450

13.6%

2,147

10.6%

4,030

16.7%

1,273

12.1%

Dementia

2,366

4.3%

621

3.1%

1,518

6.3%

227

2.2%

COPD

12,925

23.6%

4,872

24.1%

5,735

23.8%

2,318

22.1%

Rheumatism

2,286

4.2%

801

4.0%

1,087

4.5%

398

3.8%

PUD

1,593

2.9%

503

2.5%

829

3.4%

261

2.5%

Mild liver

4,344

7.9%

1,586

7.9%

1,958

8.1%

800

7.6%

VTE
History of
bleeding

disease
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Table 3.1: Demographic and clinical characteristics of patients receiving vena cava
filters by indication
All
Pulmonary
Deep Vein
No PE/DVT
Embolism

Thrombosis

N

%

N

%

N

%

N

%

549

1.0%

135

0.7%

315

1.3%

99

0.9%

Diabetes

13,623

24.9%

4,483

22.2%

6,322

26.3%

2,818

26.8%

Diabetes w/

3,663

6.7%

1,040

5.1%

1,853

7.7%

770

7.3%

Paralysis

2,244

4.1%

672

3.3%

1,228

5.1%

344

3.3%

Renal disease

6,684

12.2%

1,713

8.5%

3,836

15.9%

1,135

10.8%

Cancer

16,672

30.4%

6,251

30.9%

7,856

32.7%

2,565

24.4%

Metastatic

7,534

13.8%

3,013

14.9%

3,433

14.3%

1,088

10.4%

Stroke

9,744

17.8%

2,957

14.6%

5,240

21.8%

1,547

14.7%

Hypertension

30,918

56.5%

10,719

53.1%

14,541

60.4%

5,658

53.9%

CHD

11,125

20.3%

3,604

17.8%

5,597

23.3%

1,924

18.3%

Hyperlipidem

18,195

33.2%

6,676

33.0%

8,047

33.4%

3,472

33.1%

Severe liver
disease

complications

cancer

ia
Insurance Source
Commercial

26,350

48.1%

10,821

53.6%

9,281

38.6%

6,248

59.5%

Medicare

28,416

51.9%

9,381

46.4%

14,779

61.4%

4,256

40.5%

7,586

13.9%

2,910

14.4%

3,116

13.0%

1,560

14.9%

4,718

8.6%

1,821

9.0%

1,969

8.2%

928

8.8%

Insurance
Details
Assigned Care
Provider
Capitated
Payment
Year of IVC filter placement
2010

11,784

21.5%

4,250

21.0%

5,239

21.8%

2,295

21.8%

2011

12,750

23.3%

4,565

22.6%

5,672

23.6%

2,513

23.9%
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Table 3.1: Demographic and clinical characteristics of patients receiving vena cava
filters by indication
All
Pulmonary
Deep Vein
No PE/DVT
Embolism

Thrombosis

N

%

N

%

N

%

N

%

2012

12,210

22.3%

4,369

21.6%

5,393

22.4%

2,448

23.3%

2013

9,395

17.2%

3,596

17.8%

4,062

16.9%

1,737

16.5%

2014

8,627

15.8%

3,422

16.9%

3,694

15.4%

1,511

14.4%

Abbreviations: venous thromboembolism (VTE); myocardial infarction (MI); congestive
heart failure (CHF); peripheral vascular disease (PVD); chronic pulmonary obstructive
disease (COPD); peptic ulcer disease (PUD); coronary heart disease (CHD); inferior vena
cava (IVC)
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Table 3.2: Outcomes of patients receiving vena cava filters at one-year of follow-up
Outcome
IVC filter

Overall

PE

DVT

No VTE

7,619

14.3%

2,884

14.8%

2,686

11.4%

2,049

20.4%

Died

4,228

8.0%

1,627

8.4%

1,950

8.3%

651

6.5%

Censored

41,291

77.7%

14,971

76.8%

18,963

80.4%

7,357

73.2%

retrieval

Follow-up time
Mean (SD)
Median (IQR)

202 (144)

202 (143)

202 (145)

200 (144)

186 (56-365)

188 (58-365)

187 (54-365)

176 (56-365)

Time to retrieval
Mean (SD)
Median (IQR)

93 (78)

101 (81)

91 (79)

83 (73)

71 (35-130)

81 (38-143)

68 (33-132)

61 (32-113)

Time to death
Mean (SD)
Median (IQR)

96 (91)

94 (91)

97 (91)

100 (90)

63 (26-142)

58 (24-140)

66 (26-144)

67 (32-141)

Abbreviations: pulmonary embolism (PE); deep vein thrombosis (DVT); venous
thromboembolism (VTE); standard deviation (SD); interquartile range (IQR)
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Figure 3.1: Cumulative incidence of vena cava filter retrieval by indication over one-year of follow-up accounting for
death as a competing risk

30%

Cumulative retrieval (%)

25%

20%

15%

10%
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Time to IVCF retrieval (days)
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270

No VTE

300

Overall

330

360

Table 3.3: Cumulative incidence of vena cava filter retrieval at time intervals by key demographic and clinical factors
30 days
60 days
90 days
180 Days
365 days
Overall
3.3%
6.9%
9.8%
14.9%
18.4%
(3.1%-3.5%)
(6.7%-7.2%)
(9.5%-10.1%)
(14.6%-15.2%)
(18.0%-18.8%)
Index VTE No VTE
5.2%
11.0%
15.0%
21.3%
24.8%
(4.7%-5.6%) (10.4%-11.7%)
(14.3%-15.8%)
(20.4%-22.2%)
(23.9%-25.8%)
DVT
2.8%
5.8%
7.9%
12.1%
14.9%
(2.6%-3.0%)
(5.5%-6.1%)
(7.5%-8.2%)
(11.6%-12.6%)
(14.3%-15.4%)
PE
2.9%
6.1%
9.3%
14.8%
19.2%
(2.7%-3.1%)
(5.8%-6.5%)
(8.9%-9.8%)
(14.3%-15.4%)
(18.5%-19.8%)
Year
2010
3.1%
6.0%
8.0%
11.3%
14.0%
(2.8%-3.5%)
(5.6%-6.5%)
(7.5%-8.6%)
(10.7%-11.9%)
(13.3%-14.7%)
2011
3.0%
6.3%
8.8%
13.2%
16.1%
(2.7%-3.3%)
(5.9%-6.8%)
(8.3%-9.3%)
(12.6%-13.9%)
(15.4%-16.8%)
2012
3.4%
7.5%
9.9%
15.6%
19.2%
(3.1%-3.8%)
(7.0%-8.0%)
(9.4%-10.5%)
(14.9%-16.3%)
(18.4%-20.0%)
2013
3.3%
7.5%
11.2%
17.1%
21.6%
(3.0%-3.7%)
(7.0%-8.1%)
(10.5%-11.9%)
(16.3%-18.0%)
(20.7%-22.6%)
2014
3.7%
7.7%
12.4%
20.5%
38.2%
(3.3%-4.2%)
(7.1%-8.3%)
(11.6%-13.3%)
(19.4%-21.6%)
(19.4%-57.0%)
Age
18-34
6.8%
15.2%
22.8%
34.9%
42.8%
(5.8%-7.9%) (13.7%-16.8%)
(21.0%-24.7%)
(32.7%-37.1%)
(40.4%-45.2%)
35-44
6.1%
13.9%
18.9%
28.4%
35.5%
(5.3%-6.9%) (12.7%-15.1%)
(17.6%-20.3%)
(26.8%-30.0%)
(33.7%-37.2%)
45-54
4.9%
11.4%
15.9%
23.7%
29.3%
(4.5%-5.5%) (10.7%-12.2%)
(15.0%-16.8%)
(22.6%-24.7%)
(28.1%-30.4%)
55-64
3.9%
8.0%
11.5%
17.8%
21.8% (21.0%(3.5%-4.2%)
(7.5%-8.5%)
(10.9%-12.1%)
(17.0%-18.5%)
22.7%)

Table 3.3: Cumulative incidence of vena cava filter retrieval at time intervals by key demographic and clinical factors
30 days
60 days
90 days
180 Days
365 days
65-74
2.7%
5.3%
7.4%
11.4%
14.1%
(2.4%-3.1%)
(4.8%-5.8%)
(6.9%-8.0%)
(10.7%-12.1%)
(13.3%-15.0%)
75 and older
1.4%
2.4%
3.1%
4.5%
5.4%
(1.2%-1.6%)
(2.1%-2.6%)
(2.8%-3.3%)
(4.1%-4.8%)
(5.0%-5.8%)
Cancer
Yes
2.6%
4.5%
6.3%
9.1%
11.7%
(2.3%-2.8%)
(4.2%-4.9%)
(5.9%-6.7%)
(8.6%-9.7%)
(11.1%-12.4%)
No
3.6%
7.9%
11.1%
17.0%
20.8%
(3.4%-3.8%)
(7.6%-8.2%)
(10.8%-11.5%)
(16.6%-17.5%)
(20.4%-21.3%)
Insurance
Commercial
4.8%
10.5%
14.9% (14.5%22.6%
28.0%
source
(4.5%-5.0%) (10.1%-10.9%)
15.4%)
(22.1%-23.2%)
(27.4%-28.6%)
Medicare
1.9%
3.4%
4.6%
7.0%
8.6%
(1.7%-2.0%)
(3.2%-3.6%)
(4.3%-4.9%)
(6.6%-7.3%)
(8.2%-8.9%)
Abbreviations: venous thromboembolism (VTE); deep vein thrombosis (DVT); pulmonary embolism (PE)

Figure 3.2: Plot of times to anticoagulation and vena cava filter retrieval.
Black line represents the fit of the data, red line represents the preferred line if
anticoagulation was initiated 4 weeks prior to retrieval. Time is based on follow-up
after the discharge date from the hospitalization where the IVCF was placed.
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Table 3.4: Regression results showing patient factors associated with 90-day
(early) retrieval and 1-year retrieval
90-day retrieval
HR

95% CI

1-year retrieval
HR

95% CI

Age
18-34

Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

35-44

0.97

0.94

1.00

0.88

0.80

0.97

45-54

0.95

0.92

0.98

0.79

0.72

0.86

55-64

0.91

0.88

0.93

0.62

0.57

0.68

65-74

0.87

0.84

0.89

0.41

0.37

0.45

75 and older

0.82

0.80

0.84

0.17

0.15

0.19

Male

Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

Female

1.01

1.01

1.02

1.04

0.99

1.09

Northeast

Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

North Central

1.03

1.02

1.04

1.29

1.20

1.38

South

0.99

0.98

1.00

0.89

0.83

0.95

West

1.10

1.09

1.12

1.89

1.76

2.04

Unknown

1.01

0.98

1.04

1.24

1.05

1.46

Rural

Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

Urban

1.01

1.00

1.02

1.13

1.06

1.21

DVT only

Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

No VTE

1.05

1.03

1.06

1.24

1.17

1.32

PE

0.99

0.98

1.00

0.99

0.93

1.04

1.02

1.10

0.93

1.29

Gender

Region

Residence

Index VTE

Concurrent conditions during hospitalization
Bleed

1.00

0.99
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Table 3.4: Regression results showing patient factors associated with 90-day
(early) retrieval and 1-year retrieval
90-day retrieval
HR

95% CI

1-year retrieval
HR

95% CI

Unstable condition

0.98

0.96

1.00

0.80

0.60

1.06

Sepsis

1.00

0.98

1.01

0.92

0.76

1.12

Infection

0.98

0.97

0.99

0.84

0.76

0.91

Anemia

0.99

0.98

0.99

0.91

0.84

0.98

Trauma

0.99

0.98

1.00

1.00

0.92

1.09

Thrombolytic therapy

1.06

1.02

1.09

1.29

1.11

1.49

Embolectomy procedure

1.00

0.96

1.04

0.89

0.68

1.17

Major surgery

0.98

0.97

0.99

0.92

0.87

0.97

Pregnant

1.05

0.99

1.11

1.36

1.15

1.60

Comorbid conditions during pre-index look back
CCI score (per 1 unit)

1.00

0.99

1.01

0.97

0.90

1.05

History of VTE

1.03

1.02

1.04

1.17

1.08

1.26

History of bleeding

0.98

0.97

0.99

0.77

0.67

0.87

Myocardial infarction

0.99

0.98

1.00

0.82

0.71

0.96

Heart failure

0.98

0.97

0.99

0.67

0.60

0.74

Peripheral vascular disease

0.99

0.98

1.00

0.85

0.77

0.94

Dementia

0.97

0.96

0.98

0.31

0.22

0.43

COPD

0.99

0.98

1.00

0.88

0.83

0.94

Rheumatism

1.00

0.98

1.01

0.96

0.84

1.08

Peptic ulcer disease

1.02

1.00

1.04

1.16

0.95

1.41

Mild liver disease

1.00

0.98

1.01

1.00

0.91

1.11

Severe liver disease

0.99

0.98

1.00

0.86

0.81

0.92

Diabetes

0.99

0.98

1.00

0.96

0.85

1.09

Diabetes w/ complications

0.98

0.97

1.00

0.76

0.65

0.89

Paralysis

0.98

0.97

0.99

0.81

0.73

0.90
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Table 3.4: Regression results showing patient factors associated with 90-day
(early) retrieval and 1-year retrieval
90-day retrieval
HR

95% CI

1-year retrieval
HR

95% CI

Renal disease

0.99

0.98

1.00

0.94

0.87

1.00

Cancer

0.91

0.89

0.94

0.28

0.17

0.46

Metastatic cancer

0.92

0.90

0.93

0.43

0.38

0.49

Stroke

0.98

0.98

0.99

0.80

0.73

0.88

Hypertension

1.00

0.99

1.00

0.95

0.90

0.99

Coronary heart disease

1.00

0.99

1.00

0.87

0.80

0.94

Hyperlipidemia

1.02

1.01

1.03

1.23

1.17

1.30

Assigned Care Provider

1.00

0.99

1.02

1.03

0.94

1.12

Capitated Payment

0.99

0.97

1.00

0.84

0.75

0.94

2010 Ref.

Ref.

Ref.

Ref.

Ref.

Ref.

2011 1.01

1.00

1.02

1.19

1.11

1.28

2012 1.03

1.02

1.04

1.41

1.32

1.52

2013 1.04

1.03

1.05

1.63

1.51

1.75

2014 1.05

1.04

1.07

1.90

1.76

2.06

Insurance Details

Year filter placed

Abbreviations: venous thromboembolism (VTE); deep vein thrombosis (DVT);
pulmonary embolism (PE); chronic obstructive pulmonary disease (COPD)
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Table 3.5: Comparison of utilization for matched patients based on retrieval
status
No
Retrieval
Late
Early
retrieval
N

retrieval

retrieval

11,122

5,561

1,297

1,297

11.8 (15.8)

14.3 (16)

14.8 (10.6)

15.4 (10.8)

Median (IQR)

6 (1-16)

9 (2-20)

14 (7-20)

14 (8-21)

Outpatient VTE

Mean (SD)

6.4 (6.5)

6.9 (6.4)

6.9 (5.2)

7.2 (5.1)

visits

Median (IQR)

4 (2-8)

5 (2-10)

6 (2-10)

6 (3-10)

Hospitalizations

Mean (SD)

1.8 (1)

1.8 (0.8)

1.8 (0.7)

1.7 (0.8)

Median (IQR)

2 (1-2)

2 (1-2)

2 (1-2)

1 (1-2)

1.3 (0.7)

1.3 (0.5)

1.5 (0.7)

1.2 (0.4)

1 (1-1)

1 (1-2)

1 (1-2)

1 (1-1)

1.2 (0.5)

1.2 (0.5)

1.3 (0.6)

1.2 (0.4)

Outpatient visits

Mean (SD)

PE

Mean (SD)

Hospitalizations

Median (IQR)

DVT

Mean (SD)

hospitalizations

Median (IQR)

1 (1-1)

1 (1-1)

1 (1-2)

1 (1-1)

Emergency visits

Mean (SD)

2 (1.9)

1.7 (1.4)

1.7 (1.5)

1.7 (1.3)

Median (IQR)

1 (1-2)

1 (1-2)

1 (1-2)

1 (1-2)

1.2 (0.4)

1.3 (0.6)

1.2 (0.5)

1.3 (0.8)

1 (1-1)

1 (1-1)

1 (1-1)

1 (1-1)

1.2 (0.6)

1.2 (0.5)

1.2 (0.4)

1.2 (0.9)

1 (1-1)

1 (1-1)

1 (1-1)

1 (1-1)

PE Emergency

Mean (SD)

visits

Median (IQR)

DVT Emergency

Mean (SD)

visits

Median (IQR)

Abbreviations: pulmonary embolism (PE); deep vein thrombosis (DVT); venous
thromboembolism (VTE); standard deviation (SD); interquartile range (IQR)
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Table 3.6: Adjusted analysis comparing the association of utilization with
retrieval status
Retrieval vs. no
Early (≤90 days) vs. Late
retrieval
(≥120 days) retrieval
Odds
95% CL
Odds ratio
95% CL
ratio
≥ Median Outpatient visits
2.32
2.05 2.62
0.87
0.73
1.04
(vs. <Median)
≥ Median VTE outpatient
2.18
1.98 2.39
1.10
0.90
1.33
visits (vs. <Median)
1 hospitalization (vs. 0)
1.08
0.97 1.20
0.96
0.75
1.22
≥2 hospitalizations (vs. 0)

1.63

1.48 1.80

1.80

1.43

2.27

1 PE hospitalization (vs. 0)
≥2 PE hospitalizations
(vs. 0)
1 DVT hospitalization
(vs. 0)
≥2 DVT hospitalizations
(vs. 0)
1 Emergency visit (vs. 0)
≥2 Emergency visit (vs. 0)
1 PE emergency visit
(vs. 0)
≥2 PE emergency visit
(vs. 0)
1 DVT emergency visit
(vs. 0)
≥2 DVT emergency visit
(vs. 0)

1.28

1.06 1.56

1.03

0.67

1.59

1.70

1.25 2.31

5.37

2.33

12.37

1.16

0.98 1.37

1.35

0.94

1.95

1.42

1.02 1.99

2.62

1.30

5.29

0.95
0.64

0.85 1.06
0.56 0.73

0.81
0.93

0.64
0.70

1.02
1.23

0.80

0.60 1.07

0.70

0.36

1.34

1.14

0.62 2.13

0.58

0.14

2.44

0.66

0.53 0.84

0.84

0.51

1.39

0.46

0.29 0.74

1.67

0.55

5.04
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CHAPTER 4: COMPETING RISKS ANALYSIS OF CANCER-ASSOCIATED
RECURRENT THROMBOSIS, MAJOR BLEEDS, AND DEATH IN A GERIATRIC
COHORT RECEIVING ANTICOAGULATION OR VENA CAVA FILTERS

This study details an outcomes study looking at the effectiveness of treatments,
including vena cava filters, for cancer-associated VTE. It has been published in the
Journal of Health Economics and Outcomes Research.

Citation: Joshua D. Brown, Kelley L. Ratermann, Jeffery C. Talbert, Val R. Adams.
Competing Risks Analysis of Cancer-associated Recurrent Thrombosis, Major
Bleeds, and Death in a Geriatric Cohort. JHEOR 2015;3(2):214-23
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Abstract

Background: Individuals with cancer are at an increased risk of venous
thromboembolism (VTE). There is a continued increased of recurrent VTE after the
initial event as well as increased bleed risk related to VTE treatment.
Objectives: This study sought to observe the incidence of recurrent VTE, major
bleeding, and death in a geriatric oncology population during treatment for a
cancer-associated VTE.
Methods: We utilized an insurance claims database of Medicare Advantage
beneficiaries 65 and older. The index VTE was identified and individuals were
followed up to 180 days to observe an outcome event. Treatment groups were
classified among those receiving warfarin, low-molecular weight heparins (LMWH),
vena cava (VC) filters with or without anticoagulation, or no treatment. Treatment
groups were compared on baseline demographic and clinical characteristics and an
inverse probability of treatment weight was used to balance these factors between
the groups. A competing risks, time-to-event analysis was performed including
treatment only models as well as adjusted models with additional covariates. Causespecific hazards ratios (HR) and their 95% confidence intervals were reported.
Results: Treatment groups differed on baseline variables including age,
comorbidities, and tumor sites. After balancing the treatment groups on baseline
characteristics, those receiving LMWHs had no difference in recurrent VTE
compared to warfarin but had less than half the risk of major bleeding (HR=0.48
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[0.27-0.85]). Those receiving VC filters had increased risk of all outcome events
relative to warfarin.
Conclusions: Patients over the age of 65 with cancer are at a high risk of
experiencing recurrent VTE and major bleeding during treatment for a cancerassociated VTE. These results are consistent with United States guidelines which
recommend LMWHs over warfarin for treatment and secondary prevention of VTE.
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Background

Compared to the general population, individuals with cancer are at 4 to 7 times the
risk of developing a venous thromboembolism (VTE). 57,82-84 Malignancy induces a
prothrombotic state which includes activation of the coagulation cascade and is
further exacerbated by cancer treatment and surgery. 85 Additional risk factors for
VTE in cancer include the site and stage of the tumor, older age, prior history of
clots, and comorbidities. 86,87 Although at an already increased risk of death from
cancer, VTE carries a substantial risk of mortality with clotting events accounting
for up to 10% of all deaths in patients with cancer. 88-90 VTE events, including deep
vein thrombosis (DVT) and pulmonary embolism (PE) account for significant
lengths of stay and costs in this population with the mean hospital stay ranging from
11 days for DVT and up to 21 days for those with PE. 91

In the United States (U.S.), prevention and treatment of VTE in patients with cancer
is addressed in American Society of Clinical Oncology guidelines. 92 These guidelines
recommend the use of low molecular weight heparins (LMWHs, dalteparin,
enoxaparin, tinzaparin) for the initial and long term treatment of VTE for this
population. Warfarin is recommended when LMWHs are contraindicated or limited
in use because of cost or other factors including perceived intolerance. 93 In fact,
LMWHs have been shown to outperform warfarin in randomized controlled trials
and have further benefit in having weight based dosing, fewer drug and food
interactions, little monitoring throughout treatment, and maintain positive patient
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preference despite being an injectable. 88,94-97 However, real-world evidence shows
that warfarin is used for a vast majority of cases. 98,99 In addition to anticoagulation
therapy, vena cava (VC) filters are commonly utilized in the oncology patient
population despite no survival benefit and excess risk compared to other treatment
modalities. 100

Individuals who have had a VTE remain at high risk of experiencing a recurrent VTE
event and have high rates of bleeding. 91,101 Recurrent VTE has been reported as high
as 21% and bleeding rates as high as 12.4% in cancer patients. 102 Risk factors
related to recurrent VTE and adverse bleeding events include tumor site and
histology, presence of metastases, age, and certain biomarker or laboratory findings
as well as choice of anticoagulant therapy for acute treatment and long-term
secondary prophylaxis. 103-106 To our knowledge, no studies have identified risk
factors related to recurrent VTE, bleeding, and mortality related to geriatric patients
experiencing a cancer-associated VTE and compared treatments on these outcomes.
We sought to compare treatment selections on each of those three outcomes after
an initial VTE event. Treatment will be observed for individuals treated with
LMWHs, warfarin, VC filters, or who are untreated in a cohort of oncology patients
in a large administrative claims database. Demographic and clinical variables
associated with each of these three competing outcomes will also be explored.
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Materials and Methods

Data source and cohort identification
This retrospective cohort study used an extract from a large administrative claims
database comprised of 1.4 million unique lives with Humana Medicare Advantage
medical and pharmacy benefits from 2007 to 2009. The data included inpatient and
outpatient medical encounters with procedural codes and diagnoses fields, filled
prescription medication claims, and demographic and insurance coverage
information linked at the individual level.

The data extract required that an individual have a diagnosis for a malignant
neoplasm (104.xx-208.xx) and a DVT (451.xx, 453.xx) or a PE (415.1x) using ICD-9CM codes for primary diagnosis fields. The earliest date of diagnosis with a DVT or
PE was confirmed where at least one claim had a primary diagnosis of DVT or PE
and a specific imaging study indicative of diagnostic procedures codes (Appendix).
107

Individuals were excluded if their initial VTE event occurred before their cancer

diagnosis or if they were less than 65 years of age at cancer diagnosis. The
remaining cohort was required to have at least 180 days of continuous medical and
pharmacy coverage during the pre-index period. The 180-day pre-index period was
used to assess clinical characteristics including comorbidities and cancer treatment
patterns preceding the index event. Lastly, individuals receiving anticoagulant
treatment during the 30 days preceding their index event were excluded to ensure
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that temporality with diagnosis and treatment and to identify treatment naïve
patients.

Cohort characteristics
Individual demographics and insurance coverage were determined during the preindex period. Age was categorized 65-69, 70-74, and 75 or older. Race was
categorized white, black, and other/unknown. Region was categorized by census
regions including South, Midwest, West, and North. Insurance coverage was based
on product type (fee-for-service, FFS; health maintenance organization, HMO; or
preferred provider organization, PPO).

Tumor site was specified by ICD-9-CM codes including prostate, breast, lung,
lymphoma, colon, kidney, pancreas, brain, liver, ovarian, and others. Claims data are
limited so that tumor staging is not available. Metastases of the lymph nodes,
respiratory, digestive, and other sites were identified using ICD-9-CM codes (195.xx199.xx). Comorbidities were based on the Charlson Comorbidity Index using the
ICD-9-CM coding algorithms by Quan et al. and recorded as a continuous weighted
score and categorized by quartiles. 52 Other comorbidities and clinical
characteristics were identified by ICD-9-CM codes available in Appendix 4A and
were classified as binary variables.

Medications of interest were identified using Generic Product Identifier (GPI) codes
or Healthcare Common Procedure Coding System (HCPCS) codes. Placement of VC
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filters was identified by procedural codes in the medical claims. VTE treatment
choice was determined within the 21 days preceding the index event and was
recorded as the last outpatient anticoagulation used to allow for the possibility of
bridge therapy or treatment changes. The timing of chemotherapy or radiation
therapy was categorized based on its relative timing during the pre-index period to
the clotting event as occurring within 30 days, between 31 and 90 days, 91-180
days, or unobserved during the pre-index period using a combination of procedural
and medication codes within both the medical and pharmaceutical claims.

Inverse probability of treatment weight
A multinomial logistic regression model was estimated for treatment choice
predicting the probability of each subject to receive warfarin, a LMWH, a VC filter, a
VC filter and anticoagulation, or no treatment. All pre-index subject characteristics
deemed by the clinical team to be potential predictors of treatment choice as well as
related to the outcomes of interest were included. For each subject receiving a
particular treatment, the inverse of the probability of receiving that treatment and
the sample size within each treatment group was used to create a stabilized inverse
probability of treatment weight (IPTW) for each subject. IPTW is a variant of
propensity score methods that can be used to weight a regression analysis and has
strengths in that no matching or stratification are required; thus, no reduction in
sample size compared to other propensity score techniques. 108,109 Treatment group
comparisons and the performance of the IPTW method were assessed using
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standardized differences between the groups where a value of >0.10 is considered
significant.

Recurrent VTE, major bleeds, and mortality
Subjects were followed from the index date for up to 180 days or until: 1) they
experienced a recurrent VTE; 2) they experienced a major bleed; 3) they died; or 4)
they were lost to follow-up due to end of the study period or end of eligibility. The
earliest of these events was considered the event of interest. In the case where a
death occurred on the same date as one of the other events, that outcome was noted
as a death. Recurrent VTE were classified using the same coding algorithm as index
event identification and required: a primary diagnosis of a DVT or PE with a specific
diagnostic imaging study at least one day after the index event. This was done to
help mitigate the chance of the initial event being recoded on a medical
management claim as it is unlikely that additional imaging would be required for the
index event. Major bleeding events were classified by an algorithm developed by
Fang et al. considering a primary diagnosis of intracranial hemorrhage or a bleed
requiring a hospitalization or emergency department visit. 110

A competing risks, time-to-event analysis was performed taking into account the
interdependence of the outcome events and producing a cumulative incidence
function (CIF) for each outcome. This approach allowed for multivariable analyses
with cause-specific coefficient estimates of the predictors for each outcome. Further,
competing risks regression allows for the use of the IPTW detailed above so that

90

better direct comparisons could be made between treatment options. We computed
the overall CIF for the cohort for each outcome as well as each outcome separately
stratified by the treatment received. We fitted a competing risks regression model
and included the baseline variables of interest that may still be predictive of
outcome events even after IPTW weighting. Hazard ratios and 95% confidence
intervals of these final variables are reported.

Data management and analysis was conducted using SAS 9.4 (SAS Institute, Cary,
NC) and the manuscript was drafted adhering to the STROBE Statement guidelines
for reporting observational studies. The use of de-identified, Humana administrative
claims database was approved by the University of Kentucky Institutional Review
Board.

Results

Characteristics of treatment groups
A total of 12,965 subjects met the inclusion and exclusion criteria. Nearly two-thirds
of the index events were lower DVTs, 25.6% were PEs, and 8.7% were upper DVTs.
Treatment groups, assessed in the acute treatment phase included: 30.4% treated
with warfarin, 3.5% treated with LMWHs, 4.1% received a VC filter, 4.4% received a
VC filter and anticoagulation, and 57.5% had no observed treatment. Distribution of
the index event type was significant between treatment groups with most (82.3%)
of the upper DVT index events untreated compared to 60% of lower DVTs and
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42.6% of PEs (data not shown). Treatment groups differed significantly across
multiple demographic characteristics including age categories, gender, race, region,
plan type, and CCI score as well as comorbidities and tumor sites. Baseline
demographic and clinical characteristic comparisons between the treatment groups
are summarized in Table 4.1.

IPTW weighting
An IPTW was calculated for each individual based on the probability of receiving
each treatment based on the covariates included in Table 4.1. The IPTW performed
well when used to reweight the population to balance between the covariates. The
standardized differences were compared and are shown in Appendix B relative to
the warfarin group. Although the IPTW balanced well across all groups, some groupto-group comparisons included significant standardized differences (>0.10)
showing the need for some further adjustment in outcome models.

Outcome events
During the 180-day follow-up period, there was a median follow-up of 87 days with
a total of 3,323 person-years of follow-up time contributed by the cohort. Recurrent
VTE had a median time-to-event of 4 days (IQR 1-21 days). Median time-to-event
for death was 8 days (IQR 1-48 days) and for major bleeding the median was 14
days (IQR 2-57 days). There were a total of 1,661 recurrent VTEs (12.8% of total
cohort; 500 recurrent VTEs per 1,000 person-years) consisting of 614 PEs. Major
bleeds occurred in 6.1% (N=794) of the cohort (245 major bleeds per 1,000 person-

92

years) including 117 intracranial hemorrhages. Additionally, 3,690 individuals
(28.5%) in the cohort died within the 180-day period (1,110 deaths per 1,000
person-years) while the remainder (N=6,820; 52.6%) of the cohort was censored or
lost to follow-up before an event could be observed.

Competing risks analysis
Figure 4.1 graphs the CIF of each outcome by treatment group. The CIF curves
differed significantly across treatment groups and overall group comparisons by
Gray’s method were significant at p<0.001. Three models were estimated including
an unweighted, treatment-only model, a IPTW weighted treatment-only model, and
an IPTW weighted model including covariates which were not balanced by the IPTW
method or that were thought to potentially have residual impact on the outcomes of
interest. Table 4.2 details the outcome-specific HRs and 95% CIs for each treatment
group in the treatment-only models with warfarin as the referent treatment group.
Some major differences are observed between the unweighted and weighted models
further showing some bias in treatment group assignment. In the weighted analysis,
those treated with LMWH had similar hazard of experiencing a recurrent VTE and
over 50% reduced hazard of experiencing a major bleed (HR 0.48; 95% CI 0.270.85). Those receiving a VC filter or a VC filter with anticoagulation were much more
likely than the warfarin group to have both recurrent VTE (80-94% increased
hazard) and major bleeds (235-492% increased hazard). The untreated group had
lower hazard of experiencing a recurrent VTE and no difference in the hazard of
experiencing a major bleed. All treatment groups had higher hazards of death but
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should be interpreted with caution as will be discussed in more detail in the
Discussion section.

Further adjustment for the study covariates had marginal effects on the point
estimates between the treatment groups. Table 4.3 includes the outcome-specific
HRs and 95% CIs for the IPTW weighted model which included additional
covariates other than treatment group. Those with an index PE event had an
HR=1.83 (95% CI 1.64-2.03) for recurrent VTE compared to lower DVT index
events. Individuals who had a history of prior bleeding events during the baseline
period had over a 150% increased hazard of major bleed events as well as a 20%
increase in recurrent VTE.

Discussion
This study is the first study to our knowledge to assess the incidence of outcome
events after an initial cancer-associated VTE in a geriatric oncology population. This
population is of particular interest given the increased risk of treatment related
complications as well as a high baseline risk of mortality from multiple causes.

Our findings are consistent with previous studies showing a high rate of recurrent
VTE and major bleeding after an index VTE which differed across the treatment
modality. 98,99,102,103,111 After balancing the treatment groups on baseline
characteristics, we found no differences between warfarin and LMWHs and risk of
recurrent VTE but showed that warfarin treated patients had more than twice the
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hazard of a major bleed. Those receiving a filter had very large increases in all
outcome events relative to both LMWH and warfarin. This generally confirms the
recommendations made by U.S. clinical oncology practice guidelines which prefer
LMWHs over warfarin and only recommend VC filters when other treatments are
contraindicated. 58 VC filters have mixed results in randomized controlled trials 9,10
and observational studies 19 unless distinct population groups with high risk of VTE
or high risk of bleeding are preferentially given this treatment over the general
patient population.

LMWHs have been shown to have a large incremental cost-effectiveness ratio
compared to warfarin 112 as well as perceived patient intolerance and higher
pharmacy costs. 93 Nevertheless, oral anticoagulation with warfarin can be difficult
in practice given the patient variability in dosing, diet limitations, and required
monitoring as well as potential drug-drug interactions with chemotherapy, changes
in body weight, altered liver or renal function, and unpredictable gastrointestinal
absorption due to vomiting or mucositis. 58 These considerations will become more
important as novel oral anticoagulants (NOACs; apixaban, rivaroxaban, dabigatran,
edoxaban) are beginning to see use in this population and are currently being
investigated for efficacy and safety for primary and secondary prophylaxis of
cancer-associated VTE. 113-118

There is likely significant bias in the choice of treatment for a given individual and is
shown in our baseline comparisons. Using the IPTW in the regression analysis helps
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to balance these differences in a way analogous to the randomization process of a
randomized controlled trial. However, the IPTW is limited to the logistic regression
model specification and may not capture all the bias that is present. We included
several demographic and clinical characteristics which could drive the choice of
treatment in this population. Important factors, which could not be controlled for
given the nature of claims data, include tumor staging and histology as well as other
important clinical history that may contribute to treatment choice or baseline risk of
outcome events. However, our study is strengthened by a large sample size which
includes some relatively rare cancers, such as multiple myeloma, brain, and renal
cancers, that have lacked investigation in previous studies. 87,119

Of particular interest throughout the conduct of this study is the untreated group
which comprised the majority of the identified cohort. This finding is not unique to
our study with a recent study of real-world data in another population in the U.S.
reporting a treatment rate of 50%. 113,120,121 We hypothesize that this group could
consist of several unique profiles of individuals. For one, a proportion of this group
may include those that are unfit to receive any treatment given a poor prognosis
related to the underlying cancer or the index event. There may also be cases which
the index VTE event was considered asymptomatic or not a high priority for
treatment based on unobservable patient factors. Further, there may have been
some false positive misclassification of index events which met the coding criteria.
However, as discussed below in the limitations, the sensitivity and specificity of the
algorithm is expected to be >90% given the high risk of events in this population. 107
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It would further be expected that misclassification would not necessarily differ
between treatment groups and would be evenly distributed among the treatment
groups. While some groups have used treatment as confirmation of index VTE
events, 122 the inclusion in our study would not impact the direct comparisons made
between the other treatment groups and was considered a more thorough analysis.

Lastly, it is possible that other, non-guideline recommended treatments were used
or that medications were purchased out-of-pocket or using another insurance
benefit. Anywhere from 10-20% of warfarin prescription are purchased through
low-cost generic programs in the United States and may contribute to exposure
misclassification in this population. 123-125

Limitations
Our study is subject to several limitations inherent to claims-based studies.

79,80

We

relied on ICD-9-CM coding available in the claims to diagnose study subjects in
addition to requiring the presence of specific imaging modalities to confirm index
and recurrent VTE events. It is impossible to confirm a positive diagnosis using
these data; however, claims-based coding algorithms for VTE have been shown to
perform strongly especially when there is a high risk of VTE in the population 50,126.
In addition to this validated algorithm, we further required the presence of an
imaging procedure specific for diagnosis of VTE events to indicate an event of
interest which will have likely increased the specificity of our coding algorithm and
insured that a recurrent VTE event was a new event and not management of the
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previous index event. Further, we considered treatment group assignments based
on the pattern of medication use or procedural codes within the first 10 days of the
index events and held the treatment group assignment throughout the 180 days
follow-up. Realistically, treatment, as well as other factors, may change drastically
over the course of the study period. However, the majority of outcome events
occurred during the first 30 days post-index where treatment choice and individual
factors would generally remain stable. Future work should identify and account for
important factors that may vary over time for inclusion in analytic models.

We used a competing risks framework given that the outcome events cannot be
considered independent of each other, i.e. experiencing one may preclude
experiencing another or one event may cause another. Failure to do so can
overestimate survival for traditional Kaplan-Meier based analyses. 119 In this
population especially, the competing risk of death is a contribution by many factors
including the advanced age of the cohort, having cancer, as well as the risk of death
from the other outcome events. 119 Given the nature of the data, we could not assign
cause of death in this study. For example, if death was caused by a major bleed or
recurrent VTE but not submitted for claims adjudication, the alternative outcome
would not be observed. Thus, the findings related to the death should be interpreted
with caution. Lastly, our results are from a commercially insured population of
individuals with Medicare Advantage plans over the age of 65. Thus, our results may
not be generalizable to the general geriatric population but do provide insight into
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the burden of these outcome events in this population which makes of about 30% of
those with Medicare insurance in the United States. 127

Conclusions

There is a high rate of recurrent VTE and major bleeding events within 180 days of a
cancer-associated VTE. The risk of experiencing these outcomes varied across
treatment groups showing no difference between warfarin and LMWHs for
recurrent VTE but twice the risk of major bleeding with warfarin. Patients receiving
VCFs with or without anticoagulation were at largely increased risk of all outcome
events. These findings are consistent with U.S. clinical oncology practice guidelines
which prefer LMWH over warfarin in both the acute and long-term treatment after a
cancer-associated VTE and only recommend vena cava filters if other treatments are
contraindicated.
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Table 4.1: Baseline demographic and clinical characteristics by treatment
group
Characteristic
N (%)
Total N=12,965
Age category*

Warfarin

LMWH

VC Filter

VC Filter +
Anticoag.
574 (4.4)

None

3,946 (30.4)

458 (3.5)

536 (4.1)

65-69
70-74
75 and older

1,038 (26.3)
1,124 (28.4)
1,793 (45.3)

176 (38.4)
124 (27.1)
158 (34.5)

124 (22.4)
154 (27.9)
275 (49.7)

166 (28.8)
158 (27.4)
252 (43.8)

2,119 (27.9)
2,086 (27.5)
3,392 (44.7)

Male
Female

1,833 (46.4)
2,122 (53.7)

242 (52.8)
216 (47.2)

222 (40.1)
331 (59.9)

270 (46.9)
306 (53.1)

3,917 (51.6)
3,680 (48.4)

White
Black
Other

2,614 (66.1)
338 (8.6)
1,003 (25.4)

244 (53.3)
22 (4.8)
192 (41.9)

185 (33.5)
40 (7.2)
328 (59.3)

320 (55.6)
50 (8.7)
206 (35.8)

4,491 (59.1)
589 (7.8)
2,517 (33.1)

Midwest
Northeast
South
West

1,046 (26.5)
83 (2.1)
2,421 (61.2)
405 (10.2)

117 (25.6)
14 (3.1)
289 (63.1)
38 (8.3)

126 (22.8)
15 (2.7)
368 (66.6)
44 (8.0)

138 (24.0)
20 (3.5)
369 (64.1)
49 (8.5)

1,593 (21.0)
175 (2.3)
5,144 (67.7)
685 (9.0)

FFS
HMO
PPO

1,898 (48.0)
1,547 (39.1)
510 (12.9)

214 (46.7)
175 (28.2)
69 (15.1)

200 (36.2)
285 (51.5)
68 (12.3)

219 (38.0)
280 (48.6)
77 (13.4)

2,941 (38.7)
3,615 (47.6)
1,041 (13.7)

0-1
2-3
4-5
5+

1,079 (27.3)
1,240 (31.4)
843 (21.3)
793 (20.1)

125 (27.3)
171 (37.3)
80 (17.5)
82 (17.9)

63 (11.4)
164 (29.7)
143 (25.9)
183 (33.1)

135 (23.4)
173 (30.0)
143 (24.8)
125 (21.7)

1,821 (24.0)
2,349 (30.9)
1,593 (21.0)
1,834 (24.1)

3,181 (80.4)
103 (2.6)
158 (4.0)
513 (13.0)

278 (60.7)
15 (3.3)
28 (6.1)
137 (29.9)

404 (73.1)
21 (3.8)
36 (6.5)
92 (16.6)

435 (75.5)
13 (2.3)
30 (5.2)
98 (17.0)

6,547 (86.2)
172 (2.3)
234 (3.1)
644 (8.5)

2,484 (62.8)
150 (3.8)
1,321 (33.4)

299 (65.3)
33 (7.2)
126 (27.5)

291 (50.5)
12 (2.1)
273 (47.4)

291 (50.5)
12 (2.1)
273 (47.4)

5,212 (68.6)
943 (12.4)
1,442 (19.0)

181 (4.6)
40 (1.0)
65 (1.6)
177 (4.5)
244 (6.2)
928 (23.5)
502 (12.7)
854 (21.6)
3,011 (76.1)
413 (10.4)
321 (8.1)
399 (10.1)
954 (24.1)
896 (22.7)
731 (18.5)
110 (2.8)
1,292 (32.7)

21 (4.6)
14 (3.1)
6 (1.3)
25 (5.5)
27 (5.9)
143 (31.2)
93 (20.3)
90 (19.7)
336 (73.4)
52 (11.4)
37 (8.1)
50 (10.9)
81 (17.7)
99 (21.6)
60 (13.1)
6 (1.3)
144 (31.4)

55 (10.0)
8 (1.5)
17 (3.1)
37 (6.7)
28 (5.1)
160 (28.9)
128 (23.2)
195 (35.3)
460 (83.2)
154 (27.9)
50 (9.0)
66 (11.9)
144 (26.0)
159 (28.8)
174 (31.5)
35 (6.3)
209 (37.8)

39 (6.8)
5 (0.9)
13 (2.3)
30 (5.2)
26 (4.5)
135 (23.4)
91 (15.8)
144 (25.0)
450 (78.1)
79 (13.7)
60 (10.4)
65 (11.3)
111 (19.3)
141 (24.5)
129 (22.4)
17 (3.0)
191 (33.2)

421 (5.5)
100 (1.3)
173 (2.3)
450 (5.9)
297 (3.9)
2,146 (28.3)
1,055 (13.9)
1,927 (25.4)
5,892 (77.6)
990 (13.0)
569 (7.5)
891 (11.7)
1,679 (22.1)
2,029 (26.7)
1,431 (18.8)
245 (3.2)
2,685 (35.3)

7,451 (57.5)

Gender*

Race*

Region*

Plan type*

CCI Score*

Timing of cancer treatment
before index event *
Greater than 6 months
3-6 months
1-3 months
Less than 1 month
Initial event*
Lower DVT
Upper DVT
PE
Comorbidities
Leukocytosis*
Leukocytopenia*
Thrombocytosis*
Thrombocytopenia*
Hypocoagulatory Disorder*
Anemia*
Liver disease*
Renal disease*
Hypertension*
Prior bleed*
Obese
Myocardial infarction
Congestive heart failure*
Peripheral vascular disease*
Cerebrovascular disease*
Dementia*
Chronic pulmonary disease*
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Table 4.1: Baseline demographic and clinical characteristics by treatment
group
Characteristic
Warfarin
LMWH
VC Filter
VC Filter +
None
N (%)
Anticoag.
Rheumatic disease
196 (5.0)
24 (5.2)
31 (5.6)
27 (4.7)
366 (4.8)
Peptic ulcer disease*
96 (2.4)
11 (2.4)
38 (6.9)
15 (2.6)
256 (3.4)
Diabetes w/o complications*
1,277 (32.3) 153 (33.4)
211 (38.2)
193 (33.5)
2,692 (35.4)
Diabetes w/ complications*
436 (11.0)
43 (9.4)
78 (14.1)
63 (10.9)
1,091 (14.4)
Paraplegia/hemiplegia*
103 (2.6)
10 (2.2)
56 (10.1)
29 (5.0)
207 (2.7)
Skin ulcers/cellulitis*
534 (13.5)
57 (12.5)
95 (17.2)
91 (15.8)
1,186 (15.6)
Tumor site
Oral
67 (1.7)
10 (2.2)
14 (2.5)
13 (2.3)
153 (2.0)
Stomach*
59 (1.5)
12 (2.6)
19 (3.4)
13 (2.3)
91 (1.2)
Colon*
321 (8.1)
54 (11.8)
46 (8.3)
61 (10.6)
562 (7.4)
Liver*
69 (1.7)
17 (3.7)
14 (2.5)
10 (1.7)
132 (1.7)
Pancreas*
89 (2.3)
42 (9.2)
19 (3.4)
16 (2.8)
174 (2.3)
Lung*
409 (10.3)
89 (19.4)
76 (13.7)
80 (13.9)
815 (10.7)
Breast
469 (11.9)
53 (11.6)
49 (8.9)
54 (9.4)
846 (11.1)
Melanoma
106 (2.7)
6 (1.3)
14 (2.5)
16 (2.8)
165 (2.2)
Uterine*
73 (1.9)
18 (3.9)
14 (2.5)
27 (4.7)
120 (1.6)
Cervix*
35 (0.9)
8 (1.8)
10 (1.8)
12 (2.1)
49 (0.6)
Ovarian*
80 (2.0)
24 (5.2)
20 (3.6)
18 (3.1)
116 (1.5)
Prostate*
701 (17.7)
62 (13.5)
124 (22.4)
108 (18.8)
1,177 (15.5)
Bladder*
196 (5.0)
25 (5.5)
48 (8.7)
31 (5.4)
321 (4.2)
Kidney*
110 (2.8)
16 (3.5)
28 (5.1)
22 (3.8)
230 (3.0)
Brain*
58 (1.5)
12 (2.6)
50 (9.0)
29 (5.0)
108 (1.4)
Thyroid
21 (0.5)
1 (0.2)
5 (0.9)
5 (0.9)
62 (0.8)
Lymphoma
335 (8.5)
52 (11.4)
55 (10.0)
47 (8.2)
628 (8.3)
Myeloma
86 (2.2)
10 (2.2)
15 (2.7)
12 (2.1)
127 (1.7)
Metastatic disease*
692 (17.5)
175 (38.2)
157 (28.4)
134 (23.3)
1,160 (15.3)
*Comparisons between groups significant at p<0.001
LMWH = low molecular weight heparin; VC = vena cava; FFS = fee-for-service; HMO = health maintenance
organization; PPO = preferred provider organization; CCI = Charlson comorbidity index; DVT = deep vein
thrombosis; PE = pulmonary embolism
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Recurrent VTE

Table 4.2:Exposure treatment effect in unweighted and weighted (IPTW)
competing risk models.
Unweighted
Weighted
Treatment
HR
95% CI
HR
95% CI
Warfarin
Ref.
Ref.
Ref.
Ref.
Ref.
Ref.

Death

Major
bleeding

LMWH
0.94 0.76 1.17 0.86 0.68 1.08
Vena cava filter
1.41 1.14 1.74 1.79 1.48 2.17
Vena cava filter
1.90 1.62 2.23 1.94 1.65 2.28
and anticoagulation
None
0.31 0.27 0.34 0.34 0.31 0.39
Warfarin
Ref.
Ref.
Ref.
Ref.
Ref.
Ref.
LMWH
0.56 0.32 0.98 0.48 0.27 0.85
Vena cava filter
5.49 4.27 7.06 5.92 4.66 7.53
Vena cava filter
3.18 2.45 4.15 3.35 2.59 4.32
and anticoagulation
None
1.00 0.85 1.18 1.05 0.89 1.24
Warfarin
Ref.
Ref.
Ref.
Ref.
Ref.
Ref.
LMWH
2.02 1.75 2.34 1.36 1.16 1.60
Vena cava filter
5.03 4.44 5.69 3.41 2.98 3.91
Vena cava filter
2.39 2.08 2.75 1.91 1.66 2.19
and anticoagulation
None
1.15 1.07 1.24 1.16 1.08 1.25
HR = hazard ratio; CI = confidence interval; LMWH = low molecular weight heparin
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Table 4.3: Event specific hazard ratios and 95% confidence intervals from
IPTW competing risks analysis with all covariates included.
Recurrent VTE
Major Bleed
Death
HR
95% CI
HR
95% CI
HR
95% CI
Treatment
Warfarin
Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
LMWH
0.90 0.72 1.13 0.51 0.28 0.93 1.52 1.29 1.80
VC Filter
1.85 1.53 2.24 5.70 4.42 7.36 3.45 2.94 4.04
VC Filter +
2.01 1.71 2.37 3.47 2.68 4.50 1.80 1.53 2.12
anticoagulation
None
0.34 0.30 0.38 1.12 0.94 1.32 1.34 1.24 1.44
Age category
65-69
Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
70-74
0.96 0.85 1.09 0.99 0.82 1.20 1.09 1.00 1.20
75 and older
0.80 0.71 0.90 1.00 0.83 1.20 1.30 1.19 1.41
Race
White
Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
Black
1.10 0.91 1.32 1.33 1.04 1.70 1.32 1.15 1.52
Other
1.04 0.68 1.60 0.98 0.51 1.86 0.97 0.68 1.38
CCI Score
0-1
Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
2-3
1.10 0.94 1.29 1.32 1.02 1.72 1.22 1.08 1.37
4-5
1.03 0.82 1.31 1.46 1.05 2.02 1.39 1.20 1.62
5+
1.23 0.86 1.77 1.30 0.83 2.03 1.48 1.19 1.83
Timing of cancer
treatment before index
event
Greater than 6 months Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
3-6 months
0.73 0.49 1.07 0.97 0.61 1.57 1.27 1.06 1.52
1-3 months
0.82 0.59 1.12 0.93 0.62 1.39 1.32 1.14 1.53
Less than 1 month
0.87 0.71 1.06 0.94 0.70 1.26 1.27 1.15 1.40
Index event
Lower DVT
Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
Upper DVT
0.86 0.71 1.04 0.81 0.63 1.05 0.74 0.64 0.85
Pulmonary embolism
1.83 1.64 2.03 1.16 0.98 1.37 1.65 1.54 1.78
Comorbidities
Leukocytosis
1.18 0.94 1.47 1.62 1.26 2.08 1.36 1.21 1.53
Leukocytopenia
0.95 0.58 1.57 1.39 0.80 2.43 1.10 0.86 1.40
Thrombocytosis
1.08 0.85 1.38 1.07 0.80 1.42 1.12 0.98 1.27
Thrombocytopenia
1.07 0.75 1.54 0.89 0.54 1.46 1.08 0.87 1.34
Hypocoagualotory
0.97 0.44 2.13 0.66 0.22 2.05 2.05 1.40 3.00
disorder
Anemia
0.35 0.30 0.41 0.77 0.65 0.91 0.97 0.90 1.04
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Table 4.3: Event specific hazard ratios and 95% confidence intervals from
IPTW competing risks analysis with all covariates included.
Recurrent VTE
Major Bleed
Death
HR
95% CI
HR
95% CI
HR
95% CI
Liver disease
1.09 0.92 1.28 0.96 0.77 1.19 1.15 1.06 1.26
Renal disease
1.14 0.98 1.33 1.22 1.01 1.48 1.24 1.14 1.36
Hypertension
1.15 1.00 1.32 0.94 0.76 1.16 0.85 0.77 0.93
Prior bleed
1.19 1.01 1.41 2.53 2.10 3.04 1.20 1.08 1.33
Obese
1.21 1.02 1.43 1.13 0.89 1.44 0.96 0.84 1.09
Myocardial infarction
0.90 0.75 1.08 1.11 0.90 1.36 0.93 0.84 1.04
Congestive heart
0.85 0.74 0.98 1.18 0.98 1.40 1.23 1.13 1.34
failure
Peripheral vascular
1.02 0.90 1.16 1.01 0.85 1.20 0.92 0.85 1.00
disease
Cerebrovascular
0.86 0.74 0.99 1.26 1.06 1.49 1.01 0.93 1.10
disease
Dementia
0.85 0.62 1.19 0.68 0.43 1.07 1.38 1.17 1.63
Chronic pulmonary
1.02 0.90 1.15 1.05 0.89 1.24 1.22 1.13 1.32
disease
Rheumatic disease
1.16 0.93 1.45 1.24 0.94 1.64 1.07 0.92 1.24
Peptic ulcer disease
0.83 0.58 1.18 0.96 0.70 1.32 1.01 0.83 1.22
Diabetes w/o
0.88 0.77 1.00 1.10 0.92 1.30 0.97 0.90 1.06
complications
Diabetes w/
0.89 0.72 1.10 1.03 0.81 1.31 1.00 0.88 1.12
complications
Paraplegia/Hemiplegia 1.12 0.84 1.51 1.61 1.18 2.20 1.47 1.24 1.73
Skin ulcers/Cellulitis
0.85 0.74 0.98 0.89 0.72 1.10 1.00 0.90 1.10
Tumor site
Oral
0.68 0.43 1.06 1.20 0.74 1.94 1.05 0.87 1.27
Stomach
1.66 1.14 2.42 0.57 0.25 1.29 1.39 1.15 1.69
Colon
0.99 0.81 1.20 1.17 0.90 1.52 1.07 0.96 1.19
Liver
0.74 0.45 1.21 0.48 0.21 1.08 1.09 0.91 1.29
Pancreas
0.67 0.43 1.04 1.09 0.66 1.81 1.64 1.41 1.89
Lung
0.72 0.59 0.88 1.14 0.87 1.49 1.27 1.16 1.40
Breast
1.02 0.87 1.20 0.98 0.75 1.28 0.88 0.78 0.99
Melanoma
0.86 0.61 1.23 0.99 0.60 1.63 0.88 0.73 1.07
Uterus
0.75 0.49 1.13 0.60 0.28 1.26 1.19 0.95 1.50
Cervix
1.03 0.56 1.88 1.47 0.64 3.37 1.29 0.94 1.77
Ovarian
0.89 0.57 1.39 1.10 0.55 2.19 1.24 1.02 1.51
Prostate
0.68 0.43 1.06 1.14 0.93 1.40 0.88 0.80 0.98
Testicular
1.66 1.14 2.42
1.02 0.70 1.47
Bladder
0.99 0.81 1.20 1.37 1.02 1.84 1.24 1.08 1.42
Kidney
0.74 0.45 1.21 1.10 0.75 1.62 1.04 0.88 1.22
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Table 4.3: Event specific hazard ratios and 95% confidence intervals from
IPTW competing risks analysis with all covariates included.
Recurrent VTE
Major Bleed
Death
HR
95% CI
HR
95% CI
HR
95% CI
Brain
0.67 0.43 1.04 0.81 0.46 1.43 1.32 1.10 1.60
Thyroid
0.72 0.59 0.88 2.17 1.19 3.98 0.80 0.50 1.26
Lymphoma
1.02 0.87 1.20 0.97 0.71 1.32 1.25 1.11 1.40
Myeloma
0.86 0.61 1.23 1.56 1.02 2.40 0.91 0.72 1.15
Metastatic disease
1.14 0.24 5.37 0.60 0.46 0.79 1.85 1.69 2.03
HR = hazard ratio; CI = confidence interval; LMWH = low molecular weight heparin;
VTE = venous thromboembolism; DVT = deep vein thrombosis; VC = vena cava; CCI
= Charlson comorbidity index; IPTW = inverse probability of treatment weight
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Figure 4.1a: Cumulative incidence functions of recurrent VTE - Competing risks
time-to-event analysis by treatment group over 180 days of follow-up. Cumulative
incidence is the percent of the cohort experiencing each event. Cumulative incidence
is unweighted and no demographic or clinical characteristics are controlled.
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Figure 4.1b: Cumulative incidence functions of major bleed - Competing risks
time-to-event analysis by treatment group over 180 days of follow-up. Cumulative
incidence is the percent of the cohort experiencing each event. Cumulative incidence
is unweighted and no demographic or clinical characteristics are controlled.
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Figure 4.1c: Cumulative incidence functions of death - Competing risks time-toevent analysis by treatment group over 180 days of follow-up. Cumulative incidence
is the percent of the cohort experiencing each event. Cumulative incidence is
unweighted and no demographic or clinical characteristics are controlled.
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Appendix Table 4A: Coding algorithms used for the analysis
Deep vein thrombosis
ICD-9-CM:
Lower DVT - 451.11, 451.19, 451.81, 453.4, 453.41,
453.42
Upper DVT - 451.2, 451.9, 453.1, 453.2, 453.8, 453.9
Pulmonary embolism
ICD-9-CM: 415.1x
Imaging studies
Echocardiography CPT:
93306,93307,93308,93325,93312,93313,93314,93318,
93320,93321,93325,76881,76882,93970,93971,93975,
93976,75820,75822
Chest X-Ray CPT: 71020
V/Q Scan CPT: 78585
CT scan/CT Angiography CPT:71275, 21250, 71260, 71270, 73200, 73201, 73202,
MRI/MRI Angiography 73700, 73701, 73702, 73206, 73706
Ultrasound CPT: 71555, 73218, 73220, 73718, 73720, 73225, 73725
75820, 75822, 76882, 93970, 93971, 93975, 93976
Hypocoagulation defects ICD-9-CM: 2860 2861 2862 2863 2864 2865 28652
28653 28659 2866 2867 2869
Other coagulation
ICD-9-CM: 2870 2871 2872 2878 2879 7827
defects or hemorrhage
Thrombocytopenia
ICD-9-CM: 2873 2874 2875
Low white cell count
ICD-9-CM: 2885
High white cell count
ICD-9-CM:2886
Hypercoagulation
ICD-9-CM:28981 28982
defects
Anemia
ICD-9-CM: 280-285
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Appendix 4B: Standardized differences relative to warfarin group
(Significant value >0.10)
LMWH
Filter
Filter +
Anticoagulation
Age (categorical)
0.1070
0.0424
0.0661
Plan type
0.1294
0.0967
0.0417
Region
0.0849
0.0749
0.0323
Gender
0.0784
0.0414
0.0162
Index event
0.0323
0.1906
0.0618
Race
0.1341
0.0577
0.0452
CCI (categorical)
0.1088
0.1639
0.0630
Leukocytosis
0.0471
0.0014
0.0689
Leukocytopenia
0.0038
0.0087
0.0043
Thrombocytopenia
0.0638
0.0175
0.0132
Thrombocytosis
0.0072
0.0468
0.0379
Hypocoagulatory
0.0160
0.0724
0.0450
disorder
Anemia
0.0349
0.0239
0.0609
Liver dysfunction
0.0078
0.0325
0.0231
Renal dysfunction
0.0635
0.0707
0.0271
Hypertension
0.0357
0.0424
0.0634
Prior bleed
0.0027
0.0360
0.0206
Obesity
0.0030
0.0175
0.0046
Treatment timing
0.0608
0.0706
0.0339
Tumor site
Oral
0.0265
0.0173
0.0126
Stomach
0.0227
0.0218
0.0068
Colon
0.0260
0.0547
0.0175
Liver
0.0053
0.0423
0.0004
Pancreas
0.0198
0.0146
0.0335
Lung
0.0304
0.0960
0.0346
Breast
0.0092
0.0249
0.0117
Melanoma
0.0420
0.0699
0.0460
Uterine
0.0420
0.0699
0.0460
Cervix
0.0003
0.0217
0.0037
Ovarian
0.0226
0.0098
0.0220
Prostate
0.0477
0.0554
0.0234
Bladder
0.0016
0.0317
0.0126
Renal
0.0635
0.0707
0.0271
Brain
0.0503
0.0473
0.0014
Thyroid
0.0950
0.0064
0.0074
Lymphoma
0.0106
0.0777
0.0050
Myeloma
0.0201
0.1132
0.0160
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None
0.0147
0.0019
0.0080
0.0072
0.0097
0.0101
0.0042
0.0108
0.0063
0.0113
0.0034
0.0046
0.0100
0.0047
0.0136
0.0041
0.0023
0.0041
0.0051
0.0050
0.0040
0.0047
0.0079
0.0001
0.0068
0.0027
0.0030
0.0030
0.0109
0.0028
0.0088
0.0021
0.0136
0.0150
0.0039
0.0015
0.0023

Appendix 4B: Standardized differences relative to warfarin group
(Significant value >0.10)
Metastasis
0.0166
0.0806
0.0685
Myocardial infarction 0.0244
0.0653
0.0309
Congestive heart
0.0531
0.0904
0.0288
failure
Peripheral vascular
0.0624
0.1103
0.0303
disease
Cerebrovascular
0.0109
0.0974
0.0285
disease
Dementia
0.0044
0.0586
0.0376
Chronic pulmonary
0.0530
0.0432
0.0054
disease
Rheumatic disease
0.0453
0.1112
0.0202
Peptic ulcer disease
0.0349
0.0039
0.0095
Diabetes w/o
0.0022
0.0536
0.0579
complications
Diabetes w/
0.0252
0.0517
0.0212
complications
Paraplegia/hemiplegia 0.0751
0.0258
0.0373
Depression
0.0706
0.0236
0.0167
Skin ulcers/cellulitis
0.0677
0.0894
0.0488
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0.0020
0.0050
0.0051
0.0023
0.0136
0.0085
0.0006
0.0059
0.0064
0.0079
0.0004
0.0102
0.0013
0.0012

CHAPTER 5: EVALUATION OF A QUALITY IMPROVEMENT INTERVENTION TO
INCREASE VENA CAVA FILTER RETRIEVAL AT THE UNIVERSITY OF KENTUCKY
HOSPITAL

Introduction

The recent attention into retrieval rates of inferior vena cava filters elicited several
institutional interventions aimed at improving retrieval in the patient population.
This has been spurred by reports of overall low retrieval rates as well as FDA safety
communications calling for improved, as well as earlier retrieval of IVCFs. 28,30 In
response to these communications, the University of Kentucky Healthcare (UKHC)
Division of Vascular and Interventional Radiology (VIR) instituted a retrospective
review of retrieval rates along with a prospective letter mailing intervention to
increase retrieval in patients in whom an IVCF is no longer indicated. The design
and impact of this intervention is described herein.

Methods

As part of a clinical practice improvement initiative, a registry of all IVCFs placed at
the UKHC hospital in Lexington, KY between October 2011 and February 2016 was
created and housed within the Department of Radiology. A study coordinator
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retrospectively collected all data to create the database. Patients from VIR, surgery,
and cardiology services were included; however, detailed information was only
available within the VIR service. Information collected included patient identifying
information, referring physician, patient’s primary care physician, filter indication
and procedure details including date, and the retrieval date. There was no
prospective follow-up or data collection implemented due to the inability to extend
manpower.

Starting January 2014, all patients with IVCFs implanted by VIR and their primary
care or referring physicians were followed-up with a one-time letter sent within 3
months by the implanting physician and study coordinator regarding the need for
eventual IVCF retrieval. Contact information to the VIR clinic was provided and
contact was encouraged by the primary care physician or patient. Other than the
letters mailed, standard care was provided throughout the intervention period.

Patients were assumed to be eligible for retrieval until death was observed. The
date of retrieval was noted, otherwise patients were censored at the beginning of
the intervention period (for those in the pre-intervention group), or censored at the
end of the data collection period (February 2016). Patients who died within 30 days
of IVCF placement who did not already have retrieval were excluded from the
cohort. Death was considered a competing event in the calculation of the cumulative
incidence of retrieval using the method by Fine and Gray to allow for comparison
between the pre- and post-intervention groups. The mean, standard deviation (SD),
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median, and interquartile range (IQR) of the time-to-retrieval was also calculated
and compared.
Results

There were a total of 184 and 93 IVCFs placed at UKHC in the pre- and postintervention periods. Of those, 10 and 3 patients were excluded from follow-up
because they were deceased within 30 days after IVCF placement. Of the 90 patients
in the intervention period, all patients were sent letters and 87 letters were sent to
primary care providers (N=3 patients did not have a provider noted in the medical
record).

Of those in the pre-intervention period, 7/174 (4%) had their IVCF retrieved while
7/90 (7.8%) of those in the post-intervention period were retrieved. In the time-toevent analysis, which accounted for death during follow-up, the observed retrieval
rate at a total of 802 days of follow-up prior to the letter intervention was 4.4%
(Figure 5.1). In the post-intervention period, the observed retrieval rate at 265 days
of follow-up was 8.1% (Figure 5.1). At an equivalent follow-up period with a
cumulative incidence estimate available (288 days), the pre-intervention group’s
estimated retrieval rate was <1%, giving a relative rate of retrieval of 12.8 between
the two periods. Overall, the cumulative incidences between the two groups were
significantly different (p=0.043). The time-to-retrieval in the pre-intervention
period was a mean (SD) of 503 (207) days with a median (IQR) of 505 (301-742). In
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the post-intervention period, time-to-retrieval was a mean (SD) of 119 (83) days
and with median (IQR) of 128 (38-164) days (Table 5.1). Due to the intervention
implemented, minimal financial impact to the clinic was expected and; thus, not
evaluated.

Discussion

The minimal intervention implemented in the VIR clinic at the UKHC hospital
resulted in a significant increase in the IVCF retrievals. Overall, the magnitude of this
impact was on the order of a relative rate of 12.8 when limiting the analysis to an
equivalent follow-up time. Likewise, there was a decrease in the time-to-retrieval,
showing that retrievals were occurring at earlier intervals. This can be expected to
decrease the risk of complications reported with longer indwell times such as IVCF
fracture, migration, and IVC thrombosis.

Despite the large relative change in IVCF retrieval, UKHC’s observed rates of 4.4%
and 8.1% represent some of the lowest reported retrieval rates in the literature.
Only one other known institution has reported a similar rate of 8.5%. 64 Due to this
low rate, that institution also implemented an intervention that increased their
retrieval rate to over 50%. 39

These low rates can be due to several factors. For one, UKHC is a level 1 trauma
center serving a largely rural population, including the health disparate Appalachian
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region, making follow-up difficult. The patient case-mix at UKHC is also known to be
the worst in the state with higher comorbidity burdens along with the highest
utilization of IVCFs.
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More importantly, these retrieval rates are indicative of

practice culture. However, it should not be inferred that UKHC is dramatically
different from other institutions where retrieval rates have been reported to be
much higher than that observed in our institution. 28 Rather, it is likely that a
publication bias is present wherein institutions are not willing to discuss low
retrieval due to concerns about how releasing these figures would change the
perception of quality.

Although in context this minimal intervention can be perceived as successful, how it
compares to other interventions is important for planning future improvements to
the clinical workflow. This intervention included only mailed letters and
retrospective collection of patient data. Other interventions instituted at other
hospitals have generally included three facets: 1) patient and physician education
regarding IVCFs; 2) a method of tracking patients (e.g. automated alerts through
electronic medical records or active tracking); and 3) an individual who takes
responsibility for the entire process.

128

Patient education has included pre-

discharge education sessions as well as informed consent prior to implantation. 41,129
Physician education examples have included continuing medical education grand
rounds, which have both increased retrieval along with reduced overall utilization
of IVCFs.
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Many studies also institute IVCF “registries” so that patients are

catalogued continuously in a dedicated record developed specifically for the
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population.

39

Further, the movement of responsibility for follow-up from the

patient’s referring or primary care physician to the implanting physician creates an
environment of quality assurance and cross-communication between specialties.
41,42

The addition of these workflows and responsibilities has been shown to not

increase workload significantly and has also been shown to increase clinic revenue
because of increased patient follow-up and billable clinical visits. 78 All of these
factors should be incorporated into a future intervention to further increase the
retrieval rates at UKHC. Moreover, such an intervention should be expanded to
incorporate inter-departmental collaboration and communication in all implanting
and referring specialties, not only VIR.
Conclusion

Utilizing a minimal letter mailing intervention, retrieval rates at our institution were
increased approximately 12-fold with dramatic changes in the time-to-retrieval.
However, given the post-intervention retrieval of only 8.5%, much more progress
can be made to increase retrieval rates with a more thorough intervention. Lessons
from other institutions that have implemented such interventions will be utilized to
design a future intervention in order to transform the practice environment and
ensure patient safety associated with IVCFs.
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Figure 5.1: Cumulative incidence plot of time to retrieval after vena cava filter
placement
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Table 5.1: Time to retrieval comparison pre and post letter mailing
intervention

Mean (SD)
Median (IQR)

Pre-intervention (N=7)

Post-intervention (N=8)

503 (207) days

119 (83) days

505 (301-742) days

128 (38-164) days

Standard deviation (SD); Interquartile range (IQR)
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CHAPTER 6: A LITERATURE REVIEW OF INTERVENTIONS TO IMPROVE
RETRIEVAL RATES OF VENA CAVA FILTERS AND LESSONS LEARNED FOR
FUTURE EFFORTS

Introduction

In response to the observed poor retrieval rates at UKHC hospital and the small
impact of the letter intervention, a literature review was undertaken to explore
interventions instituted in other institutions. The overall goal was to define the key
aspects of interventions and the overall impact an intervention could have on
retrieval rates. A sub-aim of the review was to evaluate financial aspects of these
interventions to understand the feasibility of interventions

Methods

Abstract and full-text search terms including “vena cava filters”, “IVC filters”, and
“inferior vena cava filters” were used in conjunction with “retrieval” in
MEDLINE/PubMed, Google Scholar, and Cochrane databases. Published studies from
January 2003 up to August 1, 2016 were included. Identified abstracts were
screened by two independent reviewers, one health services researcher and one
interventional radiology resident. Reviewers selected studies that indicated that an
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intervention was implemented and compared to a control group or a preintervention period. Of those identified from abstract review only, full-text versions
of the articles were acquired. Additional articles were discovered from identification
in the references of collected manuscripts. Articles that did not meet the
requirements of evaluating an intervention during full-text review were excluded.

After relevant studies were identified, the two reviewers independently read the
manuscripts and extracted a priori defined data of interest including the study
setting and year, type of institution and country of study, details of the intervention
and the intervention staff, the comparison or control group, sample size, retrieval
rates and indwell times, retrieval failures, complications, and loss to follow-up rates.
All studies were included which reported both a pre-intervention and postintervention comparison of retrieval rates. The only exclusion criteria of studies
consisted of no pre-intervention measure being present to evaluate the impact of
the intervention. Data were entered into a spreadsheet, which was consolidated and
reviewed by an additional attending interventional radiologist reviewer for
correctness. An a priori meta-analysis was planned. Based on the extracted
information, the large heterogeneity in measurement definitions, interventions, and
patient populations, no further analyses were deemed feasible. Ultimately, the goal
was to make general recommendations for future interventions based on the
findings from the reviewed studies. A brief narrative of each study is included.
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Results

A total of 288 abstracts were screen from all sources with 18 included for full text
review. Of these, 5 studies were excluded as they either described an intervention
with no control or comparison group (N=4) and one study was a review article
itself. An additional 3 studies were identified from full-text review of other studies
and underwent abstract screening and full-text review. One of these additional
identified studies was excluded, as it did not include a comparison group or period.
A total of 15 studies underwent detailed review and are described below.
Summaries of the study characteristics and interventions implemented are provided
in Table 6.1. Sample size, retrieval rates, and other study data are provided in Table
6.2 and 6.3.

Twelve of the 15 studies were conducted in the U.S., one each in Ireland, the United
Kingdom, and New Zealand (Table 6.1). Of these, 13 were conducted in single, public
institutions, primarily tertiary care centers, with 5 additionally indicated as level 1
trauma centers. The other two studies included an evaluation of a national military
medical center, which tracked patients across multiple settings, and an evaluation of
14 urban hospitals linked within a single, integrated, regional healthcare system
(Kaiser Permanente Northern California). Five of the studies included an
intervention only in trauma patients for both prophylactic and secondary
prevention efforts.
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Absolute changes in retrieval rates ranged from 0% to nearly 70%. Relative changes
ranged from 0% to over 2,200% changes in retrieval rates (Table 6.3). One study
showed no change in their retrieval rate (45%) while showing a slight decrease in
the average indwell time. 1 This study may have been limited by a small sample size
(N=66 for pre- and post-intervention periods combined). The largest absolute and
relative increase was from a pre-intervention retrieval rate of 3.1% to 73% an
absolute change of 69.9% and a relative change of 2,254.8%. Ten out of the 15
studies reviewed at least doubled the baseline retrieval rate after the intervention
was in place. All but two of the studies achieved post-intervention retrieval rates
≥50%.

Time-to-retrieval, or the indwell time for the IVCF, was reported for both the preand post-intervention periods in 11 studies. Of those, only 3 showed a decrease in
the indwell time after the intervention. While some other studies showed increases
in indwell times, most of the studies were limited in these comparisons due to
sample size.

Charlton-Ouw 2015
This article details the implementation of planned retrievals at a single institution. 75
Charlton-Ouw and colleagues note that their institution is unique in that it has a
large number of uninsured or underinsured persons (Houston, TX), thus, they also
included a financial feasibility analysis due to this issue.
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The authors report that they focus their analysis on trauma patients only and
describe that they are in a level 1 trauma center with >6000 trauma admissions
annually. Prospective enrollment into the retrieval program began in May 2011 with
patients being referred to the program via electronic medical record, ordering
system, or by telephone referral. The study involved collaboration between
trauma/general surgery services and the interventional radiology department. After
written consent , patients were followed-up by a clinic nurse or a study coordinator
via mail, telephone, and e-mail. Determination of the need for IVCF retrieval was
made by the study physicians (vascular surgeons) in consultation with the patient’s
primary healthcare providers. Patients not enrolled in the program were provided
usual care.

The explicit goal of this program was to remove eligible filters within 6 months after
placement, noting that this should be regardless of insurance status. They also note
that an initial goal of retrieval prior to discharge failed due to difficulties in
scheduling as well as ongoing indications for IVCFs. Patient were in the study until
the filter was removed or until the filter was deemed permanent. Patients with
filters that could not be removed or deemed permanent were followed yearly for an
abdominal X-ray and initiated on daily aspirin.

For the cost analysis, commercial and Medicare insured individuals were grouped
together while those with no insurance or Medicaid was grouped. Cost-to-charge
ratios and payment-to-charge ratios were assessed for procedures. For patients

124

with no insurance or Medicaid, their costs were counted as losses to the hospital.
Data analysis included univariate analyses to determine the effectiveness of the
program.

Prior to the retrieval program, 64 trauma patients received an IVCF with only 2
being retrieved (3.1%). During the 2 years of the program, 247 trauma patients
received IVCFs, 111 (45%) were enrolled into the retrieval program and 136 were
followed in the standard of care arm. Those involved in the program had higher
retrieval compared to those that were not: 73% vs. 18%, odds ratio 12.6 [6.6-24.3].
This retrieval rate represents attempted retrievals whereas the success rate of
retrieval was 85%. The mean time to retrieval was 6.2 months (range 0.5-31.8
months). The financial analysis showed that overall, the hospital revenue from
retrieval higher than the cost, which was a balance between payments received
from those with insurance (60% of sample) making up for losses from those without
insurance. This financial analysis is only generalizable to this individual hospitals
practice, however. They describe the population as generally younger trauma
patients that are uninsured, which makes follow-up and continuity of care a
challenge. They recognize the need to make follow-up of patients dependent on the
physicians and healthcare team rather than the patient. The opt-in feature of the
program, via physician referral and patient agreement, creates the opportunity for
some selection bias to be present in this study.

Davies 2015
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This study was based in New Zealand through a partnership of Departments of
Vascular Surgery and Interventional Radiology and the Venous Thromboembolism
Clinic in a single institution. 40 The partnership developed a clinical pathway, i.e. a
defined, streamlined clinical workflow for IVCF retrieval. IVCF placement between
June 2010 and June 2012 were analyzed retrospectively as the control group with
information collected including acute vs. elective, medical vs. surgical referrals,
vascular surgeons vs. interventional radiologists performing the implant, etc. For
the clinical pathway intervention, all placed IVCFs during July 2012 through June
2014 were included with retrievals documented through August 2014. All patients
with IVCF placement were identified in a monthly report and entered into a
dedicated IVCF database that was maintained by nurses in the Venous
Thromboembolism Clinic. Patients with their IVCF in situ longer than 6 weeks were
each discussed with the VTE consultant and the patient was subsequently followedup in the clinic or via telephone consultation. If retrieval was warranted, an
appointment was made or, if the filter was to remain in place, an additional followup consultation was scheduled. IVCFs were deemed permanent if the indication for
placement was expected to extend for a long period or if retrieval was considered
too risky. Statistical analyses included Kaplan-Meier survival plots including
stratified analyses for key variables. They comment that patients were censored if
they died, which was not incorporated in the statistical analysis.

In the control group, 39 patients had an IVCF placed. Of these, 15 underwent
retrieval (14 successful) and 9 died. Time to retrieval was 97 (range 15-293) days.
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Of those 24 with no retrieval, 5 were deemed permanent, 2 had scheduled
retrievals, and 8 were lost to follow-up. The Kaplan-Meier estimate at 12 months
was 63%. The authors note that there were differences between retrieval based on
referring specialty (surgical 78% vs. medical 40%) and elective (85%) versus acute
(55%) care settings.

In the post-intervention group, 56 patients had an IVCF placed with 29 retrievals, 12
deaths, and 7 deemed permanent. The Kaplan-Meier estimate at 12 months showed
100% retrieval. Similar results for differences between acute vs. elective and
medical vs. surgical referrals were present. Pre-intervention the time-to-retrieval
was 7.4 months and post-intervention it was 4.1 months (overlapping CIs) –
suggesting an improvement in this metric as well. Overall, this study had much
higher pre- and post-intervention retrieval rates than most other studies. This could
be drive by hospital practices already established, but is also confounded due to the
small sample size and the way in which patients were censored. Further, given the
large proportion of patients who died in each period, the use of Kaplan-Meier
methods will overestimate the retrieval rate since death is considered a censoring
event instead of a competing risk, i.e. the retrieval rate is credited each time
someone dies wherein they were still eligible for retrieval up to their death. The
authors note the need for dedicated follow-up so that patients are not lost after
implantation. They also note the need to place the burden of follow-up on either the
implanting physician or a dedicated team aware of the IVCF status.
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Gasparis 2011
This intervention was implemented in a tertiary care hospital in the United States.
129

The study presents results from the prospective intervention from January 2010

to January 2011. A specialized “DVT team” was developed including a vascular nurse
practitioner (NP) and a physician. The NP followed-up with patients and managed
the development of a dedicated database. Phone calls and letters were sent to
patients and referring physicians suggesting the best retrieval. In addition, patients
were educated prior to discharge regarding IVCF retrieval benefits and risks. A
“rigorous” coordination system between the NP and referring physician was
maintained, including accommodating patient and physician schedules and having
dedicated room in the interventional procedural suite. IVCFs could be deemed
permanent prior to insertion if (1) the patient could not be anticoagulated for a long
period of time (e.g. due to fall risk, intracranial bleed, etc.), or (2) patients with short
life span. IVCFs were made permanent if the patient refused retrieval, IVC thrombus
was present, they had recurrent VTE, or patients had a short life span. Patients who
died during follow-up were excluded. The comparison group’s retrieval rate (18%)
was reported from a prior study. Statistical analysis included basic Fisher’s exact
test with no survival analysis included.

During the 12-month period, 42 patients had an IVCF placed by vascular surgeons,
with 40 being included in the analysis. Of these, 13 were placed as permanent. Most
were placed for absolute contraindications to anticoagulation (58%), relative in
25%, and 17% were used prophylactically. An additional 5 IVCFs were converted to

128

permanent after placement – leaving 27 eligible for retrieval. Attempted retrieval
was done in 22 of 27 patients with 86% success, giving a successful retrieval rate of
70% and 81% retrieval attempt rate. Post-intervention time-to-retrieval was 21
days (range 4-140 days) while pre-intervention time was not reported. They report
a significant benefit of the intervention and note an added benefit that no patients
were lost to follow-up.

Inagaki 2015
This study reports an intervention to increase IVCF retrieval implemented with
Boston Medical Center during August 2012 to September 2014 and compared it
retrospectively with data from September 2003 to July 2012. 39 Starting with the
intervention, prospective data was collected for each patient including physician
specialty, indication, filter type, retrieval, etc. IVCFs were placed by multiple
departments included interventional radiology, vascular surgery, and cardiology. A
multidisciplinary task force encompassing the implanting departments with trauma
surgery and hematology was established and a new IVCF retrieval protocol was
developed. The protocol included four facets: (1) patient educational pamphlets, (2)
additional IVCF procedure form, (3) a centralized IVCF registry, and (4) a dedicated
administrative coordinator. Patient education materials included descriptions of the
risks, benefits, and process of implantation and retrieval and emphasized that most
IVCFs should be removed once anticoagulation is tolerated. The procedure form
documented the indication for placement and the estimated duration it would
remain implanted with permanent, immediate (<1 month), short-term (1-6 months),
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and long-term (≥6 months) filter placement. An additional form was completed at
retrieval to document success and any reasons for failure. The administrative
coordinator maintained the IVCF registry and also coordinated between
departments to ensure patient follow-up through the process. They note that this
coordinator took on these roles as part of the daily job duties with negligible effect.
Patients were contacted by phone or mail, differing slightly between departments,
using standardized guidelines to determine suitability for retrieval. Statistical
analyses included chi-squared and ANOVA tests.

The clinical pathway was detailed in the article and is reproduced in Figure 6.1. The
pathway included flow based on indication (VTE or prophylactic), accounted for
time since implant, and if the patient was anticoagulated. In the comparison group,
1,088 IVCFs were placed with 784 (72%) being placed as retrievable devices, 47
(4%) of these died, and 17 (2%) were later deemed permanent. Of the 720
remaining eligible for retrieval, 99 (14%) had attempted retrieval; with 82 (83% )
successful; with median indwell time of 119 days (range 0-1882 days). In
comparison, the post-intervention group included 151 IVCF placements, 32 (21%)
were inserted as permanent, 14 (9%) of patients died, and 31 (21%) became
permanent – leaving 74 (49%) eligible for retrieval. Retrieval attempts were
performed in 49 (66%) of these with 40 (82%) being successful and median indwell
time of 175 days (range 8-664). Reasons for failure were reported and included the
IVCF being imbedded in most cases and abnormal positioning of the IVCF being
second most common. Between the pre- and post-intervention periods, there was a
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significant decrease in the proportion of prophylactic indications for IVCF
placement (suggesting a potential Hawthorne effect or other practice changes
during the time period), differences in the IVCF models used, and changes in the
implanting service. Further, there were large differences in retrieval based on the
classification of the retrieval: immediate IVCFs retrievals attempted in 92% of
patients (successful in 83%) and median indwell time of 23 days; short-term IVCFs
retrievals attempted in 62% of patients (successful in 82%) and median indwell of
164 days; and long-term IVCFs retrievals attempted in 50% (successful in 75%) and
median indwell of 245 days – all significant differences.

Irwin 2010
This article discussed an intervention implemented in a level 1 trauma center in the
United States between Q2 2007 and Q2 2008 with retrospective data back to 2003
for comparison. 76 The authors distinguish that when retrievable IVCFs became
available in 2003, the trauma team attempted to coordinate retrieval with the
interventional radiology department. They noted that the overwhelming issue was a
lack of patient follow-up, problematic because many patients would be indicated for
retrieval later. In response, a multidisciplinary team was formed consisting of
trauma nurses and surgeons and nurses from several departments. The team met
each morning (M-F) and reviewed patient needs and to coordinate care. The nurse
for the interventional radiology department would then follow-up with scheduling.
They note that this team secured communication between services and improved
patient follow-up between departments.
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Prior to implementation, 82 IVCFs were placed with 53 removed (65%) and 15
remaining in place without indication. After implementation of the team approach,
of 33 IVCFs placed, 28 were removed (84%) and 3 remained in place without
indication. The majority of IVCF placement in the trauma setting was for
prophylactic indications over both time periods, and those with prophylactic
indications had higher retrieval than those with active VTE (82% vs. 53%). They
report multiple reasons for the 35 IVCFs that were not removed in the whole cohort
including 8 transferred care to another facility, 3 lost to follow-up, 4 failed attempts
at retrieval, 6 with contraindications to anticoagulation, 9 with IVC thrombosis, 2
with DVT while on anticoagulation, 3 who had need for multiple surgeries.
Indwelling times were not reported but multiple filter repositioning procedures
(N=30) were reported.

Kalina 2012
This study describes the impact of having a filter registry in a level 1 trauma center
in the United States. 131 The filter registry was established in 2006 and its impact
was evaluated using retrospective data. Information collected included Injury
Severity Score, indications, etc. and was maintained by acute practice nurses (APN)
working in trauma. The registry was updated every 2 weeks from inpatient charts.
Patient cases were presented by the APNs to trauma physicians and APNs scheduled
procedures or consultations accordingly. Outpatient follow-up was conducted with
the in-house clinic by APNs as well. The filter registry was also reviewed monthly at
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the trauma department so that implementation plans could be coordinated. Data
analysis included basic statistical tests (Chi-square) and stepwise logistic to find
independent factors associated with non-retrieval.

During the study period, 142 pre-registry and 165 post-registry IVCFs were placed.
Significant differences existed in the length of stay, indications for placement, and
the specific IVCFs utilized between the two periods. The reported retrieval rate in
the pre-registry period was 15.5% (22 of 120) compared to 31.5% (52 of 113) in the
post-registry period (P<0.001). The largest reason for non-retrieval was loss to
follow-up, which was 21.1% and 27.6% in the two periods. In controlled analyses,
IVC thrombosis, DVT, and loss to follow-up predicted non-retrieval.

Ko 2009
This study was based in a tertiary care hospital with a level-1 trauma center. 132 The
author compared pre-intervention retrieval rates from 2004 to 2007 and
implemented an intervention in August 2007. A physician assistant (PA) was given
the duty to compile a prospective database of patients receiving an IVCF and
subsequently coordinated the retrieval procedure to follow. Reasons for leaving the
IVCF implanted were documented in the medical chart. Inpatients with IVCFs in
place were highlighted on the rounding list daily and ongoing education of all
trauma providers was given on the proper indications for IVCFs to re-enforce when
they should be retrieved. Patients were electronically tracked with automated
reminder e-mails sent to their admitting attending physician. Coordination between
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hospital departments of vascular surgery, trauma, and interventional radiology was
encouraged for inpatients and outpatients to increase retrieval. Basic statistical
analyses (Chi-squared) were conducted.

In the pre-intervention period, 94 patients received IVCFs while 61 patients
received the devices in the post-intervention period (an increase in utilization on a
per trauma patient basis between the periods). Of the 94 patients in the preintervention period, 76 (80.9%) were deemed eligible for retrieval and retrieval was
attempted in 32 (42.1%) of these with 28 (36.8%) being successful with an average
indwell time of 24 days. In the post-intervention period, of the 37 (60.7%) were
deemed eligible for retrieval and 35 (94.6%) of these underwent an attempted
retrieval with 31 (83.8%) being successful at an average indwell time of 20 days.
Except for the indwell time, each comparison (eligibility, attempt %, retrieval %)
were statistically different. Reasons for non-eligibility were reported and differed
between the two periods. In the pre-intervention period, 39 of 66 (59.1%) nonretrievals were due to “clinical oversight,” i.e. loss to follow-up, and “medical
reasons” (10, 15.2%). There were no cases of “physician preference” in the preintervention period. In the post-intervention group, “physician preference” was the
most common reason, 11 of 30 (36.7%), representing a potential bias introduced by
knowing that your practice is being evaluated, or differences between the
prospective and retrospective data collection.

Lee 2012
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This study was based in the UK and was inspired by a warning by the FDAequivalent Medicines and Healthcare products Regulatory Agency (MHRA)
regarding the complications related to IVCFs that remain indwelling.
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The

intervention design removed the responsibility of follow-up from the referring
physician and placed it on the intervention radiology who performed the
implantation. They used a pre-intervention comparison during May 2007 to April
2008 and implemented their intervention from May 2008 to April 2008. The
radiologist-led approach to the follow-up of patients comprised of a log-sheet that
generated standardized reports. These reports were faxed to the referring physician
and suggested a retrieval date. In cases where retrieval was refused or not yet
appropriate, additional reports were generated every 30 days. Statistical analyses
included basic bivariate tests. Of the 28 IVCFs placed in the pre-intervention period,
14 (50%) retrievals were attempted (10 successful, 35.7%). Of the 14 not retrieved,
6 reasons for non-retrieval were undocumented while the other 8 were, leaving an
effective retrieval rate of 14/20 (70%). In the post-intervention period, 29 IVCFs
were inserted and 16 (55%) retrievals were attempted with 13 (44.8%) being
successful. Of those not retrieved, only 1 was lost to follow-up, leaving an effective
attempted retrieval rate of 16/17 (94.1%) (these figures were calculated and not
reported in the original article). The authors note the importance of choosing a prespecified time period to pursue retrieval (here 30 days) in that it is likely a clinically
accepted interval and that retrieval rates beyond this time decrease dramatically
(e.g. due to loss to follow-up and difficulty in retrieval) along with increased risk of
complications.
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Logan 2016
This report details an audit instituted at a tertiary care center in Ireland. 134 Audits
of retrieval rates were conducted before and after the implementation of a
coordinated management strategy for IVCF follow-up using The Royal College of
Radiology’s audit template. This audit template for IVCF states that 100% of
retrievable IVCFs should have a retrieval attempt at all possible.

The intervention included a multidisciplinary team of interventional radiologists
and hematologists. A framework was developed with a 3-point approach of (1) a
specialist nurse keeping a registry, (2) hematology consultation if IVCFs are to
remain in situ or for complex removals, and (3) beds in a day ward were made
available. There was a 7-month lead-in period and then a 15-month evaluation
period is presented from November 2013 to December 2014. This is compared to
the retrospective period of January 2012 to March 2013.

Prior to the intervention, 33 patients received IVCFs largely for indications of
planned surgeries or concurrent bleeding, low platelets, or active cancer. Thirtythree patients also received IVCFs in the intervention period, with a larger
proportion receiving them for bleeding/low platelet indications along with a
significant decrease in IVCF use for surgery indications. Between the two periods,
more IVCFs were deemed permanent (12% vs. 39%) during the interventional
period while the proportion removed was the same (15%). There was a noted

136

increase in documented retrieval plans (70% vs. 91%) between the two periods.
There was also a reduction in average indwell time (61 vs. 44 days) and fewer
patients were considered lost to follow-up (27% vs. 9%)

Lucas 2012
This study presented a unique patient population consisting of military trauma
patients at a national military medical center. 135 The authors describe most of their
patients coming from the theater of war, passing through medical facilities in
Germany, then moving throughout the country in military, veteran, and civilian
medical facilities – making tracking and follow-up of these patients difficult. An IVCF
tracking system was implemented incorporating medical record review and
communications between providers to increase retrieval rates in this population
starting in January 2007, compared to the 2 years prior. The registry included all
IVCF placements unless the patient died within 30 days of placement. Basic
statistical testing between groups was utilized.

The control and registry groups comprised 20 and 93 patients, respectively. In the
control period, 6 (30%) retrievals were attempted and successful while 65 (70%)
attempted and 56 (605) successful retrievals were conducted in the registry period.
The number lost to follow-up decreased from 65% to 5% between the two periods
as well as the time to retrieval (210 to 84 days). The authors note a sub-analysis
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within both periods showing that there was a non-significant difference between
times to attempted retrieval for successful versus failed retrievals.

Lynch 2011
This report describes an intervention implemented in a tertiary care center in the
United States.

41

A retrospective period (May 2002 to October 2005) and an

interventional period (October 2005 to May 2010) were compared. At this facility,
they note the need for proper patient selection and follow-up. Thus, they outline
that patients only received a retrievable filter if their need for one would be
temporary, otherwise a permanent device would be placed, a decision that was also
part of the informed consent process with patients. Retrievable IVCFs made of 42%
of the IVCFs placed. Starting in the interventional period, the responsibility of
follow-up was placed on the implanting interventional radiologist instead of the
referring physician, including initiated follow-up of patients who received IVCFs
prior to the intervention implementation. Patients were tracked in a departmental
quality assurance database (iSchedule) and a custom Access database. If an IVCF
was not removed in 90 days, a medical record review was performed and patients
were given a status of “declared permanent,” “candidate for future removal,” or
“candidate for immediate removal.” Patients eligible for future removal were
reviewed again in 1-3 months. To follow-up, patients were contact via form letter
that reviewed why the initial implant was done as well as the rationale for removal.
If no response, additional letters (up to 3) were sent at 1-3 month intervals. Initially,
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a phone call was given after failed communication but was abandoned due to
workload for a final letter, and patients were declared lost to follow-up at that point.

Before the intervention, 154 IVCFs were placed and 973 were placed afterward (a
large increase in overall utilization, 5.8/month increased to 17.5/month). Of those
in the pre-period, 37 (24%) were removed compared to 574 (59%). Additionally,
IVCFs placed in the pre-period that were prospectively contacted resulted in an
additional 47 IVCF removals. Loss to follow-up remained similar during those time
periods (18.2% vs. 16.2%). The time to retrieval increased dramatically from a
mean/median of 103/91 days in the pre-period up to 307/224 days in the postperiod. The proportion of those declared permanent also decreased from 25.3% to
16.7% between the periods. A large number also remained candidates for retrieval,
(32% and 85 in pre- and post-periods), indicating that patient contact remained. Of
all attempted retrievals reported, there were a low number of failures (9/667,
1.3%). Listed indications for permanence in 202 were need (101, 50%), death (72,
35.6%), and patient refusal (20, 9.9%). The authors note that the patient population
resides in a generally rural and affluent area, which made follow-up easier than
other settings. They also note the utility gained from an electronic medical record so
that such an intervention can be implemented by a single individual.

Minocha 2010
The authors implemented an intervention starting in January 2009 and compared it
to retrospective data from the 8 years prior at an urban tertiary care center. 42 A
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dedicated IVCF clinic was established with a dedicated clinic database. The clinic
staff included a nurse coordinator and interventional radiologist; tasks were added
to their clinical responsibility. The nurse coordinator updated the prospective
database with all patients receiving IVCFs by interventional radiology. Before
placement, the interventional radiologist consulted with the referring physician to
confirm the indication for IVCF placement, including the need for permanent versus
optional devices. The IVCF clinic nurse and radiologist monitored the database and
coordinated retrieval with the referring physician when indicated. Referring
physicians were contacted 2-3 weeks after placement to discuss the possibility of
removal otherwise, or if the device was to be made permanent. Retrieval procedures
were initially scheduled after patient visits to the clinic. This was replaced by
telephone calls, unless the case was complicated, due to the inefficiency of having
multiple visits. Basic statistical analyses were used in addition to Kaplan-Meier
survival analysis.

Each year, the proportion of optional IVCFs increased from 21% in 2001 to 64% in
2009. Of the 369 implanted in the pre-intervention period, 108 (29%) were
retrieved compared to 60 of 100 placed (60%) in the post-intervention period.
Between those two periods, there was a shift in the IVCFs utilized and no difference
in the retrieval failure rate (6% vs. 5%). There was a general increase in the number
of IVCFs placed per month over these two periods from a median of 3 during 20002008 up to a median of 10 per month in 2009. Of those IVCFs not retrieved in the
post-intervention phase, 33/40 (82.5%) were deemed permanent. The median time
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to retrieval, in which 50% of all IVCFs are placed, was 1.5 months via Kaplan-Meier
estimation. Estimated retrieval at 3 months was near 80% according to the survival
analysis. Only 2/100 patients experienced complications in the post-intervention
period and only 1 was considered lost to follow-up.

O’Keeffe 2011
This study describes an intervention instituted at a level 1 trauma center in the
United States. 136 At the time of IVCF placement, a fluorescent label was placed on
each patient’s chart along with an arm bracelet. Such patients were tracked by
trauma nurse practitioners (NPs), which confirmed patient contact information
prior to discharge. Three months after discharge, the NPs contacted patients to
schedule pelvic and lower extremity venous duplex ultrasound. If no DVT were
found along with no other contraindications, the NP would schedule IVCF retrieval
with the radiology department. In cases of uncertainty, the attending trauma
surgeon was consulted for final decision. Non-trauma patients receiving IVCFs
received standard care. All IVCFs placed and included in the final analysis were for
prophylactic indications only. The authors compared retrieval between trauma and
non-trauma patients during the same time period using basic statistics as well as
multivariable regression.

Among the trauma group, 91 patients received IVCFs and met criteria for inclusion.
Of those, 14 were deemed ineligible for retrieval (3 deaths, 4 DVT present, 7
surgeon judgment). Of the 77 eligible for retrieval, 42 (54.5%) were removed. The
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non-trauma group consisted of 76 patients and 45 were deemed ineligible for
retrieval (10 deaths, 13 DVT present, 22 still indicated). Of the 31 eligible nontrauma patients, 6 (19.4%) were removed. Overall, the authors reported that there
was a total retrieval of There was a difference in median age between the two group
of over 20 years, large differences in gender, and shorter indwell times in the nontrauma group (median 14.5 vs. 48.5 days). Regression analysis found that trauma,
younger age, and the specific trauma team (i.e. specific to one NP in particular)
utilized predicted retrieval overall. Distance from hospital and insurance status
were not significant. There is remaining concern over how balanced one can
consider the trauma vs. non-trauma comparison, especially for wholly prophylactic
indications.

Sutphin 2015
This article describes an intervention at a tertiary care hospital with a level-1
trauma center.
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The article specifically mentions utilizing the DMAIC (Define,

Measure, Analyze, Improve, Control) Methodology of Six Sigma as their process for
implementation. To define the problem, they retrospectively analyzed retrieval at
their institution and found that of all patients receiving IVCFs, 92% were lost to
follow-up and 8% were retrieved. Two measures were determined to evaluate,
mainly the retrieval rate achieved as well as the proportion of patients followed-up
in the clinic. The authors created a process to increase these metrics including
increased communication between referring and implanting physicians on how to
schedule retrieval. A multidisciplinary team also met to outline issues related to this
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workflow and categorized each issue into barriers associated with providers,
patients, clinical, and systems and further divided into controllable or
uncontrollable (Figure 6.1 reproduced). Key factors included provider knowledge
and follow-up, patient knowledge and follow-up after the procedure, lack of a
clinical database and a shortage of permanent filters for patients in whom they were
indicated. New workflows were designed after recognizing these shortfalls. One
workflow addressed patients with an IVCF already in place. A letter was sent to the
primary physician to schedule a visit with a lower venous ultrasound study. Letters
were repeated every two weeks up to three letters. The second workflow addressed
prospective patients and included automatic scheduling of a clinic visit 4 weeks
after IVCF placement as outpatient or 4-6 weeks after discharge as inpatient. The
clinic visit included consulting and educating the patient about the potential
retrieval. In addition, an IVCF database was maintained by a physician assistant,
who also investigated non-compliant patient cases. Core monthly meetings and
quarterly team meetings evaluated the intervention for adjustments. The cohort
was divided into baseline (52 patients, pre-intervention), “letters” (43 patients
retrospectively contacted), and prospective (45 patients, scheduled follow-up at
placement) for evaluation. Deceased patients were excluded from eligibility, making
up 15 (28.8%), 6 (14%), and 12 (26.7%) patients in each group. Basic statistical
analyses were conducted.

The baseline group had a retrieval rate of 8% (4/51). This increased to 40%
(17/43) in the letters group, and 52% (22/45). Between the groups, the average
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time to retrieval was 64, 137, and 59 days, with no reported failures. In addition to
the retrievals, ~20% of patients in the letters group and ~50% of those in the
prospective group were followed-up in clinic. This increased the revenue per 100
IVCFs implanted from $2,249 in the baseline group, $10,518 in the letters group,
and up to $17,022 in the prospective group – showing nearly eight-fold increase in
revenue with prospective intervention. The financial analysis is unique among
studies and the inclusion of an intervention for a retrospective group shows
feasibility beyond only a prospective intervention.

Wang 2016
This unique study presents the systemic effect of multiple continuing medical
education seminars on the practice patterns in an integrated healthcare system
(Kaiser Permanente Northern California). 130 A system-wide IVCF tracking database
was also implemented. Twelve in-hospital CME-approved grand rounds were given
by a vascular and interventional radiologist specializing in IVCFs. These
presentations were also broadcast to satellite clinics and 2 more medical facilities.
The 14 facilities serve a combined 3.5 million members of the healthcare system. A
new practice model for IVCFs was also introduced and included: (1) the radiology
department assumed responsibility for follow-up; (2) a color-coded database alerts
users when filters are approaching 9- or 12-week indwell times, the database was
also capable of presenting dashboards to each facility if requested; (3)
recommendation made to follow ACCP guidelines for IVCF use; (4) established
collaboration with the anticoagulation clinic; (5) a monthly procedural code
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generated list was made by each facility to double check no patient oversight; (6) a
9-12 week retrieval interval was generally recommended. Outcomes measured
were IVCF utilization and retrieval as well as concordance with ACCP and SIR
guideline recommendations for IVCF indications.

There was an 18.7% decrease in overall utilization of IVCFs, with changes ranging as
low as decreases of 38.7% to increases in 16.7% at individual facilities. There was a
significant correlation in the decrease in IVCF utilization and overall physician
attendance. In the entire health system, this represented a net decrease in IVCF
utilization of 22.2%. Prior to the intervention, 38.9% (111 attempts, 92 successful)
of IVCFs were retrieved compared to 54.0% (127 attempts, 109 successful) in the
post-intervention group (15.1% change). There was no significant change in indwell
time (mean 10.2 vs. 10.8 weeks) or successful attempts (82.3% vs. 85.8%). There
was a significant correlation in physician attendance and increased retrieval
attempts. There were no differences in guideline concordance between the two
periods, but overall compliance with ACCP guidelines was 75.9% (other institutions
report 33.3% to 54% compliance with these conservative guidelines). The authors
note that there are differences between West and East coast IVCF practices, and also
differences between practices by patient payer status and the need for “defensive”
medicine. They note these factors are decreased in a closed healthcare system like
Kaiser Permanente.
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Overall, differences in institutional characteristics, baseline practices, and
interventional approach showed a broad range of impacts of these interventions.
Absolute changes in retrieval rates ranged from 0% to nearly 70%. Relative changes
ranged from 0% to over 2,200+% changes in retrieval rates (Table 6.3).

Discussion

During this literature review, several key points were recognized and noted
including: definition of retrieval (attempted vs. successful), inclusion and exclusion
criteria implemented in each study, the statistical analyses utilized, and the
potential of observed “Hawthorne” effects. Additionally, few studies reported on the
financial aspects of the interventions and there was a large discussion about the
responsibility of follow-up being shifted. Each is discussed below with case
examples to illustrate how these points can impact how these interventions are
evaluated.

Definition of retrieval
Studies differed on how they reported attempted versus successful retrievals
although all studies used successful retrievals as the primary metric. Nearly all
(13/15) reported the number of failed retrievals which ranged from none to nearly
30%; thus, the attempted retrieval rate can at least be calculated if it is not explicitly
reported. Generally, retrieval failures can be expected to be 15% of all attempts,
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although this can be variable depending on a combination of institutional, physician,
and patient factors. In most of these studies, the differences in failed retrievals
between pre- and post-intervention periods were not significantly different,
although these comparisons were limited because of sample size. Further, if
differences exist between the pre and post periods, in the failure rate, reporting and
comparing these figures can be more important, more so if the intervention can be
expected to impact failure rates in some way. Further, evaluation of these
interventions must put in context the goal of the program. Follow-up is generally the
goal in that if patients are followed-up with, then retrievals will naturally increase.
Thus, both attempted and successful retrieval rates should be reported in such
evaluations. Similarly, as the goal is often to retrieve earlier, comparison of indwell
times between intervention periods is called for.

Inclusion and exclusion criteria
There was wide variation in the patient populations between studies (e.g. trauma,
prophylactic, etc.) along with variation in the definition of eligible and included
patients in each study. A clear definition of the patient population is paramount to
evaluation and how these inclusion and exclusion criteria impact the assessment
should be considered. More importantly, the same definition should be applied
across pre- and post-intervention periods to allow an unbiased assessment of the
program.
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Statistical analyses
Most studies utilized “simple” statistical analyses in that they included only
bivariate tests of significance, mostly chi-squared, Fisher’s exact, or equivalent nonparametric or multiple groups tests. Two studies, Minocha and Davies utilized
survival analysis in their studies. In each study, details about follow-up, censoring
events, and competing events are limited. In Minocha’s study, there were few
patients lost to follow-up and it is not discernible how many died and were
considered censored due to death. In the Davies study, they specify that patients
were censored at death including 9/39 (23.1%) patients in the pre-intervention
period and 12/56 (21.4%) patients in the post-intervention period.

The general assumption in Kaplan-Meier survival analyses is that censoring is
uninformative, which can be interpreted as patients who are censored should not be
different that patients that remain in the risk set. In the case of random censoring,
e.g. true loss to follow-up, this assumption may generally hold. In the case of death
as a censoring event, however, those that die are likely generally different. Thus,
death is informative and should be considered a competing event, or a competing
risk, and accounted for in estimates of the cumulative incidence of retrieval.
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Ignoring competing risks will inflate the cumulative incidence as those who die are
removed from the risk set (denominator) when the Kaplan-Meier product limit
estimator is calculated. This essentially will bias the estimated retrieval rate from
these methods; a bias that is on a magnitude determined by the actual death rate in
the cohort. In the Davies study, more than 1 out of 5 patients died during follow-up,
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a figure that indicates that the Kaplan-Meier estimates are tremendously biased.
Davies and colleagues report a 12-month retrieval rate of 100% although 29 of 56
(51.7%) patients actually had retrieval.

To deal with this issue two approaches could be taken, which should likely be
determined by the amount of detailed follow-up data included. For one, competing
risks could be accounted for using estimation techniques like Fine and Gray’s
estimate of the cumulative incidence. This would require clear definitions of what
constitutes loss to follow-up, censoring, and competing events. Further, studies
should consider the impact of when follow-up begins. This is imperative where
patients are assessed for ongoing indications for IVCFs and, intuitively, the followup for retrieval has not clinically been initiated. The other approach is more
conservative and could involve calculating the retrieval rate in basic statistical
analyses, i.e. like the majority of the studies in this review. Most important here is to
develop a clear definition of who would be included in the denominator and to
ensure that a set follow-up time is achieved, so not to punish the retrieval rate due
to limited follow-up in those enrolled late into the study. For example, the base
calculation of the 51.7% retrieval in the Davies study includes patients who had
planned procedures and ongoing indications for retrieval. These patients should
likely be excluded from any calculation of retrieval (including the survival analysis).

I may also be more prudent for studies to investigate retrieval rates within a defined
time period, especially given the large interest in having shorter indwell times to
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decrease device related complications. 30 Thus, we propose investigating retrieval
rates with 90-180 days as an outcome versus longer periods. Such a calculation
should consider the above recommendations of clear definitions of outcomes, as
well. This will avoid potential biases related to follow-up and how eventually
patients can be removed from the cohort.

Hawthorne effect of intervention
The classical dynamic explains how individuals behave differently when they are
aware of ongoing evaluation. This could certainly be the case in most of these
studies as those who implemented the interventions had their practice directly
affected. Interesting questions can be posed to add to the understanding of the
longevity of these policy changes.

However, there also remains the possibility that some pervasive effects could occur
due to the ongoing evaluation. One example where this may have occurred is in the
article by Logan et al. In this study, during the pre-intervention period, 12% of all
patients eventually had their IVCFs deemed permanent. Based on the study
definition of retrieval rate, this removed these patients from the denominator. In the
post-intervention period, this proportion rose to 39% in the post-intervention
period. While this could be influenced by several factors, a possible pervasive factor
could have included physicians within the clinic becoming more likely to deem
IVCFs as permanent, which would inflate the estimated retrieval rate due to the way
this study defined this metric.

150

Financial analyses
Two studies, Sutphin et al and Charlton-Ouw et al, featured financial analyses in
their evaluation of retrieval interventions. The Charlton-Ouw financial analysis was
done to account for the known issue at this institution of patients being uninsured
or having less generous insurance (i.e. Medicaid).
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Thus, these patients

represented potential losses for the IVCF clinic in the hospital, especially if follow-up
was increased and more procedures performed. Their analysis showed that the
charges from patients with insurance (commercial and Medicare) were enough to
“cover” the uninsured group and still result in small revenue for the clinic. While
similar considerations may be relevant at other institutions that treat large
uninsured populations, this financial analysis is not generalizable.

The financial analysis by Sutphin provided a more generalizable analysis of the
financial impact of such an intervention and provides a picture of how increased
manpower and relatively simple interventions can be allotted to improve clinic
revenue. Using the standardized metric of clinic revenue per 100 IVCFs placed, they
show that the baseline revenue was $2,249/100 IVCFs in the baseline group,
$10,518/100 IVCFs in the letters group, and up to $17,022/100 IVCFs in the
prospective group. As described, the letters intervention with retrospective patients
required little application of person-time to implement, i.e. letters were sent and
patients or their primary provider could then follow-up. This is somewhat
analogous to the simple letter campaign conducted within the UKHC IR clinic. Thus,
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it is intuitive that clinic revenue will increase linearly with improvements in
retrieval rates and Sutphin has shown it here.

Costs to the clinic are not only procedurally based. Retrievable IVCF equipment and
devices are more costly than that of permanent IVCFs. In the context of few
retrievals occurring, these devices become de facto permanent; thus, a permanent
device could have been used in its place. A study by d’Othée and colleagues showed
that when both types of devices are available, a minimum retrieval rate of 41% is
needed for retrievable devices to be cost-effective compared to permanent devices.
77

All this shows that retrieval impacts costs in multiple ways. Dedication to good

practice of retrieving devices can increase both procedural revenue and help recoup
costs from increased device costs.

Responsibility for patient follow-up
Multiple studies in this review pointed at that the responsibility of patient follow-up
was shifted from the patient’s referring or primary physician to the physician who
performed the implant or the clinic itself. Lynch’s article discusses how he himself
took on this responsibility to increase retrieval rates, which represents a paradigm
shift in physician-to-physician and physician-to-patient communication in this
setting, both prior to and after IVCF placement.

41

Minocha and colleagues

implemented a similar practice with a dedicated interventional radiologist and
nurse conducting follow-up. 42 Each of these studies also included the creation of an
IVCF registry or database which assists these clinicians in implementing these plans.
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Further, some studies also point out the importance of IVCF retrieval plans being
included in discharge plans, enhancing the communication between providers. 81 In
Logan’s study, this was shown by tracking retrieval rates in those who had thorough
documentation of the IVCF implant as well as plans for retrieval in the discharge
notes. In the total population, the baseline retrieval rate was 45%, but increased to
91% in patients who had plans documented.

Applicable guidelines
In general, two guideline statements can be thought to cover the practice of
implanting IVCFs and included the American College of Chest Physician (ACCP)
guidelines on the management of VTE 4 and the Society for Interventional Radiology
(SIR) guidelines for management of pulmonary embolism. 32 In medicine, the ACCP
guidelines are generally considered “conservative” calling for use of IVCFs only if
there are clear contraindications to anticoagulation. The ACCP guidelines do not call
for prophylactic use. The SIR guidelines are more liberal allowing for prophylactic
use in those who do not have an active VTE but are considered contraindicated or
are high risk.

Only one study in this review evaluated these SIR and ACCP guidelines in their
institution. The study by Wang et al of 14 medical centers included evaluation of the
concordance of IVCF practices with these guidelines. 130 What they observed was
that around 80% of all implantations were supported by ACCP guidelines and 20%
were supported only by SIR guidelines. Thus, for this study, it seems the institutions
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are practicing conservatively. However, this study was conducted within a selfcontained health system where patients and physicians are insured and employed
by the insurer (Kaiser Permanente) in fully owned medical centers. Because of this,
the authors cite that factors that may lead to more liberal use, e.g. defensive
medicine practices and need to increase reimbursement, are not present in this
setting. To compare, a study not included in this review showed that in two
hospitals in New York, compliance with ACCP guidelines was lower at 41.3% and
reached 95.7% compliance with SIR guidelines.

33

The main discrepancy being

prophylactic use of IVCFs.

Conclusions

As has been shown, there is wide variation in practices of IVCF utilization and
retrieval. This is due to a combination of physician preferences, practice
environment, patients, and healthcare system qualities. 78 In the end, the general
issue seems to be patient follow-up, which is a result of the aforementioned
characteristics. To improve IVCF utilization, continuing medical education of
accepted indications for use, indications for retrieval, and how these influence
effectiveness and complications related to IVCFs is needed and has been shown to
decrease utilization and increase retrieval. Patient education is also needed to
ensure informed consent is provided to provide what is generally seen as a “lowvalue” healthcare service and to reinforce the concept of compliance with future
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follow-up. A method of tracking these patients in combination with an individual or
team of individuals who take clinical responsibility for this important quality of care
issue is needed. 128
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Figure 6.1: Action items for improvement of IVCF retrieval rates

Reproduced from Sutphin (2015) 78 with permission
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Table 6.1: Characteristics of studies evaluating interventions to increase inferior vena cava retrieval rates
Study citation

Study Year(s)

Setting

Intervention

Charlton-Ouw
2014 (USA) 75

Pre: 4/20092011; Post:
5/2011-2013

Level 1
trauma
center

Mail, email, telephone
follow-up with patients
after EMR referral

Davies 2015
(NZ) 40

Pre: 6/20106/2012; Post:
7/012-6/2014

Tertiary
center

Gasparis 2011
(USA) 129

Post: 1/20101/2011

Tertiary
center

Inagaki 2016
(USA)

Pre: 9/20037/2012;
Post:8/20129/2014

Tertiary
center

Irwin 2010
(USA)

1/2003-6/2008

Level 1
trauma
center

Clinical coding registry and
PACS review, monthly
report. Phone and/or
scheduled clinic follow-up.
Clinical pathway
developed. Focused on
filters placed >6 weeks
NP coordinated with
patients and referring
physician for follow-up.
Educated patients predischarge about IVCF
benefits and risk. Dedicated
time in suite.
Retrospective review
followed by prospective
retrieval program; EMR
review. Task force,
standardize retrieval
process. 1) patient
educational pamphlets, 2)
procedure form, 3)
centralized registry,
dedicated coordinator
Team met each morning
(M-F) to review patient
care. Coordinated with IR
staff to schedule retrievals.

Intervention staff

Implanting
services
IR: 23%; VS:
3%; trauma:
74%

Control/Comparison
group
Retrospective, preintervention

Indications for
insertion
Trauma patients,
prophylactic and
secondary

IR, VS

Retrospective, preintervention

Med-surg
patients

Dedicated NP
maintained database
and follow up.
Dedicated "DVT
Team" with NP and
physician.

VS

None: compared to
baseline retrieval rate
that was from previous
study

Med-surg
patients

Multidisciplinary task
force from VS, IR,
cardiology, trauma,
and hematology.
Retrieval coordinator

VIR, VS, Cards

Retrospective, preintervention

Med-surg
patients

Multidisciplinary task
force of clinical
nurses, executed by
IR clinical nurse, led
by trauma nurses in
consultation with

VIR

Retrospective, preintervention

Trauma patients,
prophylactic and
secondary

Clinic nurse or study
coordinator. Vascular
surgery, trauma, IR
physicians in
multidisciplinary
team.
VTE clinic nurses
coordinated effort
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Kalina 2012
(USA)

Pre: 1/200312/2005
Post: 1/200612/2009

Level 1
trauma
center

Ko 2009 (USA)

Pre: 1/20042/2007
Post: 8/20077/2008

Level 1
trauma
center

Lee 2012 (UK)

Pre: 5/20074/2008
Post: 5/20084/2009

Tertiary
center

Logan 2016
(IRL)

Pre: 1/1/20123/31/2013
Post: 11/201312/2014

Tertiary
center

Lucas 2012
(USA)

Pre: 12/200512/2006
Post: 1/20071/2011

National
Military
Medical
Center

Lynch 2011
(USA)

Baseline/retrosp
ective: 5/200210/2005

Tertiary
center

Filter registry. APNs
managed data collection
every 2 weeks, presented
cases to trauma physicians,
directly scheduled
procedures. Registry
reviewed monthly by
department
Institutional protocol
developed, automated
email sent to ordering
physician as reminder.
Highlighted on rounding
list for physicians.
Proactive f/u organized by
IR instead of referring
physician. Clinical team
contacted every 30 days by
radiologist via fax to
schedule retrieval.
Nurse in charge of filter
registry; consult with
hematology to decide
eligibility for retrieval; bed
available for retrieval at
short notice
Tracking system, medical
record review and provider
communication; Follow-up
plans at the time of
discharge

Chart review and multiple
f/u letter communications.
IR was given responsibility

trauma surgeons
Trauma surgeon,
acute care nursing
staff

Placement:
trauma, VIR
Retrieval: VIR

Retrospective, preintervention

Trauma

PA, coordination
between trauma, VS,
IR

VS and IR.
Mostly VS:
60% pre and
90% post

Retrospective, preintervention

Trauma patients:
1. very high risk;
2.
contraindication
to anticoag

IR

VIR

Retrospective, preintervention

Various

Multidisciplinary
team with
interventional
radiologists,
hematologists, and
nursing staff
Administrative
trauma coordinator
in charge of tracking
system,
Multidisciplinary
meeting and
communication with
providers
A single
interventional
radiologist

VIR

Retrospective, preintervention

Various: major
indications
varied pre vs.
post

N/R

Retrospective, preintervention

Military combat
trauma

VIR

Retrospective, preintervention.
Additional f/u with

SIR guideline
indications:
various
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Post: 10/20055/2010

Minocha 2010
(USA)

Pre: 1/200012/2008
Post: 1/20091/2010

Tertiary
center

O'Keeffe 2011
(USA)

1/1/200612/31/2006

Level 1
trauma
center

Sutphin 2015
(USA)

Baseline:
1/2012-8/2012
Letter (retro):
9/2012-4/2013
Prospective:
5/201312/2013

Tertiary
center

Wang 2016
(USA)

Pre: 12/201103/2013
Post: 2/20135/2014

14 urban
centers in
northern
CA
(Kaiser

of follow-up. Informed
consent included
discussion of IVCFs.
Registry maintained in
iSchedule and Access
database. Non-retrieval
flagged if >90 days. Letters
for f/u sent, up to 4
Retrospective for preintervention pts and
prospective for postintervention pts. Dedicated
registry. Contacted
referring physician every 23 weeks until removed or
deemed permanent.
Prospective only: label,
tracked by NP for f/u
venous duplex US. F/u in
90 days for imaging and
removal.

DMAIC methodology from
Six Sigma. Retrospective
letters to patients and
physicians. Auto scheduling
in 4-6 weeks. Correcting
issues of physician,
patients, clinical, and
systems. Separate
pathways for past and
future patients.
Gave 12 CME grand rounds.
Deployed IVC clinic model
and tracking system in IR
clinics. 9/12 week dwell
alerts, optional dashboards.

past patients.

Interventional
radiologist and nurse
coordinator dedicated IVCF clinic

VIR

Pre: before IVC filter
clinic
Post: after IVC filter
clinic established in
1/2009

SIR guideline

Multidisciplinary
team with trauma
surgeons,
radiologists, and NPs,
while NPs are in
charge of aggressive
patient follow up
Multidisciplinary
team, IR
physician/nurse,
internal medicine
nurse, and hospital
quality facilitator

N/R

Trauma (intervention):
vs. Non-trauma
(standard care):

Prophylactic use
only in trauma
and non-trauma
groups

N/R

Baseline: no follow-up
“Letters”: Patients
receiving retrospective
f/u. Post: Prospective
f/u after full
implementation

Various

Board-certified VIR
physician, clinical
model coordinated IR
with anticoagulation
clinics at each

VIR - IR
(57/59) or NIR
(2/59)
physicians

Pre- vs. postintervention, each for
one year period.
Changes tracked at
each institution and

Various
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Permane
nte)

Recommended
conservative ACCP
guidelines.

institution

overall.

Table 6.2: Results from studies evaluating interventions to increase inferior vena cava filter retrieval rates
Study citation

Comparison
(N)
64

Intervention
(N)
111

Comparison
retrieval (%)
3.1%

Intervention
retrieval (%)
73%

Comparison
indwell time
N/R

Intervention
indwell time
6.2±4.0 months

Failed
retrievals
15%

1.95%

1 patient

39

56

63%

100%

7.4 months

4.1 months

3.2%

N/R

0%

Gasparis 2011
(USA)
Inagaki 2016
(USA)
Irwin 2010 (USA)
Kalina 2012
(USA)
Ko 2009 (USA)

14

40

Retrieval: 18%

N/R

0%

None

74

119 days

33
113

unclear
N/R

unclear
N/R

Pre: 17%
Post: 18%
3.5%
N/R

N/R

82
120

Attempt: 14%
Retrieval: 11%
65%
15.5%

21 days (4 to
140)
130 days

14%

720

Attempt: 81%
Retrieval: 70%
Attempt: 66%
Retrieval: 54%
84%
31.5%

76

37

20±15 days

29

16 days (median)

Logan 2016 (IRL)

33

33

Lucas 2012 (USA)

20

93

45%
(84% with
retrieval plan)
Attempt: 30%
Retrieval: 30%

45%
(91% with
retrieval plan)
Attempt: 70%
Retrieval:60%

10 days
(median)
61 days
Failed: 94 days

Pre: 12.5%
Post: 11%
Pre: 28.6%
Post: 18.8%
Pre: 15%
Post: 9%

0%

28

Attempt: 95%
Retrieval: 84%
55%

24±30 days

Lee 2012 (UK)

Attempt: 42%
Retrieval: 37%
50%

34% lost to
follow up
9.56%
Pre: 21.1%
Post: 27.6%
0%

210±190 days

84±101 days

Pre: 0
Post: 13.8%

N/R

Pre: 65%
Post: 5%

Lynch 2011
(USA)
Minocha 2010
(USA)
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973

24%

59%

N/R

100

29%

60%

Mean: 307 days
Median: 224 days
Mean: 45 days

1.3%

369

Mean: 103 days
Median: 91 days
N/R

Pre: 6%
Post: 5%

2%

Pre: 18.2%
Post: 16.2%
Post: 2.5%

O'Keeffe 2011
(USA)
Sutphin 2015
(USA)

31

77

19.4%

54.5%

14.5 days

48.5 days

N/R

1.2%

N/A

36

Letters: 25
Prospective:4
2

8%

Letters: 40%
Prospective:
52%

64 days

Letters: 137 days
Prospective: 59
days

None

N/R

Wang 2016 (USA)

285

235

38.9%

54.0%

71.4 days (10.2
weeks)

75.6 days (10.8
weeks)

Pre: 17.7%
Post: 14.2%

1.6%

Unclear.
19% of letters
and 49% of
prospective
patients not
retrieved still
had ongoing f/u
0%

Charlton-Ouw
2014 (USA)
Davies 2015 (NZ)

44 days
Failed: 92 days

Complications

N/R
N/R

0%
N/R

Loss to f/u

Pre: 21%
Post: 3%
Pre: 27%
Post: 9%

Table 6.3: Impact of interventions to increase vena cava filter
retrieval rates
Study
PrePostAbsolute
Relative
intervention
intervention
change
change
retrieval rate
retrieval rate
Charlton3.1%
73%
69.9%
2254.8%
Ouw 2014
(USA)
Davies 2015
63%
100%
37.0%
58.7%
(NZ)
Gasparis
2011 (USA)
Inagaki 2016
(USA)
Irwin 2010
(USA)
Kalina 2012
(USA)
Ko 2009
(USA)
Lee 2012
(UK)
Logan 2016
(IRL)
Lucas 2012
(USA)
Lynch 2011
(USA)
Minocha
2010 (USA)
O'Keeffe
2011 (USA)
Sutphin 2015
(USA)
Wang 2016
(USA)

18%

70%

52.0%

288.9%

14%

66%

52.0%

371.4%

65%

84%

19.0%

29.2%

15.5%

31.5%

16.0%

103.2%

42%

95%

53.0%

126.2%

50%

55%

5.0%

10.0%

45%

45%

0.0%

0.0%

30%

70%

40.0%

133.3%

24%

59%

35.0%

145.8%

29%

60%

31.0%

106.9%

19.4%

54.5%

35.1%

180.9%

8%

52%

44.0%

550.0%

38.9%

54.0%

15.1%

38.8%
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CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS

These studies have evaluated the utilization and retrieval of VCFs in both Kentucky
and Nationally to put in context the quality of care surrounding this medical device.
IVCFs are commonly utilized in the U.S. population with patient selection generally
consisting of those with significant comorbidities that may affect their risk for VTE
or bleed events. In these patients, and in a medical environment that encourages
defensive medicine, IVCF use has increased to nearly 1-in-5 and 1-in-10 patients
with PE and DVT. Further, IVCF use is in nearly equal quantities as prophylactic
devices, an indication that is both refuted and supported by conflicting guidelines
and remains, technically, off-label use, with little evidence for effectiveness. In fact,
IVCF utilization has been used as one of several procedures to track low quality
hospitals, physicians, and clinics as a procedure that has not be definitively shown
to be effective. It is telling that when physicians are educated on the evidence
behind these devices, the utilization decreases significantly and the retrieval
increases significantly. 130

In Kentucky, utilization was on par with national estimates, with similar findings in
the epidemiology of use. Use is high in those with bleeding, cancer, or other
conditions related to VTE or bleed risk. Interestingly, compared to another study in
California, IVCF utilization between hospitals in Kentucky was less variable, and
explained strongly by patients’ clinical characteristics. The fact that use was less
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variable shows that there is even more variability between states, regions, etc. in
how these devices are used. Often, when variability on this scale is observed, there
can be inferred a large quality of care issue. That is, when your propensity to receive
a certain procedure is largely determined by where or by whom you receive care,
the standard of care needs to be evaluated.

This is precisely the motivation for future work that have been driven by these
studies as I transition from observational to interventional considerations. As
Chapter 5 shows, quality of care at the University of Kentucky hospital VIR clinic is
poor in terms of VCF retrieval and follow-up care. Chapter 6 was devoted to
reviewing what other institutions have implemented to increase their own retrieval
rates. Our aim was to glean a list of concepts from these interventions that are
associated with success, i.e. increases in retrieval rates and decreases in the time-toretrieval. Since that time, the initial planning of a quality of care intervention has
begun, including a letter of intent to the translational research institute at the
University. This intervention will acknowledge and look to improve upon the poor
retrieval rates in the VIR clinic by incorporating learnings from the literature review
including: 1) a prospective patient registry; 2) dedicated follow-up visits with the
implanting VIR physician; 3) certified mail letters sent to patients and physicians.
Using these interventions, we hypothesize that we can increase the retrieval rate in
the VIR clinic to over 50%, shorten the time-to-retrieval, maximize anticoagulation
and VTE therapy, as well as increase clinic revenue from additional patient visits
and procedures. We hope that the intervention will be successful, most importantly,
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but also that it will also pay for itself so that instituting it permanently can be
broadly supported by the institution.

Lastly, future work also hopes to fill significant knowledge gaps regarding the
optimal time for retrieval. The Morales study that informed the FDA safety
communication synthesized the data and developed simulation models specified for
a prophylactic indication. 31 Thus, as mentioned earlier, there is a general lack of
knowledge regarding the optimal retrieval time in a patient with active VTE disease.
Such information must account for confounding factors, patient age, VTE type, etc.
and must be specialized to some distinct patient subgroups (e.g. cancer). Future
work will expand on the Morales model by adding inputs that account for the risk of
recurrent VTE (DVT or PE), VCF-related complications, and complications from
anticoagulation. The establishment of a time-scale for retrieval and a deeper
understanding of the net clinical benefit has the potential to influence the quality of
care with VCFs, ensuring that the right device is used in the right patient at the right
time.
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